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ABSTRACT 
Castration improves responses to radiotherapy (RT) in prostate cancer with unknown 
mechanism. An understanding of what happens at the cellular and molecular level in 
prostate cancer cells, while reducing their access to androgens and then exposing them to 
ionizing radiation (IR), would give us an opportunity to optimize the treatment and may 
also inspire novel therapeutic approaches. 
Paper I: Growth of solid tumours such as prostate cancer is characterized by 
neovascularization and increased glycolysis as a result of the hypoxic microenvironment of 
the tumour. HIF-1α is an important transcription factor that regulates cell adaptation to 
hypoxia and transcription of genes involved in angiogenesis, cell survival, glucose 
metabolism, and tumour invasion. To test whether any connection between castration 
therapy and intra-tumoural hypoxia, measured by HIF-1α expression, prostate biopsy 
specimens from 14 patients with prostate cancer were investigated. Downregulation of HIF-
1α expression after castration was observed in five patients with initial high HIF-1α 
expression. HIF-1α expression was also reduced in two of three patients with initial low 
HIF-1α expression. These data suggest that neoadjuvant castration reduces tumour cell 
hypoxia in prostate cancer, which may contribute to the increased radiosensitivity after 
castration. 
Paper II: We investigated whether castration impairs non-homologous end-joining (NHEJ) 
repair of DNA double-strand breaks (DSBs) by downregulation of Ku70 expression. The 
same cohort of patients used in paper I was analysed. After castration, the nuclear Ku70 
levels were reduced in 12 patients (levels varied from 43% to 97% after castration, p 
<0.001). The reduction in Ku70 expression correlated significantly with the decrease of 
serum PSA level after castration, suggesting that AR activity regulates Ku70 protein levels 
in prostate cancer tissue. Our conclusion was that castration results in decreased levels of 
Ku70 protein. Since Ku70 protein is necessary for NHEJ repair of DSBs, a downregulation 
of DNA repair leads to increased radiosensitivity. 
Paper III: Emerging data demonstrate homologous recombination (HR) defects in 
castration resistant malignant prostate tumours, rendering these sensitive to PARP inhibitor 
treatments. Here, we demonstrate a direct link between the androgen receptor (AR) being 
required for maintenance of HR gene expression and activity in prostate cancer cells, as 
well as in maintenance of DNA damage response signalling. As a consequence, we show 
PARP-mediated backup repair pathway is upregulated in prostate cancer tissues in patients 
following androgen-deprivation therapy (ADT). Furthermore, upregulation of PARP 
activity is essential for prostate cancer survival, and we demonstrate a synthetic lethality 
between ADT and PARP inhibitors in vivo. These data demonstrate that HR may be 
functionally impaired earlier in prostate cancer etiology as a consequence of ADT; prior to 
emerging castration resistance and that this potentially can be exploited therapeutically 
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of non-homologous end joining (NHEJ) repair of DNA double-strand breaks (DSBs). To 
test this, forty-eight patients with localized prostate cancer were enrolled in two arms, either 
treating with RT upfront or after receiving neo-adjuvant castration. We biopsied patients at 
diagnosis, before and after castration and RT treatments to monitor androgen receptor 
(AR), NHEJ and DSB repair in verified cancer tissue. We show that patients receiving neo-
adjuvant castration prior to RT had reduced levels of the NHEJ protein Ku70, impaired RT-
induced NHEJ activity and a higher level of unrepaired DSBs, measured by γ-H2AX foci in 
cancer tissues. This study demonstrates that castration impairs NHEJ activity in prostate 
cancer tissue, explaining improved RT responses in tumours. 
Paper V: Despite the early diagnosis and subsequently effective treatment of intermediate 
and high-risk prostate cancer, the recurrence rate remains regrettably high. Here, we wanted 
to investigate how effectively castration suppresses androgen receptor (AR) signalling, 
thereby affecting DNA damage repair in primary hormone-naïve prostate cancer. From the 
same cohort of patients as in Paper IV, four patients from arm 1 and one patient from arm 2 
were analysed. The levels of AR, Ku70, phosphorylated DNA-PKcs and PAR were 
measured.  A significant correlated reduction in the mean intensity of nuclear AR was 
observed in four patients whose serum PSA was reduced to the greatest extent, about 90% 
(ρ=1, p <0.001). Although complete castration was obtained using serum testosterone levels 
in these patients, the levels of AR, and consequently of Ku70 and phosphorylated DNA-
PKcs remained high and positively co-varied in clusters of cells throughout prostate tumour 
areas. Meanwhile, a tendency towards an inverse correlation was observed between AR, 
Ku70 and phosphorylated DNA-PKcs as compared with PARP-1 activity.  In conclusion, 
we are first to demonstrate the heterogeneous landscape of AR and the consequent 
divergent although co-varied response of DNA damage repair. To date, it remains unclear 
whether the emergence of these castration-resistant cells in hormone-naïve prostate cancer, 
is due to the high levels of intra-tumoural residual androgen following castration and 
consequently suboptimal androgen suppression of otherwise androgen-dependent cells or 
caused by quiescent castration-resistant cells that promote progression according to clonal 
selection pressure. The current finding certainly warrants further investigation in the future.  
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 1 
1 INTRODUCTION  
Prostate cancer (PCa) is the second most common diagnosed cancer and a major cause of 
cancer-related death worldwide [1, 2]. The highest incidence is found in Western Europe, 
North America, and Australia/New Zeeland, which might be due to the frequent use of 
prostate specific antigen (PSA) testing and subsequent biopsies of the prostate in these parts 
of the world. The goal of treatment of non-metastatic PCa is to cure the patient, and extend 
survival. One treatment modality with curative intention is the combination of radiotherapy 
(RT) and neoadjuvant castration; a short-term endocrine therapy prior to and during RT, 
which has shown a significant improvement in local tumour control and disease-specific 
survival combined with reduced incidence of distant metastases. However, the overall 
survival is improved only in a subset of patients with locally advanced disease and low 
graded tumours [3-5]. 
Several randomised trials demonstrate the synergistic effect between castration and RT. Yet 
the underlying mechanisms are not fully understood [6]. An understanding of the 
mechanisms at the cellular and molecular level in PCa cells, how reducing their access to 
androgens and then exposing them to ionizing radiation (IR) kill cells, would give us an 
opportunity to optimize the treatment and may also inspire novel therapeutic approaches. 
1.1 HISTOPATHOLOGY AND STAGING OF PROSTATE CANCER 
The prostate gland is located below the urinary bladder neck. There are three distinct zones, 
the peripheral zone about 70%, the central zone about 25% and the transitional zone about 
5% of the prostatic volume (Figure 1). The prostate gland consists of glandular and non-
glandular tissue. Glandular tissue consists of epithelial cells forming glands and their main 
function is to elaborate and secrete prostate-specific antigen (PSA). Non-glandular tissue 
consists of fibromuscular stroma. The vast majority of prostatic cancer is acinar 
adenocarcinoma 90-95 % and the remaining 5-10% are neuroendocrine prostate carcinomas; 
a non-acinar carcinoma that includes a subset of rare prostate cancer phenotypes, which are 
characterized by low or negative PSA levels, androgen receptor resistance and aggressive 
phenotype [3, 7]. About 80% of prostatic acinar adenocarcinomas arise in the peripheral 
zone. It is multifocal in about 85% of cases. Adenocarcinomas of the prostate are 
histologically scored according to Gleason; the most widely accepted grading system that is 
based on the architectural pattern of the prostate tumour. 
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Figure 1. Side view, shows the location and the 
different zones of the prostate gland.
The Gleason grading system combines the two most common (primary and secondary) 
architectural patterns of cancer within the sampled specimen. Each of the two most common 
patterns is assigned a grade from one to five, with the grade 1 being the most well-
differentiated and least aggressive and grade 5, the poorly differentiated or most aggressive. 
Gleason score, which is a number from 2-10, is reported as the sum of the two dominant 
patterns added together [4, 7, 8] (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Modified Gleason grading system. 
Pattern 1: Circumscribed nodule of closely packed 
but separate, uniform, rounded to oval, medium-
sized acini (larger glands than pattern 3). Pattern 2: 
Like pattern 1, fairly circumscribed, yet at the edge 
of the tumor nodule, there may be minimal 
infiltration. Glands are more loosely arranged and 
not quite as uniform as Gleason pattern 1. Pattern 3: 
Discrete glandular units; typically smaller glands 
than seen in Gleason pattern 1 or 2; infiltrates in and 
among nonneoplastic prostate acini; marked 
variation in size and shape; smoothly circumscribed 
small cribriform nodules of tumor. Pattern 4: Fused 
microacinar glands; ill-defined glands with poorly 
formed glandular lumina; large cribriform glands; 
cribriform glands with an irregular border; 
hypernephromatoid. Pattern 5: Essentially no 
glandular differentiation, composed of solid sheets, 
cords, or single cells; comedocarcinoma with central 
necrosis surrounded by papillary, cribriform, or 
solid masses. Epstein et al. Adv Anat Pathol. 2006 
Jan; 13(1): 57-9
 
2 
 
Figure 1. Side view, shows the location and the 
different zones of the prostate gland.
The Gleason grading system combines the two most common (primary and secondary) 
architectural patterns of cancer within the sampled specimen. Each of the two most common 
patterns is assigned a grade from one to five, with the grade 1 being the most well-
differentiated and least aggressive and grade 5, the poorly differentiated or most aggressive. 
Gleason score, which is a number from 2-10, is reported as the sum of the two dominant 
patterns added together [4, 7, 8] (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Modified Gleason grading system. 
Pattern 1: Circumscribed nodule of closely packed 
but separate, uniform, rounded to oval, medium-
sized acini (larger glands than pattern 3). Pattern 2: 
Like pattern 1, fairly circumscribed, yet at the edge 
of the tumor nodule, there may be minimal 
infiltration. Glands are more loosely arranged and 
not quite as uniform as Gleason pattern 1. Pattern 3: 
Discrete glandular units; typically smaller glands 
than seen in Gleason pattern 1 or 2; infiltrates in and 
among nonneoplastic prostate acini; marked 
variation in size and shape; smoothly circumscribed 
small cribriform nodules of tumor. Pattern 4: Fused 
microacinar glands; ill-defined glands with poorly 
formed glandular lumina; large cribriform glands; 
cribriform glands with an irregular border; 
hypernephromatoid. Pattern 5: Essentially no 
glandular differentiation, composed of solid sheets, 
cords, or single cells; comedocarcinoma with central 
necrosis surrounded by papillary, cribriform, or 
solid masses. Epstein et al. Adv Anat Pathol. 2006 
Jan; 13(1): 57-9
 3 
1.2 TNM CLASSIFICATION   
The clinical staging of PCa is according to the TNM system. 
•  T represents the size of the primary tumour. 
•  N describes the involvement of regional lymph nodes 
•  M describes distant metastases in different organs. 
T1 - The tumour remains confined to the prostate and is too small to be detected on digital 
rectal examination (DRE).  
T1a - Incidentally diagnosed tumour through transurethral resection of prostatic adenoma in ≤ 
5% of resected tissue. 
T1b - Incidentally diagnosed tumour through transurethral resection of prostatic adenoma in 
≥ 5% of resected tissue. 
T1c -The tumour diagnosed through needle core biopsy following elevated PSA value. 
T2 - The tumour is still confined to the prostate, but is now large enough to be felt on DRE. 
T2a- The tumour invades one-half or less of one lobe of the prostate gland. 
T2b- The tumour invades more than one half of only one lobe of the prostate gland. 
T2c- The tumour invades both lobs of the prostate gland. 
T3 - The tumour has extracapsular extension.  
T3a -The tumour spread through the prostatic capsule. 
T3b - The tumour invades the seminal vesicles. 
T4 - The tumour invades adjacent organs or structures other than     the seminal vesicles, i.e. 
external sphincter, rectum, levator muscles, or pelvic wall.  
(TNM Classification of Malignant Tumours, 7th Edition. Oxford, UK: Wiley-Blackwell, 
2009) 
1.3 RISK STRATIFICATION OF LOCALIZED PROSTATE CANCER 
ACCORDING TO D´AMICO CRITERIA [9]: 
Low risk prostate cancer: PSA<10 and Gleason score < 7 and T1-2a 
Intermediate risk prostate cancer: PSA 10-20 or Gleason score =7 or T2b 
High risk prostate cancer: PSA >20 or Gleason score = 8-10 or T2c-T3a 
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1.4 DIAGNOSIS OF PROSTATE CANCER USING THE PSA TEST 
Prostate specific antigen (PSA) is a protein produced by normal and malign prostatic cells 
and its expression is primarily regulated by the androgen receptor (AR). PSA is considered 
the most effective single biomarker for monitoring the metabolic activity of PCa cells before, 
during and after treatment [10, 11]. The PSA test measures the serum levels of this protein 
and is often elevated in men with PCa. However, neuroendocrine differentiated carcinomas of 
the prostate may appear without initial significant high levels of serum PSA [3]. 
1.5 TREATMENT FOR LOCALIZED PROSTATE CANCER 
Treatment of organ confined PCa may differ according to risk classification of cancer and 
expected survival of patients [12]. Conventional treatment options for men with intermediate 
risk and high risk, clinically localized PCa have included radical prostatectomy (RP) and 
radiotherapy (RT) techniques. However, active surveillance may be recommended for 
patients with an indolent low risk tumour. Moreover, the combination of RT with 
neoadjuvant castration has proven beneficial in patients with intermediate and high risk 
disease [13]. 
1.6 SURGERY 
RP is an established therapeutic option for treatment of patients with localized PCa. RP, 
which means removal of the entire prostate gland and the seminal vesicles, can be achieved 
through different techniques like open, laparoscopic or robotic assisted laparoscopic radical 
prostatectomy. Although neoadjuvant castration using gonadotropin releasing hormone 
(GnRH) analogues have been demonstrated to produce significant reduction in the positive 
surgical margin rate, yet they have not shown to affect disease-specific or overall survival and 
are therefore not recommended prior to surgery [14, 15].  
1.7 RADIOTHERAPY 
RT is an alternative curable approach widely used to treat localized and locally advanced PCa 
in patients, in whom surgery is either not suitable or not desired. However, to date, there are 
still no comparative, randomised studies between radiotherapy and surgery as primary 
treatment in prostate cancer. Nevertheless, substantial evidence based on pre-treatment 
prognostic markers such as serum PSA level, Gleason score and T-stage, suggest equivalent 
outcome of RT to radical prostatectomy in low risk prostate cancer [16, 17]. Different 
delivery technique of RT, e.g. external beam radiation therapy (EBRT) or brachytherapy as 
well as different RT-fractionation regimes, e.g. hypofractionation, hyperfractionation, and 
accelerated fractionation are used as single treatment modalities or in combination. Rather 
poor historical results of RT as a single modality in patients with intermediate and high risk 
PCa have led to the use of dose escalation conformal RT methods like three-dimensional 
conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT), 
which has proven to be highly effective in intermediate risk cancer [18]. Nevertheless, Hanks 
et al has shown that RT dose escalation does not improve the 5-years biochemical non-
evidence of disease rate (bNED) for patients with high risk disease [19]. 
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1.8 ENHANCED RADIOSENSITIVITY  
Experimental and randomised clinical trials have shown that PCa patients have longer 
survival after combined castration and RT of the primary tumour than after RT alone [13, 21]. 
Thereby one might conclude that the reduction of androgenic stimuli makes PCa cells more 
sensitive to RT. Animal studies in vivo have shown that castration before radiation decreases 
the number of clonogenic cancer cells and increases the overall cell kill and diminishes 
growth velocity of the surviving PCa cells [22, 23]. Another in vitro study using cell line 
LNCaP (PCa metastatic to lymph nodes) could not demonstrate any increased radiosensitivity 
after removal of androgens from the culture medium [24]. 
Today the most accepted rationale underlying the synergistic effect between castration and 
RT is that the volume reduction and shrinkage of the prostate tumour achieved with 
neoadjuvant castration facilitates the dose escalation of RT with higher dosage applied to the 
prostate without increasing the toxicity on the adjacent organs [25]. Furthermore, the 
neoadjuvant approach is believed to induce apoptosis and reduce tumour hypoxia, which may 
explain improved radiosensitization [26]. 
1.9 COMBINATION OF HORMONAL THERAPY AND RADIOTHERAPY 
Neoadjuvant castration combined with RT is currently the standard of care treatment for a 
patient with a localized and unfavourable tumour. It may in addition to its systemic effect on 
any subclinical distant disease, aim on improving local disease control, disease-specific and 
overall survival. Using gonadotropin-releasing hormone (GnRH) analogues, castration levels 
of serum testosterone will be achieved after approximately four weeks [27], while bilateral 
orchiectomy leads to an almost immediate castration effect. The often-quoted EORTC-study 
[13] showed an advantageous disease-specific and overall survival after neoadjuvant 
castration with RT versus. RT alone. However, in that study, the hormonal therapy with a 
GnRH analogue was started concurrently with RT, which meant that the castration effect was 
not achieved until the second half of RT. Presumably, the effect of combined castration and 
RT is more beneficial, if serum testosterone is on castration level from the start of the RT. 
The optimal duration of androgen deprivation in conjunction with RT is not clear. To date, 
many studies have tried to relate the time of neoadjuvant hormonal therapy to its effect on 
prostate volume [28]. However, other studies have tried to find out a cut-off point for the 
serum prostate specific antigen (PSA) level [29, 30]. A widespread international 
recommendation points out that two months of neoadjuvant castration will be enough before 
the start of RT [31, 32]. The changes in the PSA value indicate the overall metabolic activity 
in PCa cells before, during and after treatment [10]. 
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1.10 ANDROGEN RECEPTOR  
The androgen receptor (AR) plays an important role in the initiation, growth and survival of 
normal prostate tissue. However, AR knockout in ARKO male mice model showed a 
feminized appearance with prostate growth agenesis [33]. It is believed to play an important 
role in the development of resistance to hormonal therapy [34]. Animal models show that 
prostate epithelial cells express AR already in early fetal life, where it has a role in 
morphogenesis of the prostate [35]. The AR is a protein molecule in the cell cytoplasm, to 
which steroid molecules bind as ligands. Such complexes then act as transcription factors in 
the cell nucleus and regulate the genes involved in prostate cell growth and survival. AR is a 
110-kDa protein and a member of the nuclear receptor super family [36] and consists of an 
N-terminal transactivation domain, central DNA binding domain and a C-terminal ligand-
binding/transactivation domain [37, 38]. Epidemiological studies have failed to show any 
relevance between elevated serum levels of testosterone, dihydrotestosterone, or adrenal 
androgen and the risk for PCa [39]. Reduction of serum DHT after castration results in 70 % 
loss of secretary epithelial prostate cells by apoptosis in an adult rat model [40]. In cytoplasm, 
AR is found in an inactive complex bound to heat shock protein HSP 70 and HSP 90 and co-
repressor. DHT binds to AR as a ligand, which lead to homo-dimerization and nuclear 
translocation of AR where it binds to androgen response elements (AREs) of androgen 
responsive genes as a transcription factor [34] (Figure 3). 
 
Figure 3. Basic mechanism of androgen 
receptor (AR). Testosterone (T) or adrenal 
androgens (AA) are converted to DHT in PCa 
cells. Ligand activation induces a 
conformational change and nuclear 
translocation of AR. Within the nucleus, AR 
binds AREs in target genes to regulate their 
transcription and modulate PCa cell behavior. 
Pre-receptor level ADT interferes with AR 
ligand production. Receptor level ADT impedes 
AR-ligand interaction. Post-receptor level ADT 
exploits AR-dependent action downstream of 
AR for therapeutic intervention. Heemers HV. 
Int J Biol Sci. 2014 Jun 1; 10(6): 576-87. doi: 
10.7150/ijbs.8479
 
Androgen ablation either by bilateral orchiectomy or by GnRH analogues results in 90-95% 
reduction of serum testosterone levels with no difference in long term survival between these 
two methods [41, 42]. As shown in clinical and animal studies, the effect of androgen 
ablation on prostate tumours leads to decreased proliferation determined by Ki67, but there is 
no significant effect on the rate of apoptosis [43, 44]. The castration level of serum 
testosterone (< 1.7 ng/ml) is achieved almost immediately after surgical castration and in 
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approximately four weeks after the first injection of a GnRH analogue [27]. Randomised 
clinical trials have shown longer survival of prostates cancer patients after combined 
castration and RT of primary tumour than after RT alone [13, 21, 45]. This clinically 
observed increased radiosensitivity of PCa after androgen ablation has failed to be shown in 
vitro studies using prostate cancer cell lines LNCaP and PC3 [24, 47].  
Castration results in 75-80% decrease of intraprostatic androgens; testosterone and DHT, 
levels in benign prostatic hyperplasia (BPH) patients [48]. However, in castration resistant 
prostate cancer (CRPC) tissue the intraprostatic testosterone remains at a normal level despite 
castration, whereas DHT levels are reduced by 75% [49]. In patients with aggressive cancer 
castration reduces intraprostatic DHT levels less than in patients with more favourable 
disease [50]. The CRPC is a heterogeneous disease but the cancer cells are still dependent 
upon androgen signalling for their survival and growth. In fact, many of patients with CRPC 
remain androgen-dependent and respond to further hormone manipulation such as second-
generation antiandrogens [51].  Together these results demonstrate that serum androgen 
concentration does not directly reflect the high levels of intraprostatic androgens, which 
probably are sufficient to stimulate the growth of aggressive PCa.  
1.11 IONIZING RADIATION AND DNA DAMAGE  
The therapeutic effect of ionizing radiation (IR) in cancer relies on its ability to induce lethal 
DNA damage of tumour cells leading to their death. The tumour responses to IR depend on 
the magnitude of delivered dose as well as on the DNA damage response (DDR) of the 
tumour cells. The IR-induced DNA damages trigger a DDR signalling cascade that 
determines the final fate of each single cell. Successful repair of the DNA lesions will allow 
the cell to survive and continue its cell cycle (Figure 4). However, an unsuccessful DNA 
repair results either in tumour cells leaving the cell cycle, entering senescence or apoptosis, or 
in emerging of DNA mutations, which might lead to drug- or radioresistance.  
IR generates different kinds of DNA damage either due to direct effect on the DNA molecule 
or indirectly by free radicals [52]. It may lead to a variety of DNA lesions including base 
damage, base release, crosslinking and strand breakage [53]. The most lethal DNA lesion is 
the double strand break (DSB), which triggers DDR and repair pathways that are mainly 
dependent non-homologous end joining (D-NHEJ) and homologous recombination (HR) 
(Figure 4). Nevertheless, when none of these repair pathways are active, an alternative 
PARP-mediated repair pathway called backup non-homologous end joining (B-NHEJ) will 
repair DSBs (Figure 6).
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determines the final fate of each single cell. Successful repair of the DNA lesions will allow 
the cell to survive and continue its cell cycle (Figure 4). However, an unsuccessful DNA 
repair results either in tumour cells leaving the cell cycle, entering senescence or apoptosis, or 
in emerging of DNA mutations, which might lead to drug- or radioresistance.  
IR generates different kinds of DNA damage either due to direct effect on the DNA molecule 
or indirectly by free radicals [52]. It may lead to a variety of DNA lesions including base 
damage, base release, crosslinking and strand breakage [53]. The most lethal DNA lesion is 
the double strand break (DSB), which triggers DDR and repair pathways that are mainly 
dependent non-homologous end joining (D-NHEJ) and homologous recombination (HR) 
(Figure 4). Nevertheless, when none of these repair pathways are active, an alternative 
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repair DSBs (Figure 6).
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Figure 4. The two major DSB repair pathways. 
IR-induced DSB leads to activation of DDR 
signalling cascade that leads to activation of the 
error-prone pathway of D-NHEJ in G0/G1 of 
the cell cycle or the error–free pathway of HR 
in S/G2 phase of the cell cycle and the repair of 
DSB. 
 
 
 
1.12 DNA DAMAGE SIGNALLING 
The DNA damage response (DDR) is a complex of protein signalling network that monitors 
the genome integrity during different phases of the cell cycle. Diverse genotoxic insults 
induced by replication stress, various kinds of genotoxic drugs or IR activates the DDR 
machinery, which subsequently activates a plethora of signalling pathways and may lead to 
cell cycle arrest followed by DNA repair, cellular senescence or apoptosis [54]. 
Following DNA damage, two master protein kinases, the ataxia telangiectasia mutated 
(ATM) and the ATM-Rad3-related (ATR) are activated. ATM is mainly activated in response 
to DSBs through all the cell cycle, meanwhile ATR activity is restricted to S/G2 phases and it 
is mostly triggered in response to replication stress [55]. The MRN (Mer11-Rad50-Nbs1) 
complex, which plays a vital role in various DNA repair pathways, including NHEJ and HR, 
act as a DSBs sensor that initiate DDR. MRN complex recognize DNA damage and activates 
ATM and ATR [56]. ATM phosphorylates a number of target proteins including the MRN 
complex, a histone variant H2AX that generates γ-H2AX foci which in turn activates DNA 
damage checkpoint protein 1 (MDC1). Analogously, 53BP1; a key regulator of DSB repair, 
rapidly recruited and makes large foci at the DNA damage sites. The MRN complex together 
with 53BP1 governs whether D-NHEJ or HR repairs a DSB.  During the G1 phase of the cell 
cycle, 53PB1 binds to RAP1-interacting factor1 (Rif1) that block the end-resection of DSB 
and preventing further accumulation of breast cancer susceptibility gene 1(BRCA1) at the site 
of DNA damage, hence promoting NHEJ repair. However, during S/G2 phase of the cell 
cycle and in a cyclin-dependent kinase (CDK)-dependent manner, CtBP-interacting protein 
(CtIP) recruits by Nbs1; part of MRN complex, at the site of DSB. CtIP binds to BRCA1 and 
block Rif1 from further binding to 53BP1, allowing extensive end-resection and 3´overhang 
formation at the site of DSB, thereby promoting HR repair [46, 58, 59] (Figure 5). 
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Figure 5. Cell cycle dependent mutual exclusion of BRCA1 and Rif1 from DSBs. In G1, Rif1 prevents 
the accumulation of BRCA1 at DSBs and acts downstream of 53BP1 to block resection, thereby 
promoting D-NHEJ. In S/G2, phosphorylated CtIP blocks Rif1 from binding to 53BP1, thereby 
allowing resection and promoting HDR. CtIP also plays a part in promoting resection but this attribute 
appears to be independent of its binding to BRCA1. Abbreviations: D-NHEJ, dependent non-
homologous end joining; HDR, homology-directed repair; Cdk2, cyclin dependent kinase 2; CycE,A, 
cyclin E, cyclin A. 
 Zimmermann M et al. Trends Cell Biol. 2014 Feb;24(2):108-17. doi: 10.1016/j.tcb.2013.09.003. 
After DNA damage, activated ATM/ATR lead to activation of cell cycle checkpoints that leads 
to cell cycle arrest and more time for the cell to repair the damage. ATM/ATR phosphorylate 
and activates Chk2 and Chk1, respectively. ATM/Chk2 pathway controls mainly G1/S 
checkpoint and ATR/Chk1 controls G2/M checkpoint [57]. In order to initiate cell cycle arrest, 
Chk2 and Chk1 phosphorylate Cdc25A to be inactivated and degraded. Lack of active Cdc25A 
lead to accumulation of inactive cyclin E-CDK2 complex; a vital regulator proteins promoting 
cell cycle progression from G1 to S phase of the cell cycle, and cell cycle arrest in G1 phase. In 
addition, inactive Cdc25A leads to inactivation of cyclin B-Cdc2; regulator proteins that 
promote the cell cycle progression from G2 to M phase, thus the cell will remain in G2 phase 
until the damage is repaired. Furthermore, to maintain the cell cycle arrest, activated 
ATM/ATR and subsequent activation of Chk2/Chk1 leads to phosphorylation and thus 
stabilization of p53; a tumour suppressor gene and transcriptional activator, which activate 
several target genes including p21. Activated p21; a potent CDK inhibitor that regulate cell 
cycle proliferation and DNA replication, leads to further inhibition of cyclin E-CDK2 / B-Cdc2 
complexes, thereby the cell will continue arrested in G1/S or G2/M phase until the DNA 
damage is sufficiently repaired and the cell re-enter the cell cycle again. Otherwise it will go to 
apoptosis if the damage is remained unrepaired.  
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1.13 NON-HOMOLOGOUS END JOINING  
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) dependent non-homologous end 
joining (D-NHEJ) is the major DNA repair pathway involved in repair of toxic DNA double-
strand breaks (DSBs) after IR [58]. D-NHEJ is operating during all phases of the cell cycle 
however mainly in G0/G1. Since D-NHEJ is directly ligated DSBs without the need for a 
homologous template, it is an error-prone process, which might contribute to intra-
chromosomal deletion and translocation [59]. Misrepaired DSBs lead either to cell death or 
chromosomal deletion, chromosomal translocation and genomic instability. The cornerstone in 
D-NHEJ repair pathway is the Ku heterodimer, which consists of two tightly, associated 
polypeptides of approximately 70 kDa (Ku70) and 80 kDa (Ku80). Ku proteins are the 
regulatory subunits that detect and bind the two ends of DSB, tethering them together and 
recruits DNA-PKcs to form the DNA-PK complex [60, 61]. DNA-PKcs then attracts the ligase 
IV complex (comprised of ligase IV, XRCC4 and XLF), which together seal the DNA ends 
[59]. AR interacts via its ligand-binding domain (LBD) directly with both Ku70 and Ku80 
regulatory subunits of DNA-PKcs in a DNA-independent manner. Ku proteins bind the AR in 
both the cytoplasm and the nucleus and are recruited to the promoter of AR target genes such 
as prostate specific antigen (PSA) promoter in an androgen-dependent manner. A Ku-protein 
defines as a recycle co-activator of AR [62]. Cells deficient in Ku proteins are more sensitive 
to IR [63]. 
1.14 HOMOLOGOUS RECOMBINATION  
Homology directed repair or homologous recombination (HR) is another pathway involved in 
repair of IR-induced DSBs. HR accomplished by using a homologous DNA template (often on 
a sister chromatid or rarely from a homologous chromosome) from which the missing 
sequence is copied. In contrast to D-NHEJ, HR is generally error-free and mainly operating in 
the S and G2 phases of the cell cycle. The initiating step of HR is 5′ to 3′ end resection, 
generating a 3′ ended single-stranded overhang. Resection involves MRN complex activation. 
Replication protein A (RPA) rapidly binds to the ssDNA overhang, preventing the formation 
of secondary structures. Subsequently, RPA is displaced by RAD51 via a breast cancer 
susceptibility gene 2 (BRCA2)–dependent process. RAD51 loading promotes invasion onto 
the undamaged template and strand displacement, generating D-loop formation, which is 
necessary to generate a Holliday junction and a heteroduplex molecule with help of Rad54. 
Repair synthesis uses the undamaged strand as a template, followed by ligation of the DNA 
ends. It is generally believed that there is a second Holliday junction formed. Finally, 
resolution of the Holliday junctions completes the process, giving crossover or non–crossover 
products, depending on the direction of resolution. 
Since D-NHEJ does not require homologous template, it is a faster repair process compared to 
HR and hence predominates repair of IR-induced DSBs [59]. 
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1.15 PARP1 AND DNA DAMAGE RESPONSE  
Poly (ADP-ribose) polymerases-1 (PARP1) is the most important member of PARPs protein 
family that is involved in cellular stress responses such as inflammatory, metabolic or 
genotoxic stress including DNA repair. PARPs proteins composed of different ADP-ribosyl 
transferase enzyme that regulate the synthesis of Poly (ADP-ribose) (PAR); a branching 
polymer chain of several hundred ADP-ribose units, via process called Poly (ADP-
ribosyl)ation (PARylation) [64, 65]. PARP1 can be triggered by several forms of DNA 
damages and consequently catalyses the PARylation of different target proteins, including 
itself, that involves in a wide range of cellular response, such as chromatin remodelling, 
transcriptional regulation, DNA repair, cell cycle arrest, cell senescence or cell death [20, 66]. 
Alternative or backup non-homologous end joining (B-NHEJ) is PARP1-dependent DNA 
repair of DSBs, activates in D-NHEJ deficient cells [67] (Figure 6). PARP-1 is effectively 
competing with Ku-heterodimer for DNA end-binding and repair of DSBs, however the higher 
bindings affinity of Ku70 to damaged DNA ends inhibit its recruitment and subsequent 
PARylation. B-NHEJ, like D-NHEJ, is an error-prone process and it is active throughout the 
cell cycle, however mainly during S and G2. PARP-1 is mainly involved in base excision and 
single strand break (SSB) repair of DNA [68]. Compelling evidence suggest its dual action in 
HR repair and showed that PARP-1 senses and binds to the stalled replication forks and 
promoting recruitment of MRN complex in HR-dependent repair process [69]. Failing HR 
repair caused by defective BRCA1/BRCA2, during S/G2 of the cell cycle, leads to 
predominance activation of backup DNA repair machinery mediated by PARP-1 [70] (Figure 
6). Currently, taking the advantage of synthetic lethality, which is defined as independent loss 
of function one of two compatible genes will not affect cell survival, whereas simultaneous 
loss of function of these two genes is lethal [71]. This fact provides PARP inhibitor a key role 
as a target cancer therapy in patients with BRCA1/BRCA2 defected tumours.  
 
 
 
11 
1.15 PARP1 AND DNA DAMAGE RESPONSE  
Poly (ADP-ribose) polymerases-1 (PARP1) is the most important member of PARPs protein 
family that is involved in cellular stress responses such as inflammatory, metabolic or 
genotoxic stress including DNA repair. PARPs proteins composed of different ADP-ribosyl 
transferase enzyme that regulate the synthesis of Poly (ADP-ribose) (PAR); a branching 
polymer chain of several hundred ADP-ribose units, via process called Poly (ADP-
ribosyl)ation (PARylation) [64, 65]. PARP1 can be triggered by several forms of DNA 
damages and consequently catalyses the PARylation of different target proteins, including 
itself, that involves in a wide range of cellular response, such as chromatin remodelling, 
transcriptional regulation, DNA repair, cell cycle arrest, cell senescence or cell death [20, 66]. 
Alternative or backup non-homologous end joining (B-NHEJ) is PARP1-dependent DNA 
repair of DSBs, activates in D-NHEJ deficient cells [67] (Figure 6). PARP-1 is effectively 
competing with Ku-heterodimer for DNA end-binding and repair of DSBs, however the higher 
bindings affinity of Ku70 to damaged DNA ends inhibit its recruitment and subsequent 
PARylation. B-NHEJ, like D-NHEJ, is an error-prone process and it is active throughout the 
cell cycle, however mainly during S and G2. PARP-1 is mainly involved in base excision and 
single strand break (SSB) repair of DNA [68]. Compelling evidence suggest its dual action in 
HR repair and showed that PARP-1 senses and binds to the stalled replication forks and 
promoting recruitment of MRN complex in HR-dependent repair process [69]. Failing HR 
repair caused by defective BRCA1/BRCA2, during S/G2 of the cell cycle, leads to 
predominance activation of backup DNA repair machinery mediated by PARP-1 [70] (Figure 
6). Currently, taking the advantage of synthetic lethality, which is defined as independent loss 
of function one of two compatible genes will not affect cell survival, whereas simultaneous 
loss of function of these two genes is lethal [71]. This fact provides PARP inhibitor a key role 
as a target cancer therapy in patients with BRCA1/BRCA2 defected tumours.  
 
 
 12 
 
 
Figure 6. DNA damages are repaired by AR-dependent D-NHEJ and homologous 
recombination repair pathways. However in the absence of AR, PARP is activated as a backup 
pathway to mediate survival. 
1.16 HYPOXIC MICROENVIRONMENT IN SOLID TUMOURS  
It is well established that solid tumours, such as PCa, are characterized by hypoxic 
microenvironment, which promotes resistance to IR-induced DNA damage. 
Hypoxia-inducible factor-1 alpha (HIF-1α) is an essential transcription factor that activates 
transcription of genes involved in angiogenesis, cell survival, glucose metabolism and tumour 
invasion. HIF-1α level is affected by several genetic, epigenetic and environmental elements. 
Microenvironment and intra-tumoural hypoxia generates reactive oxygen species (ROS) by 
mitochondria, which lead to stabilization and upregulation of HIF-1α and subsequent vascular 
endothelial growth factor (VEGF) production [72, 73]. Clinical data show high levels of HIF-
1α in primary and metastatic PCa as compared to benign prostate tissue [74]. Studies in the 
Transgenic Adenocarcinoma Mouse Prostate (TRAMP) transgenic model of PCa support the 
correlative clinical observations and HIF-1α is associated with the angiogenic switch in early 
PCa progression [75].  
In vitro studies on androgen positive LNCaP cells have shown that DHT stimulates HIF-1α 
transcription activity, leading to a high level of HIF-1α protein and VEGF, while an anti-
androgen agent (flutamide) leads to the converse effect [76]. AR regulates expression of HIF-
1α and VEGF in androgen sensitive tumours [77], through androgen-regulated autocrine 
receptor tyrosine kinase receptor signalling [76]. 
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2 AIMS OF THE STUDIES 
The overall purpose of this thesis is to explore the mechanism behind the synergistic effect of 
neoadjuvant castration on radiotherapy. We investigate 
1: If castration reduces the expression of HIF-1α levels, as a measure of hypoxia, in prostate 
tumour cells, thereby enhancing radiosensitivity. 
2: If castration downregulates expression of the Ku70 protein in PCa cells leading to 
defective DNA repair. 
3: If androgen deprivation therapy (ADT) reduces the expression of HR repair and activates 
PARP signalling. If so, ADT is synthetically lethal with PARP inhibitors.  
4:  If combination of castration and RT provides superior suppression of D-NHEJ mediated 
DNA repair compared with RT alone. 
5: The heterogeneous landscape of AR in hormone-naïve PCa.  
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3 PATIENTS AND METHODS 
3.1 PAPER I & PAPER II 
Ethical approval was granted from regional ethics committee at Uppsala University (Dnr 
2007/170). We enrolled 20 patients with locally advanced and metastasized PCa. All patients 
were treated with castration. Surgical castrations with bilateral orchidectomy were performed 
in eight patients and pharmacological castration with leuprorelin, a GnRH analogue, was 
performed in twelve patients. Several needle core biopsy specimens were obtained from each 
patient at diagnosis and after castration, approximately one month after surgical castration or 
two months after pharmacological castration (see Flowchart 1). 
 
Flowchart 1. Flowchart of patients enrolled in papers I & II. After enrolment, all patients treated with 
castration. Needle core biopsy specimens were obtained before and after treatment.   
All biopsies were paraffin embedded and sectioned. First section from each biopsy was 
haematoxylin and eosin (HE) stained and examined for identification of cancer areas that has 
been graded according to the Gleason grading system. Before and after castration two biopsy 
specimens rich in cancer cells, were analysed with immunofluorescence staining in each 
patient. Since six patients were excluded from the study because their post-castration biopsy 
specimens were free from cancer, fourteen patients were included. The base-line 
characteristics are summarized in Table 1. 
Table 1. Base-line characteristics of the patients in Paper I & Paper II 
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Abbreviations: cT, clinical tumor stadium; GS, Gleason score; ND, not done. 
Al-Ubaidi FL et al. Clin Cancer Res. 2013 Mar 15; 19(6): 1547-56. doi: 10.1158/1078-0432.CCR-12-
2795. 
3.2 PAPER III  
For comprehensive details, see supplementary information in Paper III. 
3.2.1 Cell culture 
LNCaP, PC3, PNT1a, DUCaP are different prostate cell models used for diverse analyses in 
the study. We generated and cultured C4-2-NT control (expressing non-targeting RNA; 
siNT) and C4-2-shAR cells achieved by the doxycycline-mediated induction of a short-
hairpin RNA targeting the AR. To investigate the role of AR expression on cell growth under 
genotoxic stress, we employed an isogenic inducible AR mutant (T877A) expressed in the 
PC3 cell line in which doxycycline treatment triggered AR expression. 
3.2.2 Cell viability assay  
Cell viability was determined by incubating the culture with MTS reagent based (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
colorimetric assay as per manufacturers protocol (Promega). Using a Vicell instrument, cells 
were trypsinised and counted. Cell growth assay was carried out in 96 well plates.  
3.2.3 Clonogenic assay 
The clonogenic potential of PCa cell lines after different treatments were evaluated by 
colony formation assays using colony analyser from Oxford Optronix.  
3.2.4 Live cell imaging/confluence analyses  
Using the IncuCyte instrument from Essen Bioscience, confluence analyses were performed.  
Live cell images were recorded every three hours. However, for ease of understanding only 
12 hours time interval data are shown. 
3.2.5 Ex vivo prostate explant culture 
After informed consent according to the institutional policy, patients with locally advanced, 
hormone-naïve PCa and median PSA levels of 82 ng/ml were enrolled. Needle core biopsy 
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Abbreviations: cT, clinical tumor stadium; GS, Gleason score; ND, not done. 
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2795. 
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3.2.6 Generation of tumour xenografts 
PC3/PC3-AR and C4-2 xenografts experiments were performed in compliance with the 
Home office directive of Animal (scientific procedures) act, under a project and personal 
license. Tumour size was measured weekly with callipers. The mice were culled at the 
completion of the experiment or when the tumours had reached 10% of body weight.  
3.2.7 Patients and leuprorelin (GnRH analogue) study design 
Ethical approval was granted from regional ethics committee at Uppsala University (Dnr 
2011/066). For details information, see patients and methods in Paper IV &V or in 
supplementary information Paper III. 
3.2.8 Degarelix study design 
Full ethical approval was obtained (11/H0311/2) for clinical studies NCT01852864 and 
NCT00967889. 15 patients with high risk organ confined PCa were treated with degarelix, a 
GnRH antagonist, seven days before surgery. Fresh PCa tissue samples were obtained at 
radical prostatectomy and were snap frozen. Degarelix treated patients achieved castration 
levels of serum testosterone. These samples were compared with matched controlled samples 
from 19 untreated patients. They were spotted on microscopic slides to generate tissue 
microarray. 
3.3 PAPER IV  
Ethical approval was granted from regional ethics committee at Uppsala University (Dnr 
2011/066). Fifty-two patients with newly diagnosed, localized or locally advanced, non-
metastasized PCa were recruited for the study. All patients had high risk cancers and were 
thereby eligible for combined neoadjuvant castration with RT. The patients were allocated to 
one of the two study arms following the assignment of a written informed consent by each 
patient. Three patients in arm 1 and one patient in arm 2 were excluded from the study since 
they refused further subsequent biopsies during the study. Thus 48 patients were eligible for 
the final analysis, 25 in arm 1 and 23 patients in arm 2. Their base-line characteristics are 
summarized in Table 2. 
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Table 2. Base-line characteristics of the patients in Paper IV  
 
Patients in arm 1 received neoadjuvant pharmacological castration, leuprorelin followed by 
external beam RT, 2 Gy fractions daily to a total dose of 78 Gy. Patients in arm 2 started 
treatment with external beam RT, 2 Gy fractions daily for five consecutive days, followed by 
neoadjuvant pharmacological castration, and after that an equivalently higher dose RT to a 
total of 82 Gy. The first prostate needle-core biopsy setting was obtained from all patients at 
diagnosis. In arm 1, a second biopsy setting was obtained eight weeks after the leuprorelin 
injection and a third biopsy setting obtained about three hours after the fifth RT fraction. In 
arm 2, a second biopsy setting were obtained about three hours after the fifth RT fraction and 
a third biopsy setting was obtained eight weeks after the leuprorelin injection (see Flowchart 
2).  
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Flowchart 2. Flowchart of patients enrolled in the paper IV & V. Patients received castration treatment 
by GnRH-agonist for 8 weeks. 2 Gy x5 radiotherapy (RT) treatments were given on consecutive days 
and biopsies taken 3 hours after the fifth dose RT 
3.4 PAPER V: 
From the same cohort of patients in paper IV, we investigated 5 patients (4 from arm 1 and 
one patient from arm 2) (see Flowchart 2). Their base-line characteristics are summarized in 
Table 3. 
Table 3. Patients and tumour characteristics 
 
Abbreviations: cT, clinical tumour stadium; GG, Gleason grade; GS, Gleason score; AR, androgen 
receptor; AU, arbitrary unit. 
3.4.1 Histological and immunofluorescence evaluation 
We embedded all prostatic needle biopsy specimens in paraffin before they were sectioned 
and stained with haematoxylin and eosin (HE).  A pathologist examined all specimens, 
identified the cancer areas in each specimen and scored those areas according to the Gleason 
system [78]. From all patients and from every biopsy setting, two cancer-rich biopsy 
specimens were selected and sectioned for immunofluorescence analysis. These sections 
were deparaffinised and rehydrated for antigen retrieval with Tris/EDTA (paper I and II) and 
buffer A (paper III-V), pH 9 in a pressure cooker. After blocking with 2% BSA, the sections 
were incubated with different primary antibodies at 40C overnight. Extensive rinsing was 
performed once; the sections were incubated with the secondary antibodies (donkey anti 
mouse IgG-alexa 488 (1:500), Molecular probe and donkey anti rabbit IgG-alexa 555 
(1:500), Molecular probe) for one hour at room temperature. DNA was counterstained with 
TO-PRO-3 iodide (Molecular probe) and slides mounted with ProLong Gold (Molecular 
probe). 
In Paper I, the chosen biopsy sections where immunofluorescence stained with HIF-1α 
antibody. 
In Paper II, the chosen biopsy sections where immunofluorescence stained with Ku70 and 
γ-H2AX antibodies. 
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In Paper III, the chosen biopsy sections where immunofluorescence stained simultaneously 
with PARP-1 and PAR antibodies. 
In Paper IV, the chosen biopsy sections where immunofluorescence stained simultaneously 
with two antibodies on the same slide; AR together with Ku-70, 53BP1 together with γ-
H2AX, while phosphorylated DNA-PKcs and finally Ki67 where stained alone.  
In paper V, the chosen biopsy sections where immunofluorescence stained simultaneously 
with AR together with Ku-70 and phosphorylated DNA-PKcs together with PAR.  
Images from a tumour area with a good degree of immunofluorescence signals were selected 
from each biopsy. The corresponding areas in the HE-stained section were identified for 
histological verification of the tumour area. 
In papers I and II, three images 100 × 100 μm, containing approximately 50 to 150 cells, 
were chosen for analysis. 
In papers III and IV two images from each slide containing 300-600 cells were chosen for 
analysis.  
In paper V the whole slides were analysed. ToPro (Molecular probe) was used as a DNA 
marker. Slides were mounted with prolong gold (Molecular probe). 
All images were analysed, with respect to medium intensity inside the nuclei and in the 
cytoplasm. The nuclear area was defined by the ToPro signal and the cytoplasmic area as a 5 
µm extension outside the nuclear area. For proteins with exclusive nuclear localisation 
(53BP1 and phosphorylated DNA-PKcs), the cytoplasmic intensity was subtracted as 
background activity.  For other proteins, with both nuclear and cytoplasmic localisation 
(Ku70, AR and PARP-1), intensity values are presented without background subtraction. The 
number of Ki67 positive cells was counted with a threshold for Ki67 intensity in the nucleus 
in order to distinguish positive from negative cells. For markers forming foci the number and 
area of foci per DNA unit were measured. All measurements were performed using in house-
written programme for NIH-imageJ [79]. 
Fluorescence images were obtained with either a Zeiss LSM 510-inverted confocal 
microscope or a Zeiss LSM 780-inverted confocal microscope, using a planapochromat 
40X/NA 1.2 objective. Through-focus maximum projection images were acquired from 
optical sections 0.5 μm apart and with a section thickness of 1.0 μm. HE-stained images were 
obtained with a Leica scan system (Figure 7). 
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Figure 7. A whole needle biopsy is shown at the left panel. Each of the consecutive panels shows a 
magnification of the square plotted in the panel on its left.  The biopsy is stained for DNA (blue), KU 
70 (green) and Androgen receptor (red). 
3.4.2 Coimmunoprecipitation of AR with Ku70 (Paper II): 
The disintegrated frozen prostate tissue biopsies were incubated with lysis buffer (10 mM 
HEPES pH 7.5, 300 mM NaCl, 0.2 mM EDTA, 10 mM DTT, 20% glycerol, 0.1% Triton X-
100, protease inhibitors) and after centrifugation the supernatant was incubated with anti-
Ku70 Ab and Protein A/G-agarose beads. The proteins eluted from beads were separated by 
SDS-PAGE, blotted onto nitrocellulose membrane and probed with the anti-human AR Ab 
(Dako, M356201-2), anti-Ku70 Ab (sc-12729) and anti-actin Ab (sc-1616) followed by 
incubation with HRP-conjugated secondary antibody and protein bands were visualized 
using SuperSignal West Femto chemiluminescence substrate (Thermo Scientific). 
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4 STATISTICAL ANALYSIS 
Paper I: Data in the bar graphs are shown as the mean ± SEM (standard error of mean). 
Non-parametric Wilcoxon matched pair’s tests and 2-tailed student´s t-test were applied. 
Statistical significance is expressed as follows: *P < 0.05, **P < 0.01, ***P < 0.001. 
Paper II: Data in the bar graphs are shown as the mean ± SEM and 2-tailed student´s t-test 
was applied. Correlation was measured using Spearman rank correlation coefficient. 
Statistical significance is expressed as follows: *P < 0.05, **P < 0.01, ***P < 0.001.  
Paper III: 2-tailed Student's t-test was used in all statistical analyses. In ex vivo culture and 
xenograft experiments used Mann-Whitney U test.  Data in the bar graphs are shown as the 
mean ± SEM., and statistical significance is expressed as follows: *P < 0.05, **P < 0.005, 
***P < 0.0005. 
Paper IV: Non-parametric test methods were applied. Related outcomes after different 
treatments within each arm were compared using the Wilcoxon Signed Ranks Test. 
Unrelated outcomes between the two arms were compared using the Mann-Whitney U Test. 
Correlation analysis was conducted using Spearman´s rho rank correlation test (ρ). All 
statistical tests were two-tailed with significance established at p <0.05.  Statistical analysis 
was performed using the Statistical Package for the Social Sciences (SPSS), version 21.0. *P 
< 0.05, **P < 0.01, ***P < 0.001. 
Paper V: Correlation analysis was conducted using Spearman´s rho rank correlation test (ρ). 
All statistical tests were two-tailed with significance established at p <0.05.  Statistical 
analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 
21.0. *P < 0.05, **P < 0.01, ***P < 0.001. 
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5 RESULTS 
5.1 PAPER I:  
5.1.1 Castration reduces the levels of HIF-1α protein 
Divergent levels of HIF-1α were observed among patients enrolled in this study. The HIF-1α 
levels varied from strong expression (mean intensity > 30) in five patients, week expression 
(mean intensity 10-30) in three patients, to background expression (mean intensity 0-10) in 
six patients. Castration reduced HIF-1α levels predominantly in patients who initially had a 
strong expression. However, in patients with initially background levels the HIF-1α were 
unaffected. Furthermore, the reduction in the level of the HIF-1α after castration was only 
correlated to initial levels of HIF-1α before castration. We observed no correlation between 
reduction in the level of HIF-1α and other parameters investigated like initial serum PSA and 
testosterone levels before castration or their levels after castration, age, Gleason grade, or 
days between biopsies (Figure 8). 
 
Figure 8. HIF-1α is up-regulated in a fraction of prostate tumors. Quantification of HIF-1α immunofluorescent 
staining intensity in prostate tumor biopsy specimens before (white bars) and after (black bars) castration. 
Upregulation of HIF-1α was classified as strong, weak, or at background level. (A) Patients pooled after HIF-1α 
classification. The means and standard errors of indicated number of patients are shown. Values marked with 
asterisks are statistically significant (p < 0.001; t test). (B) Individual patients are depicted. The means and 
standard errors of six images from two different biopsy specimens are shown (s = significant, p < 0.05; ns = not 
significant, p > 0.05; t test). (C) HIF-1α levels in prostate tumors decrease after castration. Prostate tumor biopsy 
specimens from prostate cancer patients before castration (left) and after surgical castration (right). Above, 
common hematoxylin and eosin staining. Below, immunofluorescent staining with antibodies against HIF-1α. 
Middle, HIF-1α expression (red) superimposed on ToPro-staining (DNA, blue). Bar = 100 μm. Al-Ubaidi FL et 
al. Int J Radiat Biol Phys. 2012 Mar 1;82(3):1243-8. doi: 10.1016/j.ijrobp.2011.10.038. 
 
 
 
 
 
22 
5 RESULTS 
5.1 PAPER I:  
5.1.1 Castration reduces the levels of HIF-1α protein 
Divergent levels of HIF-1α were observed among patients enrolled in this study. The HIF-1α 
levels varied from strong expression (mean intensity > 30) in five patients, week expression 
(mean intensity 10-30) in three patients, to background expression (mean intensity 0-10) in 
six patients. Castration reduced HIF-1α levels predominantly in patients who initially had a 
strong expression. However, in patients with initially background levels the HIF-1α were 
unaffected. Furthermore, the reduction in the level of the HIF-1α after castration was only 
correlated to initial levels of HIF-1α before castration. We observed no correlation between 
reduction in the level of HIF-1α and other parameters investigated like initial serum PSA and 
testosterone levels before castration or their levels after castration, age, Gleason grade, or 
days between biopsies (Figure 8). 
 
Figure 8. HIF-1α is up-regulated in a fraction of prostate tumors. Quantification of HIF-1α immunofluorescent 
staining intensity in prostate tumor biopsy specimens before (white bars) and after (black bars) castration. 
Upregulation of HIF-1α was classified as strong, weak, or at background level. (A) Patients pooled after HIF-1α 
classification. The means and standard errors of indicated number of patients are shown. Values marked with 
asterisks are statistically significant (p < 0.001; t test). (B) Individual patients are depicted. The means and 
standard errors of six images from two different biopsy specimens are shown (s = significant, p < 0.05; ns = not 
significant, p > 0.05; t test). (C) HIF-1α levels in prostate tumors decrease after castration. Prostate tumor biopsy 
specimens from prostate cancer patients before castration (left) and after surgical castration (right). Above, 
common hematoxylin and eosin staining. Below, immunofluorescent staining with antibodies against HIF-1α. 
Middle, HIF-1α expression (red) superimposed on ToPro-staining (DNA, blue). Bar = 100 μm. Al-Ubaidi FL et 
al. Int J Radiat Biol Phys. 2012 Mar 1;82(3):1243-8. doi: 10.1016/j.ijrobp.2011.10.038. 
 
 
 
 
 23 
5.2 PAPER II:  
5.2.1 Ku70 interacts with the androgen receptor and is reduced by castration 
We showed that the AR and Ku70 proteins bind and interact with each other directly in 
prostate tissue both under normal circumstances and after castration and this interaction was 
not influenced by castration (Figure 1, Paper II).  In paired slides, immunofluorescence 
staining of Ku70 in cancer areas before and after castration demonstrates a higher intensity of 
Ku70 proteins inside nuclei than in cytoplasm (Figure 9). However, the variation in these two 
fractions before castration was well correlated for each patient (R2 = 0.817, P < 0.0001). 
Despite the observed large individual variations in Ku70 expression both in nucleic and 
cytoplasmic fractions before castration, a decrease in the Ku70 level was seen in both 
fractions after castration in almost all patients (p=0,001, p=0,006). Furthermore, the 
reduction of Ku70 levels after castration was significantly correlated to initial Ku70 levels 
before castration both in nucleic and cytoplasmic fractions (R2 = 0.811 and R2 = 0.944 
respectively, P ≤ 0.0001 for both). Despite of castration method, there was a significant 
correlation between the decrease in Ku70 levels and the decrease in serum PSA levels after 
castration ((chemical nuclear R2 = 0.91, P = 0.003, cytoplasmic R2 = 0.77, P = 0.023 and 
surgical nuclear R2 = 0.73, P = 0.018, cytoplasmic R2 = 0.84, P = 0.005). Nevertheless, there 
was no such correlation between the decrease in Ku70 and the decrease in serum testosterone 
levels after castration (chemical nuclear R2 = 0.014, P = 0.96, cytoplasmic R2 = 0.002, P = 
0.70 and surgical nuclear R2 = 0.002, P = 0.96, cytoplasmic R2 = 0.11, P = 0.62). An insight 
analysis of Ku70 and PSA kinetics revealed significant correlation between the decrease in 
Ku70 and serum PSA levels and the interval between first and second biopsies only among 
patients treated with surgical castration (R2 = 0.77, P = 0.02 and R2 = 0.84, P = 0.019 
respectively). However, despite of castration method, no such correlation was observed 
between the decreased serum testosterone levels and the interval between first and second 
biopsies.  
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Figure 9. Determination of Ku70 in prostate tumours. A, top left, an immunehistofluorescence-stained 
section of a prostate biopsy before castration. The 3 squares outlined in the middle of the image mark the 
area chosen for intensity measurement. Ku70 is stained with a mouse-monoclonal antibody (green) and 
the DNA is costained with TO-PRO-3 (blue). Top right, a corresponding area from an adjacent section 
stained with hematoxylin and eosin. The 3 panels below are close-ups of the 3 areas depicted for 
intensity measurements. B, as in A, but the biopsy is taken after castration, but from the same patient. C, 
effect of castration on Ku70 in prostate tumours. Mean intensity of Ku70 in nuclei before (white bars) 
and after (black bars) castration. Error bars show SEM. ***, P < 0.001, Student t test. Al-Ubaidi FL et al. 
Clin Cancer Res. 2013 Mar 15; 19(6): 1547-56. doi: 10.1158/1078-0432.CCR-12-2795. 
 
5.2.2 Ku70 reduction after castration correlates with an increase of γ-H2AX 
foci 
Furthermore, to assess the repair kinetics, γ-H2AX staining was carried out and found a 
positive correlation between reduced Ku70 level and the increased expression of γ-H2AX 
foci after castration (R2 = 0.37, P = 0.022) (Figure 6E, paper II).  
There were large individual variations in the initial Ku70 levels in both the nuclei and the 
cytoplasm. However, neither nuclear nor cytoplasmic fractions of initial Ku70 showed any 
significant correlation between Ku70 and prostate size, serum PSA, serum testosterone, 
Gleason score, or patient age. 
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5.3 PAPER III  
5.3.1 Androgen Receptor promotes Homologous Recombination Repair  
Since HR has a major role in IR-induced DSB repair in the late S/G2 phase of the cell cycle, 
we wanted to investigate whether there is a functional link between AR signalling and HR 
and whether castration downregulates expression of HR signalling in PCa.  
We observed that AR signalling mediates the expression of many key mediators of HR in 
LNCaP prostate cancer cell line (Figures 1A, paper III). To investigate the AR regulatory 
role of HR, DR-GFP was performed and AR knockdown cells showed 40% reduction of HR 
activity (Figure 1C, paper III). Furthermore, using CRPC model cell line C4-2 with “high 
AR” and “low AR” levels, we showed that AR promotes IR-induced Rad51 foci, hence 
further support the functional link between AR and HR (Figures 1B, paper III).  
To test the effect of androgen signalling on the DDR, in vivo study observed that the levels 
of γ-H2AX foci, a marker involved in early DDR, were reduced in PCa specimens after 
castration (Supplementary Figure 1E, paper III). Furthermore, in vitro study observed that 
AR promotes IR-induced γ-H2AX foci in C4-2 “high AR”, whereas siRNA depletion of 
ATM in “high AR” cells bring down the γ-H2AX intensity to “low AR” levels 
(Supplementary Figure 1F, paper III). Moreover, reduced the expression of AR and ATM 
synergistically repress the growth kinetics of C4-2 cells following IR. There were no 
differences in growth kinetics in PC3-EV cells or PC3-AR cells prior to IR irrespective to 
AR status. IR repressed the growth response in PC3-AR cells, which expressed low AR (AR 
null) as compared with cells expressing high AR (AR full). However, those differences were 
abrogated upon ATM inhibition suggesting that AR regulates DDR via ATM signalling 
(Supplementary Figure 1G, paper III). The expression of MRE11, an integral component of 
the MRN complex that is involved in early activation ATM signalling, was reduced in AR 
knockdown cell lines (Supplementary Figure 1I & 1J, paper III). Furthermore, hydroxyurea-
induced replication stress leads to increased MRE11 foci expression in C4-2 ”high AR” cells 
compared to “low AR” cells, though this gained difference was lost by MRE11 inhibition 
(Figure 1E, paper III). Studies on LNCaP cell lines showed that inhibition of AR, ATM or 
MRE11 reduced activation of ATM downstream targets such as KAP-1 or p53 (unpublished 
data). Overall these experiments demonstrate that AR regulates HR signalling throughout a 
direct regulation of MRE11 expression, which consequently stimulates activation of ATM 
signalling and thereby HR essential protein Rad51.  
5.3.2 Castration activates PARP in prostate cancer  
Previously it has been shown that PARP1 activity is increased in HR defective cells and that 
sensitivity to PARP inhibitors is related to PARP activation [80]. Since ADT perturb HR 
repair, we hypothesized that PARP activity is increased following castration. To test that in 
vivo, we set up a prospective study with 48 patients. Immunofluorescence signalling levels 
of PARP-1 and its substrate PAR were quantified in cancer areas in corresponding paired 
slides (Figure 2A, paper III). To measure the activity of the PARP-1 enzyme, we calculated 
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the ratio of PAR and PARP-1 intensity in the nuclei. In castrated patients, we found a 
significant increase in PARP1 activity as reflected in increased PARylation (p=0.003) (Figure 
2A and 2B, paper III) suggesting that PARP1 is activated as a result of androgen repression 
further strengthening our findings that AR regulates HR in Prostate cancer. 
5.3.3 Androgen deprivation therapy is synthetically lethal with PARP 
inhibition in prostate cancer 
It is well-established that PARP inhibitor can have a synthetic lethal effect in tumours with 
defective BRCA1/BRCA2, which are essential for efficient HR repair [81, 82]. Since we 
previously showed that castration leads to downregulation of HR activity, and since we 
observed high PARP activity in patients (Figure 2A, paper III) and in different PCa cell lines 
(Supplementary Figure 2B, paper III), we hypothesized that ADT combined with PARP 
inhibitor is synthetically lethal.  
We showed that the combination of anti-androgens and PARP inhibitor repressed cell 
viability and growth kinetics in CRPC model cell lines indicating synthetic lethality (Figure 
3A, 3C & Supplementary Figure 3B, paper III). Comparable repressions of cell viability and 
growth kinetics were observed when AR knockdown combined with PARP inhibitor (Figure 
3D, Supplementary Figure 3D & 3E, paper III). However, AR expression in PC3-AR cells, a 
cell model transfected with AR mutant (T877A), abrogate the growth repression induced by 
PARP inhibitor. To evaluate the long-term effect of combined ADT and PARP inhibitor, the 
clonogenic potential of cells were assessed. Significant repression of the clonogenic potential 
of androgen sensitive DuCaP cells were observed not only as expected after anti-androgens 
or PARP inhibitor when given as a single treatment but even more significantly after 
combined treatment. Moreover, anti-androgens alone did not change the clonogenic potential 
of CRPC model LN3 cells, while combined treatment with PARP inhibitors sensitize these 
cells and repress the clonogenic potential. Using xenograft models of C4-2 and PC3 cells, we 
showed that the combined treatment of anti-androgens and PARP inhibitors reduces tumour 
size and weight (Figure 4A, 4B, 4C, paper III) without any adverse effect on the mice weight 
(Supplementary Figure 4B, paper III). In summary, these experiments support our hypothesis 
of contextual synthetic lethality between ADT and PARP inhibitors in cell line models and 
AR expression opposes growth repression by PARP inhibitor.  
5.4 PAPER IV  
5.4.1 Castration combined with RT increases the level of DNA damage in 
prostate cancer  
Ki67, a proliferative marker, was used to evaluate in what way castration and/or RT would 
affect cycling PCa cells. Interestingly, the overall Ki67 cell numbers were about 7% in both 
arms prior to castration and RT (Supplementary Figure 2, paper IV). Castration treatment 
resulted in a drop to about 1.5% Ki67 positive cells in both Arms and 5 days RT treatment 
resulted in a dramatic reduction of Ki67 levels in both Arms to about 0.5%. These results 
suggest that the prostate cancer cells had exited from the cell cycle and entered into cell cycle 
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arrest, i.e. G0, following both castration and RT and hence only relying on NHEJ for repair of 
RT-induced DSBs. 
To assess the degree of DNA damage after castration and/or RT, γ-H2AX and 53BP1, DSBs 
markers, were used. In arm 1, following castration, observed non-significant changes in the 
number of nuclear γ-H2AX foci or 53BP1 foci (p=0.8, p=0.7). However, a significant 
increase in nuclear γ-H2AX foci or 53BP1 foci number following combined castration and 
RT (p<0.001 for both). In arm 2 we observed a significant increase in nuclear γ-H2AX foci 
or 53BP1 foci number following RT (p<0.001). Furthermore, we observed that subsequent 
RT to neoadjuvant castration induced significantly more γ-H2AX foci than those induced 
after RT alone. We conclude that combined castration and RT were more genotoxic than RT 
alone (Figure 10) 
 
Figure 10. Determination of nuclear γH2AX and 53BP1 levels in prostate cancer tissue before 
treatment (Base) and after different treatment modalities in Arm 1 and Arm 2. A) Different sections 
of prostate biopsies are shown and each biopsy is sectioned and stained. The first section was stained 
with haematoxylin and eosin staining for identifying cancer areas. A further corresponding adjacent 
section obtained from the same biopsy was stained with immunofluorescence staining with γH2AX 
 
27 
arrest, i.e. G0, following both castration and RT and hence only relying on NHEJ for repair of 
RT-induced DSBs. 
To assess the degree of DNA damage after castration and/or RT, γ-H2AX and 53BP1, DSBs 
markers, were used. In arm 1, following castration, observed non-significant changes in the 
number of nuclear γ-H2AX foci or 53BP1 foci (p=0.8, p=0.7). However, a significant 
increase in nuclear γ-H2AX foci or 53BP1 foci number following combined castration and 
RT (p<0.001 for both). In arm 2 we observed a significant increase in nuclear γ-H2AX foci 
or 53BP1 foci number following RT (p<0.001). Furthermore, we observed that subsequent 
RT to neoadjuvant castration induced significantly more γ-H2AX foci than those induced 
after RT alone. We conclude that combined castration and RT were more genotoxic than RT 
alone (Figure 10) 
 
Figure 10. Determination of nuclear γH2AX and 53BP1 levels in prostate cancer tissue before 
treatment (Base) and after different treatment modalities in Arm 1 and Arm 2. A) Different sections 
of prostate biopsies are shown and each biopsy is sectioned and stained. The first section was stained 
with haematoxylin and eosin staining for identifying cancer areas. A further corresponding adjacent 
section obtained from the same biopsy was stained with immunofluorescence staining with γH2AX 
 28 
mouse-monoclonal antibody (green) and 53BP1 rabbit-polyclonal antibody (red). The DNA was co-
stained with TO-PRO-3 (blue). Upper sections were from a patient in Arm 1; the upper panel was 
before treatment (base), middle panel was after castration and lower panel was after castration and 
RT. Lower sections were from a patient in Arm 2; the upper panel was before treatment (base), 
middle panel was after RT and lower panel was after RT and castration.  
B) A close up selected section from previous patients in Arm 1 after castration and RT and Arm 2 
after RT (merge γH2AX and 53BP1with DNA). C) Normalised percentage of number of γH2AX foci 
(green bars) and 53BP1 foci (red bars) in nuclei before treatment (base) and after different modalities 
of treatment in Arm 1 and Arm 2 for all patients. Error bars show standard error of mean. D) 
Normalised percentage of mean intensity of 53BP1 levels in nuclei before treatment (base) and after 
different modalities of treatment in Arm 1 and Arm 2 for all patients. Error bars show standard error 
of mean. 
 
5.4.2 Castration reduced level of AR, Ku70 and phosphorylated DNA-PKcs 
proteins 
Here we wanted to investigate the effect of castration on expression levels of AR and D-
NHEJ essential proteins, ku70 and phosphorylated DNA-PKcs. In arm 1, mean intensity of 
nuclear AR and Ku70 proteins reduced after castration (p<0.001, p=0.005) and after 
combined castration and RT (p<0.001, p=0.001). 
In arm 2 we observed no difference in the mean intensity of nuclear AR after 5 X 2 Gy RT 
(p=0.5). However, a significant increase in mean intensity of nuclear Ku70 was observed 
after similar dose radiation (p=0.014). After subsequent RT and castration the mean intensity 
of nuclear AR and Ku70 proteins were decreased significantly (p<0.001, p=0001).  A 
significant correlation was observed between the mean intensity of nuclear AR and Ku70 
before treatment (ρ=0.62, p<0.001) and following castration in Arm 1 (ρ=0.65, p<0.001). 
Furthermore we observed a significant correlation between the induced changes in nuclear 
AR and Ku70 proteins in arm 1 after castration (ρ=0.52, p<0.001), and, after combined 
castration and RT (ρ=0.33, p=0.001) and in arm 2, after RT (ρ=0.64, p<0.001) and after 
subsequent castration (ρ=0.53, p<0.001) (Figure 11). 
Phosphorylated DNA-PKcs was examined to reveal the activity of D-NHEJ repair. In Arm 1, 
the mean area of foci of phosphorylated DNA-PKcs remained unchanged after both 
castration and combined castration and RT. However in arm 2 we observed a significant 
increase in the mean area of foci of phosphorylated DNA-PKcs after RT (p=0.01) followed 
by significant reduction after subsequent castration (p<0.001) (Figure 12). 
We observed no significant correlation between mean intensity of nuclear AR, Ku70 or 
DNA-PKcs proteins and pre-treatment serum PSA levels, prostate size or Gleason grade.  
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Figure 11. Determination of nuclear androgen receptor (AR) and Ku70 levels in prostate cancer tissue 
before treatment (Base) and after different treatment modalities in Arm 1 and Arm 2. A) Different 
sections of prostate biopsies are shown and each biopsy is sectioned and stained. The first section was 
stained with haematoxylin and eosin staining for identifying cancer areas. A further corresponding 
adjacent section obtained from the same biopsy was stained with immunofluorescence staining with 
Ku70 mouse-monoclonal antibody (green) and AR rabbit-polyclonal antibody (red). The DNA was co-
stained with TO-PRO-3 (blue). Upper sections were from a patient in Arm 1; the upper panel was 
before treatment (base), middle panel was after castration and lower panel was after castration and RT. 
Lower sections were from a patient in Arm 2; the upper panel was before treatment (base), middle panel 
was after RT and lower panel was after RT and castration. B) Percentage of normalized mean intensity 
of AR (red bars) and Ku70 (green bars) in nuclei before treatment (base) and after different modalities 
of treatment in Arm 1 and Arm 2 for all patients. Error bars show standard error of mean. C) 
Spearman´s rho rank correlation test (ρ) between mean intensity of AR and Ku70 in nuclei for all 
patients before treatment (base) in Arm 1 and Arm 2. D) Spearman´s rho rank correlation test (ρ) 
between mean intensity of AR and Ku70 in nuclei for patients in Arm 1 after castration. 
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Figure 12. Determination of nuclear phosphorylated DNA-PKcs levels in prostate cancer tissue before 
treatment (Base) and after different treatment modalities in Arm 1 and Arm 2. A) Different sections of 
prostate biopsies are shown and each biopsy is sectioned and stained. The first section was stained with 
haematoxylin and eosin staining for identifying cancer areas. A further corresponding adjacent section 
obtained from the same biopsy was stained with immunofluorescence staining with P-DNA-PKcs 
rabbit-polyclonal antibody (red). The DNA was co-stained with TO-PRO-3 (blue). ). Upper sections 
were from a patient in Arm 1; the upper panel was before treatment (base), middle panel was after 
castration and lower panel was after castration and RT. Lower sections were from a patient in Arm 2; 
the upper panel was before treatment (base), middle panel was after RT and lower panel was after RT 
and castration. B) A close up selected section from previous patients both in Arm 1 after castration and 
RT and in Arm 2 after RT (merge P-DNA-PKcs with DNA). C) Induced P-DNA-PKcs foci/cell 
(normalised) in nuclei before treatment (base) and after different modalities of treatment in Arm 1 and 
Arm 2 for all patients. Error bars show standard error of mean. 
5.5 PAPER V  
5.5.1 Hormone-naïve prostate tumour cells have heterogeneous response to 
castration with a co-variation between AR and D-NHEJ activity 
In this study, we observed a heterogeneous response of prostate tumour cells to castration. 
Surprisingly, two kinds of prostate tumour cells were identified following castration. The 
majority of tumour cells had a significant low level of nuclear AR. However, sub-
populations of tumour cells that varied from a few cells to a dozens of cells and gathered as 
subclones were still expressing high levels of AR after castration (Figure 13).  
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A significant correlation was observed between the mean intensity of nuclear AR and Ku70 
levels in each examined patient before and after different treatments. Moreover, the 
expressions of AR in clusters of cells co-varied with the expression pattern of both Ku70 and 
P-NA-PKcs foci. This finding is likely to strengthen our conclusion that cells retaining high 
levels of AR after castration, may retain their ability of a proficient DNA damage repair and 
vice versa. 
 
Figure 13. Data from tiled fluorescence images of whole prostate needle biopsies stained for androgen 
receptor (AR). A) Tiled images of prostate needle biopsy stained for AR before castration and B) after 
castration. C) Close-up tiled fluorescence images of prostate epithelial cells stained for AR showed the 
homogeneous staining of AR before castration and D) after castration, where we can see an incomplete 
suppression of AR in clusters of epithelial cells in different areas throughout the prostate needle biopsy. 
E) Signals of nuclear AR from epithelial cells of the same prostate needle biopsy in 4A, plotted against 
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5.5.2 Neo-adjuvant castration may trigger alternative DNA repair machinery 
mediated via PARP-1 
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A significant correlation was observed between the mean intensity of nuclear AR and Ku70 
levels in each examined patient before and after different treatments. Moreover, the 
expressions of AR in clusters of cells co-varied with the expression pattern of both Ku70 and 
P-NA-PKcs foci. This finding is likely to strengthen our conclusion that cells retaining high 
levels of AR after castration, may retain their ability of a proficient DNA damage repair and 
vice versa. 
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tumour areas that retain high levels of AR, Ku70 and phosphorylated DNA-PKcs express 
low levels of PAR and vice versa (Figure 14).  
 
Figure 14. Determination of nuclear AR, Ku70, P-DNA-PKcs and PAR levels from prostate epithelial 
cells in prostate needle biopsies. A) Tiled fluorescence images of two matched adjacent sections in one 
needle biopsy before castration, where AR and Ku70 signals in section 1 were merged with P-DNA-
PKcs and PAR signals from a corresponding area in the adjacent section 2. B) Graphs showing signals of 
AR (red), Ku70 (green), P-DNA-PKcs (yellow) and PAR (blue) plotted against the distance along the 
length axis of two matched adjacent sections of one whole needle biopsy before castration. The graph 
shows the positive co-variation between AR (red), Ku70 (green) and P-DNA-PKcs (yellow) and how 
these three proteins inversely co-vary with PAR (blue). C) The same as in fig. 5A, although after 
castration. D) The same as in fig 5B, although after castration. 
5.5.3 Divergent responses in AR, Ku70 or PSA despite castration serum 
testosterone levels 
Previously, a significant correlation was demonstrated between the decrease in serum PSA 
and nuclear Ku70 levels in patients with metastatic PCa following castration, suggesting that 
the PSA nadir may reflect simultaneously the nadir value of DNA repair activity [83]. A 
significant reduction in the mean intensities of nuclear AR and Ku70 levels were observed 
following castration in patients 1-3 and 5, whose serum PSA reduced most, by 89-99%, after 
castration. However, in patient number 4, whose serum PSA was only reduced by70% 
despite castrate levels of serum testosterone, no reduction was observed in the mean intensity 
of nuclear AR or Ku70 after castration.  
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5.5.4 Nuclear AR and serum PSA levels correlate 
A significant correlation between the levels of AR in nuclei and serum PSA levels after 
castration was observed in all five patients (ρ=1, p <0.001). Indeed, the finding was 
expected, since AR controls PSA expression.  
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6 DISCUSSION 
Since androgens and AR signalling are crucial for the initiation and development of most 
prostate tumours, ADT remains a backbone therapeutic of the disease. Currently, RP and RT 
are radical treatment methods for localised PCa with excellent long-term results. However, in 
locally advanced and high risk disease RT is the method of choice. Yet the outcome is 
frequently poor and combined with high risk of local failure, especially when RT is 
administered as a single treatment modality. Dose-response studies have shown that dose-
escalation over 78 Gy results in non-significant difference in 5 years recurrence rate among 
patients with high risk PCa [19, 84].  
Currently several prospective randomised trials showed that combined ADT, in neoadjuvant 
setting, with RT are superior to RT alone in high risk disease. However the optimal timing 
and underlying mechanisms of neoadjuvant castration have remained undetermined [17,25, 
28-32].  
We hypothesized that castration reduces the level of hypoxia, as measured by HIF-1α level, 
in PCa and this may be a mechanistic model of how radiosensitivity improves following 
castration. We observed that castration reduces the HIF-1α levels in PCa cells with an initial 
high level of this protein. Furthermore, an individual variety of HIF-1α levels, which was in 
accordance with other previous studies, were observed [85, 86]. The hypoxic characterisation 
of PCa becomes evident in a prospective clinical study, using needle electrode measurements 
in patients with a localised disease, and obviously is the hypoxic microenvironment of the 
tumours that drives tumourigenesis to more aggressive phenotypes with an early biochemical 
relapse following RT, independent of pre-treatment tumour clinical stage, Gleason score or 
serum PSA [87]. Another prospective clinical trial [88] measured the levels of HIF-1α in 
diagnostic prostate needle core biopsies from patients with untreated localised PCa, who then 
were treated with either RT or RP. Similarly, the pre-treatment hypoxia, measured by the 
HIF-1α level, was significantly correlated with high biochemical recurrence rate after 
treatment, independent of local tumour stage, Gleason score or serum PSA. Worthwhile to 
note the diversity of factors that influence the regulation of HIF-1α including the expressions 
of tumour oncogenes or tumour suppressor genes, reactive oxygen radicals, different growth 
factors and androgens [89-91]. In in vivo studies, it has been shown that AR is co-expressed 
with HIF-1α and VEGF in androgen sensitive PCa and that AR stimulates angiogenesis in 
early PCa via changes of both HIF-1α and VEGF levels [74, 77]. Therefore, the castration-
induced reduction of the HIF-1α levels observed in our study is possibly related to altered 
AR expression.   
It is well known that the presence of tumour hypoxia is associated with increased 
radioresistance. Likewise, the need for oxygen in the target cancer tissue at the time of 
irradiation is a critical factor that enhances tissue toxicity after RT, hence influences 
irradiation efficacy [92, 93].  In an in vivo study [87], using needle electrode measurements 
on patients with localised PCa, it has been shown that castration reduces hypoxia and 
increases intraprostatic oxygen tension, a mechanism that may explain the improved 
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radiosensitivity and paralleled may suggest that the reduced HIF-1α level observed in our 
study, could be explained by the reduced hypoxia and subsequently by the improved 
oxygenation following castration. It is also well-established that hypoxic tumour cells are 
associated with impaired DNA repair [92] and acquisition of an aggressive phenotype 
frequently leading to treatment resistance and metastasis [94].  
Since RT induces a number of genotoxic events that jeopardise the genomic integrity and 
survival of tumour cells, the activation of DDR, which comprises several DNA repair 
pathways, will be essential to maintain the genomic integrity and the survival of these cells. 
Consequently, we hypothesized that ADT influences DDR in PCa. Since an in vitro study 
using LNCaP cells, has reported an interaction between AR and Ku70 [95], we hypothesized 
that castration impairs the D-NHEJ-repair system by downregulating expression of its 
essential proteins Ku70 and DNA-PKcs, thus improving radiosensitivity.  
To date, it’s well recognised that AR mediates the transcription of a network of DDR genes 
that facilitates the repair of DSBs [95, 96]. Here we confirmed the interaction between AR 
and Ku70 proteins, which may reveal a mechanistic link between castration and the reduced 
Ku70 level. Additionally, we demonstrated a correlated and a significant reduction of both 
nuclear AR and Ku70 proteins in PCa tissue following castration. Since the influential role of 
Ku70/Ku80 components of D-NHEJ are well-recognized for effective radiation-induced 
DSB repair [59, 97], severe depletion of Ku70 protein by castration will be expected to 
impair D-NHEJ in PCa and may explain the increased radiosensitivity following castration. 
Several studies have been shown that Ku70 mutant cells are the most radiosensitive [63, 98]. 
Moreover, we also demonstrated that castration reduces the levels of phosphorylated DNA-
PKcs in PCa following RT. Undoubtedly, the later bring more comprehensive evidence 
suggesting that castration suppresses D-NHEJ activity in PCa, hence promoting 
radiosensitivity. Since D-NHEJ is confirmed to have a crucial role in IR-induced DSBs 
repair and since Ku70 and DNA-PKcs proteins have an essential role in the D-NHEJ repair 
pathway [59, 97, 99-102], the up-regulation of these proteins enhances radioresistance, 
whilst their downregulation promote radiosensitivity [103-106]. In vitro models targeting the 
catalytic motif of DNA-PKcs induce radiosensitive phenotype cells [107-109]. Likewise, 
repressed expression of Ku70 and DNA-PKcs in a mutant xenograft model has been shown 
to enhance radiosensitivity [110, 111]. Furthermore, ADT in an LNCaP cell model reduces 
D-NHEJ-mediated repair [96]. It is evident that DNA-PKcs is a key target in AR-mediated 
DNA repair and DNA-PKcs activity is promoted after genotoxic insult while it is repressed 
by ADT [112]. Obviously, the aforementioned provide a plausible explanation of how the 
AR regulates DDR, supporting our hypothesis that castration improves radiosensitivity by 
downregulating D-NHEJ. 
Since the AR is a major transcription factor involved in growth regulation and progression of 
PCa and since HR is an indispensable pathway involved in DSBs repair during S/G2 phase 
of cell cycle, we wanted to further investigate the role of AR in regulating the HR signalling.  
Both in in vitro and in vivo xenograft models, we showed that several essential genes 
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regulating the HR repair pathway were downregulated following the loss of AR activity. It 
has been evident that targeting HR pathway promotes radiosensitization in in vivo studies 
[113, 114]. In fact, the observed lower levels of RAD51 foci and consequently lower HR 
activity following AR knockdown shown in paper III, support that the AR regulates the 
overall HR response. It is well-established that MRE11, a protein comprised in the MRN 
complex, is activated early as a response to DSBs and consequently activates ATM [115], 
which in turn activates ATM-mediated HR signalling [116]. Our study demonstrates that the 
AR regulates MRE11 and ATM activity, which subsequently regulates DNA end-resection, 
therefore committing cells to undergo DSBs repair via HR. Furthermore, γ-H2AX foci form 
an early response to DSBs and they co-localize with other components of DDR including 
MRE11, ATM, RAD51 and 53BP1 [117, 118]. γ-H2AX is an active component of DDR and 
is involved in ATM signalling. H2AX-depleted mice models have a defected DNA-repair 
and an increased radiosensitivity [119, 120]. In our in vivo study (n=15), we showed that 
castration significantly reduces the level of γ-H2AX foci. Moreover, in an in vitro study, we 
showed that IR induces significantly higher levels of γ-H2AX foci in AR-full cells than in 
AR-depleted cells. Expectedly, we also showed that the inhibition of ATM leads to less 
increase in γ-H2AX foci in AR-full cells suggesting that AR regulates γ-H2AX via ATM 
signalling. In summary, these experiments propose a central role of AR signalling in 
regulating DDR in PCa as it regulates a number of key steps in both D-NHEJ and HR 
mediated repair.   
Generally expected, an impaired DDR leads to slower repair kinetics, thus higher amount of 
unrepaired DSBs following IR. In fact, in our first cohort study (n=14), we observed a 
significant correlation between the decrease in nuclear Ku70 levels and the increase in γ-
H2AX foci, a marker for DSBs and sensitivity to IR [121, 122]. However, we did not 
observe any significant difference in γ-H2AX foci levels in biopsies before and after 
castration. These apparently contradictory results may be explained by the effect of 
castration on cell proliferation. Cancer cells, due to their high proliferative rate, acquire high 
levels of endogenous oxygen radicals that consequently leads to more DNA damages. If 
these damages remain unrepaired during replication, this consequently leads to collapsed 
replication forks [123] and subsequently to an accumulation of γ-H2AX foci. Since we 
demonstrate that the proliferation rate, measured by Ki67 levels, and DDR is suppressed 
after castration, we suggest that castration initiates processes that can lead to either increase 
or decrease of γ-H2AX foci. Notably, no or minor castration-induced decrease of Ku70 
levels leads to a decrease of γ-H2AX foci, meanwhile a large decrease of the Ku70 levels 
following castration leads to an increase of γ-H2AX foci, implicating a functional linkage of 
decreased Ku70 levels and impaired DDR. 
In the second cohort study (n=48) in vivo, as expected we observed that the induced changes 
of γ-H2AX foci, after combined castration and RT were significantly higher than after RT 
only. This indicates a higher accumulation of unrepaired DSBs subsequent to a lower 
rejoining-rate of the damaged DNA strands, which may further strengthen our finding of 
impaired D-NHEJ after castration. On the other hand, in an in vitro assay, we showed that 
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AR regulates γ-H2AX via ATM signalling and IR induces less γ-H2AX in AR depleted cells. 
This finding might seem contradictory. However, a newly published study showed that low 
dose IR induces a prolonged and ATM-independent expression of γ-H2AX [124]. We 
believe that several factors may contribute to these differences in dose-response for γ-H2AX 
foci in our studies. Most importantly, in the biopsies, the IR-induced DNA damages and the 
overall repair after 5 days treatment are measured. Upon IR in vivo, a repair defect will result 
in an accumulation of lesions, while in vitro, we immediately uncover the DDR defect 
observed. Other potential explanations are in the first place that there are sample 
dissimilarities, i.e. cell models in vitro vs. prostate tumour tissue in vivo with subsequently 
different postulated milieu of microenvironment and background mutation, which will react 
in different ways. Secondly, there is the deference in the exposed IR dose, i.e. single dose of 
10 Gy for in vitro experiments vs. fractionated doses of 2 Gy/day for 5 consecutive days for 
the in vivo patient situation. Thirdly, the time measured to calculate the levels of γ-H2AX 
foci after exposure to IR alone, i.e. 2 hours after a single dose of IR in the in vitro experiment 
and 3 hours after the last IR at the 5th consecutive day of the in vivo situation. The 
aforementioned may be the reasons for the accumulation of the high levels of γ-H2AX foci 
following IR alone in in vivo experiments.  
Interestingly, we observed that castration reduces the overall intensity of 53BP1 
significantly. This finding emphasizes the critical role of AR in regulating DDR in PCa and 
may lead to novel therapeutic applications in the future. However, surprisingly castration did 
not affect the number of 53PB1 foci after RT. These seemingly contradictory results might 
be explained by the decrease of overall 53BP1 intensity after castration. Hence, a shortage of 
the protein pool leads to less foci formation despite massive DNA damage following RT. 
This would be most pronounced in patients with high levels of DNA damage after combined 
castration and RT. Thus, the lower mean intensity of 53BP1 protein will probably mask the 
difference between the level of persistent DSBs after combined castration and RT as 
compared with RT alone. 
It has remained unclear which repair system dominates the IR-induced DSBs repair pathway, 
D-NHEJ or HR. Currently, it is evident that castration reduces the proliferative activity of 
prostate cells (cells in S and G2 phases), as measured by reduced Ki67 expression. However, 
there is still contradictory evidence that castration leads to a long-term apoptotic effect in 
human PCa [43, 125]. A consequence of a genotoxic event such as RT will be a varying 
amount of DNA damage and activation of DDR. We have shown that both castration and RT 
reduces cell proliferation dramatically, suggesting that the majority of cells had exited the 
cell cycle and entered into cell cycle arrest i.e. G0, where D-NHEJ is the most dominant 
DSB-mediated DNA repair pathway. Since HR repair of IR-induced DSBs predominantly 
operates during the S/G2 phase of the cell cycle, we may conclude that D-NHEJ, rather than 
HR, is the most dominant pathway involved in the repair of radiation induced DSBs 
following castration. 
 
37 
AR regulates γ-H2AX via ATM signalling and IR induces less γ-H2AX in AR depleted cells. 
This finding might seem contradictory. However, a newly published study showed that low 
dose IR induces a prolonged and ATM-independent expression of γ-H2AX [124]. We 
believe that several factors may contribute to these differences in dose-response for γ-H2AX 
foci in our studies. Most importantly, in the biopsies, the IR-induced DNA damages and the 
overall repair after 5 days treatment are measured. Upon IR in vivo, a repair defect will result 
in an accumulation of lesions, while in vitro, we immediately uncover the DDR defect 
observed. Other potential explanations are in the first place that there are sample 
dissimilarities, i.e. cell models in vitro vs. prostate tumour tissue in vivo with subsequently 
different postulated milieu of microenvironment and background mutation, which will react 
in different ways. Secondly, there is the deference in the exposed IR dose, i.e. single dose of 
10 Gy for in vitro experiments vs. fractionated doses of 2 Gy/day for 5 consecutive days for 
the in vivo patient situation. Thirdly, the time measured to calculate the levels of γ-H2AX 
foci after exposure to IR alone, i.e. 2 hours after a single dose of IR in the in vitro experiment 
and 3 hours after the last IR at the 5th consecutive day of the in vivo situation. The 
aforementioned may be the reasons for the accumulation of the high levels of γ-H2AX foci 
following IR alone in in vivo experiments.  
Interestingly, we observed that castration reduces the overall intensity of 53BP1 
significantly. This finding emphasizes the critical role of AR in regulating DDR in PCa and 
may lead to novel therapeutic applications in the future. However, surprisingly castration did 
not affect the number of 53PB1 foci after RT. These seemingly contradictory results might 
be explained by the decrease of overall 53BP1 intensity after castration. Hence, a shortage of 
the protein pool leads to less foci formation despite massive DNA damage following RT. 
This would be most pronounced in patients with high levels of DNA damage after combined 
castration and RT. Thus, the lower mean intensity of 53BP1 protein will probably mask the 
difference between the level of persistent DSBs after combined castration and RT as 
compared with RT alone. 
It has remained unclear which repair system dominates the IR-induced DSBs repair pathway, 
D-NHEJ or HR. Currently, it is evident that castration reduces the proliferative activity of 
prostate cells (cells in S and G2 phases), as measured by reduced Ki67 expression. However, 
there is still contradictory evidence that castration leads to a long-term apoptotic effect in 
human PCa [43, 125]. A consequence of a genotoxic event such as RT will be a varying 
amount of DNA damage and activation of DDR. We have shown that both castration and RT 
reduces cell proliferation dramatically, suggesting that the majority of cells had exited the 
cell cycle and entered into cell cycle arrest i.e. G0, where D-NHEJ is the most dominant 
DSB-mediated DNA repair pathway. Since HR repair of IR-induced DSBs predominantly 
operates during the S/G2 phase of the cell cycle, we may conclude that D-NHEJ, rather than 
HR, is the most dominant pathway involved in the repair of radiation induced DSBs 
following castration. 
 38 
In fact, effective DNA repair reduces the efficacy of RT. As previously discussed, a reduced 
level of hypoxia following castration would be expected to improve the DNA repair, thereby 
increasing radioresistance. However, since it is evident by many clinical studies that the 
sensitivity to RT improves after castration [13] and since it has been shown that castration 
impairs the DNA repair of DSBs, we suggest that any enhancement in DNA repair caused by 
decreased hypoxia is of less importance than the castration-induced impairment of DNA 
repair. 
Since we have shown that castration suppresses both D-NHEJ- and HR-mediated repair of 
IR-induced DSBs, it becomes crucial to investigate the role of androgen depletion on 
alternative DNA repair so called B-NHEJ mediated by PARP-1. Interestingly, a newly 
published in vivo study reported that prostate tumour cells carried TMPRSS2-ERG gene 
fusion, the most common genetic aberration, which is found in approximately 50% of 
patients with PCa [126, 127]. That means an impaired D-NHEJ repair pathway by inhibiting 
DNA-PKcs and enhancing the PARP inhibitor-mediated radiosensitization [128]. 
Furthermore, TMPRSS2-ERG expressing tumour cells have elevated levels Rad51 foci and 
HR activity after IR, indicating an HR compensatory effect for the defective D-NHEJ and the 
plausible synthetic lethal interaction that may exert between TMPRSS2-ERG expressing 
tumour cells and PARP inhibitors [128].  We hypothesised that PARP-mediated B-NHEJ 
will gain a more predominant roll in IR-induced DSBs repair following castration and 
combined treatment of ADT and PARP inhibitor leads to synthetically lethal effect in PCa. It 
is well-established that HR-defective BRCA2 mutant cells rely on PARP-1 for DSBs repair 
and PARP inhibitors have a synthetic lethal effect on these cells [70, 82, 129]. More 
interestingly, for irradiated in vivo cells, it has been shown a high binding affinity of Ku70 to 
damaged DNA-ends that hampers the contribution of PARP-1 in DSB repair. On the other 
hand, depletion of indispensable components of D-NHEJ, especially Ku70, leads to 
recruitment of PARP-1 for DSBs repair via the B-NHEJ pathway [67]. To our knowledge for 
the first time, our finding demonstrates that castration significantly increases PARP-1 
activity in vivo, hence indicating ongoing B-NHEJ-mediated DSBs repair, whereas the 
activity of essential D-NHEJ and HR repair pathways were repressed following castration in 
hormone naïve PCa. Although the role of PARP-1 in DNA-damage repair is well-
understood, a recent in vivo study demonstrates the dual function of PARP-1. In addition to 
its involvement in DNA repair, it promotes an AR transcriptional function on DNA repair 
genes in AR-positive PCa cells. Furthermore, PARP-1 inhibitors reduce the expression of 
AR-target genes [130]. Actually the fundamental issue to address here is obviously the high 
biochemical recurrence rate despite adequate local treatment of high risk PCa with combined 
neoadjuvant castration and RT [131]. Indeed this may provide a rationale to exploit the dual 
inhibition of both AR and PARP functions in early treatment of patients with high risk 
diseases. 
Our in vitro work showed that combined ADT and PARP inhibition repress growth kinetics 
and cell viability in CRPC cell lines and provide a mechanistic insight into the observed 
synthetic lethality between AR and PARP inhibition. Although germ-line BRCA1/BRCA2 
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mutations, which are often associated with aggressive malignant characteristics, are present 
in only a few percent of patients with PCa [132], a lot of sporadic PCa cells will gain a 
molecular and clinical characteristic similar to those of BRCA-related tumours, with 
BRCA1-like mutations detected in 13–46% of cases [133] and BRCA2-like and ATM 
mutations in approximately 30 % (unpublished data). The development of CRPC is 
associated with reactivation of the AR signalling through either an inadequate suppression of 
intratumoural androgen, by primary castration, or through a divergent molecular mechanism 
including gain-of-function mutations in the genes of the androgen biosynthetic pathway 
[134]), point mutations in the AR gene leading to anti-androgen resistance [135] and 
constitutively active AR splice variants [136]. On the other hand, despite PARP-1 is 
overexpressed in multiple cancer types including PCa, not all BRCA-defective cancers seem 
to respond to PARP inhibitor monotherapy. The limited success of PARP inhibitor therapy 
may relate to BRCA gene reversion [137] or other factors that functionally compensate for 
the loss of HR proficiency such as loss of 53BP1 function in BRCA1 depleted mammary 
tumours [138]. Our data support the hypothesis that prostate tumour cells treated with ADT 
may rely on B-NHEJ for DSBs repair and combination of ADT and PARP inhibitor could be 
synthetically lethal. Rather interesting in the current heterogeneity study, is the observed 
inverse correlation between PARP-1 activity and AR and D-NHEJ. In a previous in vivo 
study, we showed that PARP-1 activity was increased after castration (Asim et al., in 
preparation). The current study aimed at further investigating the correlation between AR and 
PARP-1 activity in the heterogeneous landscape of AR in prostate cancer. Interestingly, an 
individual analysis of the patients (n=5), showed significant inverse correlation between the 
levels of PAR and nuclear AR and nuclear Ku70 were observed following different treatments. 
Furthermore, in depth analysis of different tumour areas throughout the whole needle biopsy 
specimen, showed a tendency to such an inverse correlation between the PAR levels and the 
levels of AR, Ku70 and P-DNA-PKcs, suggesting that prostate tumour cells, where 
castration leads to impairment of D-NHEJ, could rely on PARP-mediated DNA repair 
pathway and vice versa.  
Another interesting finding in our AR heterogeneity study is that despite of castration levels 
in serum testosterone we can see an inadequate suppression of AR in subclones of cells 
throughout prostate tumour areas with a co-variation between the high expression levels of 
AR and nuclear Ku70 and phosphorylated DNA-PKcs proteins. This indicates an activation 
of D-NHEJ despite of castration.  
The important question addressed here is the biological nature of castration-resistant prostate 
cancer cells. Are they evolutionary mutated cells from otherwise primary androgen sensitive 
cells according to selective pressure of ADT or are they quiescent castration resistant tumour 
cells that acquire growth-promoting function according to clonal selection. The mechanism 
behind, and timing for the development of CRPC may lead to a comprehensive 
understanding of the underlying mechanism behind the emergence of such resistant cells 
after primary hormone manipulation. In line with this, two models have been proposed: the 
adaptation model which hypothesized that selective pressure of ADT encourages mutational 
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events in the androgen signalling pathway, and the clonal selection model which 
hypothesized the heterogeneous nature of prostate cancer and the pre-existing clone of 
castration-resistant cells [139, 140]. 
Several scientific observations support the adaptation models and provide a rationale for the 
emergence of these resistant subclones observed in our heterogeneity study. Gene expression 
analyses of hormone naïve PCa, PCa subjected to ADT, and CRPC have revealed that the 
overall expression patterns of genes for CRPC were more similar to those of the untreated, 
hormone-naive primary tumours than to tumours undergoing ADT [141]. Several studies 
have previously reported that ADT decreases intraprostatic androgens such as testosterone 
and dihydrotestosterone by only 75% to 80% after accomplishing castrate serum testosterone 
levels with a GnRH analogue [49, 142, 143]. Residual prostatic androgen levels in castrated 
patients are sufficient to stimulate androgen-responsive genes and activate the AR [144]. An 
in vivo study by Mostaghel et al showed that many androgen-regulated genes were not 
suppressed after 3 - 9 months of neoadjuvant castration [145]. The heterogeneity in AR 
response in the current study highlights the findings in previous studies that demonstrated 
continued substantial androgen-dependent gene expression after castration. 
Treatment with intense ADT with a GnRH analogue in combination with the novel 
antiandrogen agent, abiraterone acetate, in patients with primarily localized hormone-naïve 
PCa show further suppression of intraprostatic androgens [146]. The afore-mentioned 
support the assumption that continued AR-mediated signalling after primary hormone 
manipulation is probably driven by the presence of residual tissue androgen. Furthermore, 
clinical trials for patients with CRPC using second-generation anti-androgens, such as 
abiraterone acetate and enzalutamid, suggest that AR signalling remains a fundamental 
promoting mechanism of CRPC [147, 148]. To date, different spliced variants of AR, which 
lacks the ligand-binding domain and are functionally active despite the absence of 
androgens, have shown a putative role in developing resistance to anti-androgen therapy in 
CRPC [149]. This finding suggests that the production of an AR spliced variant could be the 
consequence of suboptimal intraprostatic androgen ablation, which in turn may lead to 
adaptation of prostate tumour cells to survive in low-level androgen environment and thereby 
undergo mutations.  
Several scientific observations back up the clonal model and provide a rationale for our 
current findings. Interestingly, they have shown that AR gene mutations were common and 
could arise in early hormone-naïve PCa, yet more frequently in advanced disease before 
ADT [150, 151]. Animal studies on the Dunning R-3327-H rat prostate adenocarcinoma 
model with a heterogeneous mixture of androgen-dependent and pre-existing androgen-
resistant tumour cells subjected to ADT, showed that castration provided selective pressure 
and enhanced growth prosperity of castration-resistant tumour cells while androgen-
dependent cells were eliminated [152]. 
The cancer stem cell (CSC) hypothesis, which has been frequently discussed during the last 
years, is another theory that can strengthen the clonal selection model.  CSCs are a subgroup 
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of tumour cells about 0.1% in number [153], characterized by a high level of expression of 
cluster differentiation 44 (CD44) and CD133 and low expression level of AR, with properties 
of self-renewal and differentiation [154]. The most important question is whether these 
castration-resistant tumour cells are CSCs or not. Since CSCs in PCa are usually characterized 
by high levels of CD44 and CD133 and low levels of AR, our finding of high AR expression in 
these cells indicates that they are not CSCs. 
Unfortunately, the absence of any CSC-marker staining such as cytokeratin (CK) or CD may 
be regarded as a limitation of our current study. 
In the current work the observed tendency of inverse correlation between PARP-1 activity 
and AR and D-NHEJ is interesting. Previously we demonstrated that PARP-1 activity was 
induced after castration (Asim et al., in preparation). In fact, PARP-1 plays pivotal roles in 
the processing and resolution of a variety of repair of DNA damages such as single-strand 
break, HR and NHEJ [155]. Our study suggests that prostate tumour cells, in which 
castration leads to impairment of D-NHEJ repair, may rely on PARP-mediated B-NHEJ 
DNA repair. We believe this to be an important finding calling for further investigations in 
the future.  
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7 GENERAL CONCLUSIONS AND FUTURE PROSPECTIVE 
Neoadjuvant castration combined with radiotherapy remains the standard of care treatment 
for patients with intermediate and high risk, localized prostate cancer. In our studies we tried 
to explore the molecular mechanisms underlying the synergistic effect between those two 
treatment modalities.  
•  Generally, we conclude that in in vivo material, RT following castration leads to impaired 
DNA repair and, therefore, increased DNA damage compared with that observed after RT 
alone.  
•  Our data show that neo-adjuvant castration lowers intranuclear AR leading to a down-
regulation of D-NHEJ activity through both the depletion of the Ku70 protein and reduced 
activity in the DNA-PKcs protein, thereby promoting the radiosensitivity of prostate cancer 
(Study II & IV).  
•  Neoadjuvant castration reduces tumour cell hypoxia, measured by expression of HIF-1α, 
which may provide a plausible mechanism of enhanced radiosensitivity following castration 
(Study I).  
•  AR regulates HR repair, which provides an additional explanation for the improved 
radiosensitivity following neoadjuvant castration (Study III).  
•  Moreover, ADT leads to activation of PARP signalling and treatment with combined ADT 
and PARP inhibitors enhance cell killing in vitro (Study III).  
•  Despite castration levels of serum testosterone and consequently significant suppression of 
the nuclear AR and Ku70 following castration, there is remarkably suboptimal suppression 
of these proteins in some subclones of prostate tumour cells. The aforementioned may 
presumably be one of the plausible mechanisms underlying radioresistance and the 
subsequent high incidence rate of recurrence among patients with high risk disease (Study 
V). 
Fundamentally, we showed that AR signalling regulates the DDR in PCa. Castration impairs 
the DNA repair pathways of DSBs and castration reduces hypoxia, hence improving 
radiosensitivity. Furthermore, our data indicate that following ADT the compromised DSBs 
repair either by D-NHEJ or HR tends to activate PARP-mediated B-NHEJ. This provides a 
rationale for synthetic lethality between ADT and PARP inhibitors and the dual targeting of 
both pathways may improve therapy outcome in advanced or high risk prostate cancer. We 
believe that castration-induced activation of B-NHEJ needs further investigation in future 
clinical studies. Stratifying patient cohorts using genetic markers could probably define 
patient populations responding to targeted therapies. This concept has been best implemented 
in the field of oncology. The tumour heterogeneity may be an important factor to predict 
response to individually based targeted therapies. In details investigation of the concept of 
intratumoural heterogeneity, to the single cell level, would be essential. It is well established 
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that tumour microenvironment and surrounding non‐malignant tissue may influence the 
growth and progression of tumour cells. The CSCs population may need to be characterized 
using single cell resolution in tumour tissues. New technology such as spatial transcriptomics 
(ST), which is a novel approach that combines histology with RNA sequencing, would be a 
promising tool in future studies.  
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8 SAMMANFATTNING PÅ SVENSKA 
Målet med behandling av icke-spridd prostatacancer är i första hand att helt slå ut tumören, 
d.v.s. bota patienten, i andra hand att förlänga överlevnaden. Med botande behandling, såsom 
radikal operation eller full dos strålbehandling med eller utan neoadjuvant 
kastrationsbehandling, kan man närma sig dessa mål, men resultaten är ibland ovissa och 
behandlingsmetoderna är förknippade med biverkningar, som tenderar att sänka 
livskvaliteten. Dessutom får en betydande del av män med högrisk prostatacancer återfall i 
sin sjukdom trots behandling med kurativ intention. 
Kliniska studier har visat att neoadjuvant kastration ger en synergistisk effekt vid 
strålbehandling av prostatacancer. Mekanismen bakom denna synergism har inte varit 
klarlagd. Strålbehandlingen åstadkommer skador i cellernas genom (DNA). Om dessa skador 
inte repareras, dör cellen. DNA-skadorna kan repareras med hjälp av vissa proteiner, som 
kallas reparationsenzymer.  
I detta arbete, ville vi undersöka om kastrationsbehandling medför en lägre nivå av 
reparationsenzymer i prostatacancerceller, vilket i så fall skulle leda till försämrad DNA-
reparation och bättre strålbehandlingseffekt. En djupare förståelse för vad som sker på 
cellnivå och molekylnivå i prostatacancercellerna, när man först reducerar deras tillgång på 
manligt könshormon och därefter utsätter dem för joniserande strålning medför, att man 
bättre kan optimera behandlingen. Förmodligen kan det även ge uppslag till helt nya 
terapeutiska angreppspunkter. 
Delarbete I. Fjorton patienter med prostatacancer rekryterades och prostatabiopsier togs före 
och efter kastrationsbehandling. Biopsierna analyserades med tanke på samband mellan 
kastrationsbehandling och nivån av HIF-1α protein som ett mått på hypoxi, brist i mängden 
syre, som når vävnaderna. Efter kastration observerades en minskning av uttrycket HIF-1α 
hos fem patienter med initialt starkt HIF-1α uttryck samt hos två av tre patienter med initialt 
svagt HIF-1α uttryck. Dessa data tyder på att neoadjuvant kastration minskar hypoxi i 
tumörceller vid prostatacancer (= ökad syrehalt), vilket kan förklara ökad strålkänslighet 
efter kastration. 
Arbetet är publicerat: Castration therapy of prostate cancer results in downregulation of 
HIF-1α Levels. Al-Ubaidi et al., 2012 Int J Radiat Oncol Biol Phys. 82: 1243-8.  
Delarbete II.  Prostatabiopsier från samma kohort patienter som i arbete I användes i detta 
arbete. Biopsierna analyserades med avseende på samband mellan kastrationsbehandling och 
Ku70-protein, ett nödvändigt protein för reparation av dubbelsträngsbrott (DSB) i DNA-
molekylen. Efter kastration observerades minskning av Ku70-nivåerna hos tio av fjorton 
patienter. Minskningen av Ku70 varierade från 43 % till 97 % (p <0,001). Den samtida 
minskningen av serum-PSA och serum-testosteron efter kastrationen korrelerade direkt med 
sänkta halter av Ku70-proteinet. 
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kastrationsbehandling, kan man närma sig dessa mål, men resultaten är ibland ovissa och 
behandlingsmetoderna är förknippade med biverkningar, som tenderar att sänka 
livskvaliteten. Dessutom får en betydande del av män med högrisk prostatacancer återfall i 
sin sjukdom trots behandling med kurativ intention. 
Kliniska studier har visat att neoadjuvant kastration ger en synergistisk effekt vid 
strålbehandling av prostatacancer. Mekanismen bakom denna synergism har inte varit 
klarlagd. Strålbehandlingen åstadkommer skador i cellernas genom (DNA). Om dessa skador 
inte repareras, dör cellen. DNA-skadorna kan repareras med hjälp av vissa proteiner, som 
kallas reparationsenzymer.  
I detta arbete, ville vi undersöka om kastrationsbehandling medför en lägre nivå av 
reparationsenzymer i prostatacancerceller, vilket i så fall skulle leda till försämrad DNA-
reparation och bättre strålbehandlingseffekt. En djupare förståelse för vad som sker på 
cellnivå och molekylnivå i prostatacancercellerna, när man först reducerar deras tillgång på 
manligt könshormon och därefter utsätter dem för joniserande strålning medför, att man 
bättre kan optimera behandlingen. Förmodligen kan det även ge uppslag till helt nya 
terapeutiska angreppspunkter. 
Delarbete I. Fjorton patienter med prostatacancer rekryterades och prostatabiopsier togs före 
och efter kastrationsbehandling. Biopsierna analyserades med tanke på samband mellan 
kastrationsbehandling och nivån av HIF-1α protein som ett mått på hypoxi, brist i mängden 
syre, som når vävnaderna. Efter kastration observerades en minskning av uttrycket HIF-1α 
hos fem patienter med initialt starkt HIF-1α uttryck samt hos två av tre patienter med initialt 
svagt HIF-1α uttryck. Dessa data tyder på att neoadjuvant kastration minskar hypoxi i 
tumörceller vid prostatacancer (= ökad syrehalt), vilket kan förklara ökad strålkänslighet 
efter kastration. 
Arbetet är publicerat: Castration therapy of prostate cancer results in downregulation of 
HIF-1α Levels. Al-Ubaidi et al., 2012 Int J Radiat Oncol Biol Phys. 82: 1243-8.  
Delarbete II.  Prostatabiopsier från samma kohort patienter som i arbete I användes i detta 
arbete. Biopsierna analyserades med avseende på samband mellan kastrationsbehandling och 
Ku70-protein, ett nödvändigt protein för reparation av dubbelsträngsbrott (DSB) i DNA-
molekylen. Efter kastration observerades minskning av Ku70-nivåerna hos tio av fjorton 
patienter. Minskningen av Ku70 varierade från 43 % till 97 % (p <0,001). Den samtida 
minskningen av serum-PSA och serum-testosteron efter kastrationen korrelerade direkt med 
sänkta halter av Ku70-proteinet. 
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Vår konklusion är att kastration resulterar i minskade nivåer av Ku70-protein som 
följaktligen medför en försämrad reparationskapacitet av D-NHEJ-systemet och därmed 
försämrad reparation av dubbelsträngsbrott, vilket i sin tur sannolikt innebär ökad 
strålkänslighet hos prostatacancerceller efter kastration. 
Arbetet är publicerat: Castration Therapy Results in Decreased Ku70 Levels in Prostate 
Cancer, Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T. 2013 Clin 
Cancer Res. 19(6);1-10.  
Delarbete III. Aktiv signalering av androgen receptor (AR) är ett kännetecken för en 
aggressiv prostatacancer. I detta arbete har vi använt olika prostatacancercellinjer med både 
kastrationskänsliga och kastrationsresistenta celler. Vi visade att AR-signalering reglerar 
DNA reparationssystemen och att den främjar homolog rekombination (HR), ett DNA-
reparationssystem, som är nödvändigt för reparation av dubbelsträngsbrott. Dessutom visade 
vi att AR främjar ATM-signalering (ataxi telangiectasia muterat) med MRN (Mre11a, 
RAD50 och Nbs1) aktivering. Androgen deprivationsbehandling (ADT) minskar 
reparationskapaciteten hos HR. I ett kliniskt material från samma kohort som i delarbete IV, 
visade vi att PARP-aktiviteten ökar i prostatacancerceller efter ADT jämfört med PARP-
aktivitet före ADT. Vår hypotes är att PARP-proteinet krävs för prostatacancercellernas 
överlevnad efter ADT. Slutligen visade vi en förbättrad hämning av tumörtillväxten genom 
att kombinera ADT och PARP-hämmare. Detta ger en logisk grund för användningen av 
PARP-hämmare i kombination med ADT. Vårt arbete ger avgörande insikter i mekanismen 
bakom androgensignaleringens betydelse för prostatacancerprogression och en logisk grund 
för samtidig hämning av AR och PARP vid behandling av prostatacancer. 
Manuskriptet ska skickas till en internationell tidskrift för publicering. 
Delarbete IV. Patienter med lokaliserad eller lokalt avancerad prostatacancer, som 
rekommenderades kurativt syftande strålbehandling inkluderades och delades i två grupper.  
Patienterna i grupp 1 fick neoadjuvant farmakologisk kastration och 8 veckor senare, d.v.s. 
när deras serum-testosteronvärde var på kastrationsnivå, fick de strålbehandling i fraktioner 
om 2 Gy till totalt 78 Gy mot prostatakörteln. Prostatabiopsier togs strax innan 
strålbehandlingen och sedan omedelbart efter att patienten hade fått inledande 5 x 2 Gy.  
Patienterna i grupp 2 fick först strålbehandling 5 x 2 Gy mot prostatakörteln och därefter 
neoadjuvant farmakologisk kastration i 8 veckor. Sedan fick de strålbehandling 36 x 2 Gy till 
totalt 82 Gy. Prostatabiopsier togs omedelbart efter den initiala strålbehandlingsstarten och 
sedan 8 veckor efter insättning av endokrin behandling d.v.s. när deras S-testosteronvärde låg 
på kastrationsnivå och innan patienterna fick kompletterande strålbehandling med 36 x 2 Gy. 
Genom att analysera nivåerna av Ki67, en proliferationsmarkör, observerades att flertalet 
prostataceller går ur cellcykeln efter både kastration och strålbehandling. Genom att 
analysera DSB-markörerna γ-H2AX och 53BP1 visade vi att strålbehandling efter 
neoadjuvant kastration ledde till betydligt mera dubbelsträngsbrott än efter enbart 
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strålbehandling. Nivåerna av androgenreceptorn (AR) och D-NHEJ-proteinerna Ku70 och 
aktivt DNA-PKcs analyserades. I grupp 1minskade medelvärdet av AR och Ku70 efter 
kastration och även efter kombinerad kastration och strålbehandling. I grupp 2 såg vi ingen 
skillnad i AR-uttrycket efter inledande 5 x 2 Gy strålning. Däremot sågs en betydande 
ökning av Ku70 efter denna stråldos. För att bedöma aktiviteten hos D-NHEJ-reparationen 
analyserades aktivt DNA-PKcs. I grupp 1 förblev detta aktivt DNA-PKcs oförändrat efter 
både kastration och kombinerad kastration och strålbehandling. Men i grupp 2 såg vi en 
signifikant ökning av aktivt DNA-PKcs efter strålbehandling. 
Sammanfattningsvis, har vi påvisat att den förbättrade totala överlevnaden efter kombinerad 
kastration och strålbehandling kan förklaras av försämrad D-NHEJ-reparation, vilket betyder 
många kvarstående dubbelsträngsbrott. Detta i sin tur ger en toxisk effekt på 
prostatacancercellerna. Denna studie visar att kastration försämrar D-NHEJ-
reparationskapaciteten hos prostatacancerceller, vilket förklarar den förbättrade 
strålkänsligheten hos tumören efter kombinerad neoadjuvant kastration och strålbehandling.  
Arbetet är accepterat av tidskriften ” Science Translational Medicine” för publicering. 
Delarbete V. Trots tidig diagnos och därefter effektiv behandling av mellanrisk och högrisk 
prostatacancer förblir återfallsfrekvensen tyvärr hög. Det är väl etablerat att primär 
prostatatumör är en multifokal sjukdom. Vi ville undersöka hur effektivt en genomförd 
kastration sänker AR-signaleringen, vilket påverkar reparationen av DNA-skador hos primär 
hormonkänslig prostatacancer. Från samma kohort patienter som i delarbetet IV, valdes fem 
patienter till denna studie. Fyra patienter ingick i grupp 1, och fick kombinerad neoadjuvant 
farmakologisk kastration och strålbehandling (RT) medan en patient i grupp 2, det vill säga 
han fick en låg dos strålning före den kombinerade behandlingen. Mellannålsbiopsier från 
prostata säkrades vid diagnos, efter kastration och efter strålbehandling. Serum-PSA mättes 
vid diagnos och efter kastration medan serum-testosteron mättes endast efter kastration. 
Nivåerna av AR, Ku70, aktivt DNA-PKcs och PAR mättes. En signifikant, korrelerad 
minskning av medelintensiteten av AR i cellkärnorna observerades hos de fyra patienter, vars 
serum-PSA reducerades med 90 % eller mera (ρ = 1, p <0,001). Trots kastrationsnivåer av 
serum-testosteron hos dessa patienter, var halterna av AR och följaktligen Ku70 och aktivt 
DNA-PKcs fortsatt höga i kluster av prostatacancerceller. Samtidigt observerades en tendens 
till en omvänd korrelation mellan AR, Ku70 och aktivt DNA-proteinkinas katalytisk 
subenhet (P-DNA-PKcs) jämfört med PARP-1-aktivitet. Sammanfattningsvis, är vi de första 
att påvisa det heterogena landskapet hos AR och dess ofullständiga respons på kastration hos 
kluster av hormonkänsliga prostatacancerceller.  Det heterogena AR-landskapet efter 
kastration medför även en korrelerad respons på det samvarierade svaret av hur DNA-skador 
repareras. Än så länge är det fortfarande oklart hur dessa kastrationsresistenta celler uppstår. 
De kan antingen vara androgenberoende celler, som trots kastrationsnivåer hos serum-
testosteron är fortsatt aktiva på grund av de höga halterna av androgen i prostatavävnaden, 
eller så är de vilande kastrationsresistenta celler, som främjar progressionen av 
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prostatacancer efter att de androgenberoende cellerna har slagits ut av kastrationsbehandling. 
Detta behöver förvisso studeras ytterligare i framtiden. 
Manuskriptet ska skickas till en internationell tidskrift för publicering. 
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CASTRATION THERAPY OF PROSTATE CANCER RESULTS IN DOWNREGULATION
OF HIF-1a LEVELS
FIRAS L. T. AL-UBAIDI, M.B., CH.B.,*y NIKLAS SCHULTZ, PH.D.,* LARS EGEVAD, M.D., PH.D.,z
TORVALD GRANFORS, M.D., PH.D.,y AND THOMAS HELLEDAY, PH.D.*x{
*Department of Genetics, Microbiology and Toxicology, Stockholm University, Stockholm, Sweden; zDepartment of Oncology-
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Background and Purpose: Neoadjuvant androgen deprivation in combination with radiotherapy of prostate
cancer is used to improve radioresponsiveness and local tumor control. Currently, the underlying mechanism is
not well understood. Because hypoxia causes resistance to radiotherapy, we wanted to test whether castration
affects the degree of hypoxia in prostate cancer.
Methods and Materials: In 14 patients with locally advanced prostate cancer, six to 12 prostatic needle core biopsy
specimens were taken prior to castration therapy. Bilateral orchidectomy was performed in 7 patients, and 7 were
treated with a GnRH-agonist (leuprorelin). After castrationm two to four prostatic core biopsy specimens were
taken, and the level of hypoxia-inducible factor-1a (HIF-1a) in cancer was determined by immunofluorescence.
Results: Among biopsy specimens taken before castration, strongHIF-1a expression (mean intensity above 30) was
shown in 5 patients, weak expression (mean intensity 10–30) in 3 patients, and background levels of HIF-1a (mean
intensity 0–10) in 6 patients. Downregulation of HIF-1a expression after castration was observed in all 5 patients
with strong HIF-1a precastration expression. HIF-1a expression was also reduced in 2 of 3 patients with weak
HIF-1a precastration expression.
Conclusions: Our data suggest that neoadjuvant castration decreases tumor cell hypoxia in prostate cancer, which
may explain increased radiosensitivity after castration.  2012 Elsevier Inc.
Hypoxia-inducible factor, HIF-1a, Prostate cancer.
INTRODUCTION
Prostate cancer is the most common cancer in the western
countries (1). Most patients with localized prostate cancer
(ie, the tumor is confined to the prostate gland), who have
relatively long life expectancy and low comorbidity, may
be offered curative treatment with either radical prostatec-
tomy or radiotherapy. In the case of poorly differentiated
high-risk tumors, the latter treatment is currently combined
with neoadjuvant hormone therapy with the use of a gonado-
tropin-releasing hormone (GnRH) agonist. Clinical studies
have demonstrated synergism between androgen ablation
and radiotherapy (2), which improves tumor control and
patient survival, although the biologic explanation of the
mechanism is not yet fully defined.
Growth of solid tumors such as prostate cancer is charac-
terized by neovascularization and increased glycolysis as
a result of the hypoxic microenvironment of the tumor.
The hypoxia-inducible factor 1 (HIF-1) complex is an
important transcription factor that regulates cellular adapta-
tion to hypoxia and transcription of genes involved in angio-
genesis, cell survival, glucose metabolism, and tumor
invasion (3).
HIF-1 is a member of the basic helix-loop-helix (bHLH)-
PER-ARNT-Sim (PAS) family of transcription factors.
HIF-1 is a heterodimer composed of the HIF-1a and
HIF-1b subunits (4). The b subunit is ubiquitously expressed
in most cells, and the a subunit, which is the critical determi-
nant of HIF-1 activity, is regulated posttranslationally in
response to hypoxia. In normoxic conditions, HIF-1a is
ubiquitinated by the von Hippel-Lindau tumor suppressor
protein (pVHL) and degraded by the proteasome. However,
in response to hypoxia, HIF-1a is stabilized and can thus
bind to the b subunit. Upon dimerization of the two subunits.
the HIF-1 complex translocates to the nucleus, where it
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binds to DNA at hypoxia-responsive elements (HREs),
which are common to HIF-1–responsive genes, thus modify-
ing transcription. Resulting gene expression increases meta-
bolic resistance of the cell to hypoxia and apoptosis
and stimulates angiogenesis by subsequent production of
vascular endothelial growth factor (VEGF) (5). HIF-1a is
upregulated in most cancers, including prostate cancer (6).
Immunohistochemical studies show upregulation of
HIF-1a in prostate cancer compared with normal prostate
and benign prostatic hyperplasia (7). Moreover, upregula-
tion of HIF-1a is likely to be an early event in the develop-
ment of prostate cancer, given that increased levels were
observed in high-grade intraepithelial neoplasia, which is
considered the precursor of prostatic adenocarcinoma. Fur-
thermore, prostate tumor tissue adjacent to the intraepithelial
neoplasia showed an even more pronounced upregulation of
HIF-1a expression (8).
Tumor hypoxia is associated with poor prognosis and
increased resistance to radiotherapy. HIF-1a has an impor-
tant role in regulating tumor radiosensitivity through its
impact on apoptosis, metabolism, proliferation, and angio-
genesis (9). Tumor cells with upregulated HIF-1a levels
are more radioresistant than HIF-1a–deficient counterparts
(10). For localized prostate cancer, it has been shown that
increased expression of HIF-1a identifies patients at high
risk for biochemical failure (11). Studies in prostate cancer
cell lines have found that acute hypoxia promotes a more
aggressive metastatic phenotype (12). Here, we hypothesize
that androgen ablation downregulates hypoxia, as measured
by the expression of HIF-1a in human prostate cancer.
METHODS AND MATERIALS
Patients and biopsy specimen collection
After approval from the regional ethics committee at Uppsala
University (Dnr 2007/170), 20 patients with newly diagnosed pros-
tate cancer were enrolled. At diagnosis, six to 12 prostatic needle
core biopsy specimens were taken from each patient. All patients
were treated with castration. After castration (ie, approximately
1 month after surgery or 2 months after initiation of pharmacologic
castration, respectively), another two to four core biopsy specimens
were taken. At diagnosis, the biopsy specimens were taken
randomly. After castration, we took fewer samples and focused
on palpable nodules to increase the likelihood of finding cancer
cells.
Both before and after castration, we chose biopsy specimens rich
in cancer cells and used them for HIF-1 staining. Thus, there was
a high probability that the same tumor areas were represented at
both biopsy occasions. In 6 patients the postcastration biopsy spec-
imens did not include representative cancer areas and hence were
excluded from this study. The median age of the 14 patients
included in this study was 78 years (range, 59–87 years). Thirteen
patients had locally advanced cT3-4 tumors, and only 1 patient had
an organ-confined cT2 tumor. The median serum prostate-specific
antigen was 98 ng/mL (range, 3–1021 ng/mL). The median serum
testosterone level was 11.0 nmol/L (range, 6.6–23.0 nmol/L). The
median prostate volume measured with transrectal ultrasound was
52 mL (range, 20–100 mL).
Bilateral orchidectomy was performed in half of the patients,
and the other half was treated with a GnRH agonist (leuprorelin)
(Table 1). The mean time and standard deviation from orchidec-
tomy to repeated biopsy was 26 19 days and from administration
of GnRH-agonist to repeated biopsy 54  14 days. At the time of
postcastration biopsy, the serum testosterone levels varied from
0.3 to 0.9 nmol/L in surgically castrated patients and 0.3 to
1.7 nmol/L in patients receiving GnRH agonist therapy.
Histologic and immunofluorescence evaluation
Two biopsy specimens before and two after castration were
analyzed in each patient. The biopsy speciens were embedded in
paraffin and sectioned. One section from each biopsy specimen
was stained with hematoxylin and eosin (HE) and graded according
to the Gleason system (13). Sections adjacent to the HE-stained
sections were used for immunofluorescence studies. These sections
were deparaffinized and rehydrated before antigen retrieval in Tris/
EDTA pH 9.0 in a pressure cooker. After blocking in 3% BSA, the
sections were incubated with the primary antibody HIF-1a (1:500,
H-206 St. Cruz) at 4C overnight. After extensive rinsing, the
sections were incubated with the secondary antibody (donkey
Table 1. Characteristics of patients and tumors in the study
Patient
number
Patient
age (y)
Prostate
volume, mL cT GS
PSA, ng/mL Testosterone, nmol/L
Days between
biopsies
Castration
method
Before
castration
After
castration
Before
castration
After
castration
6 70 71 4 8 1021 21 12 0.9 53 GnRH agonist
9 83 20 3 7 8 0.3 14 0.8 70 GnRH agonist
10 87 59 3 7 34 1.9 15 0.7 60 GnRH agonist
12 61 26 2 7 17 6.4 ND 1.7 42 GnRH agonist
14 78 90 3 7 326 55 7 0.3 88 GnRH agonist
18 69 50 3 10 380 5.4 11 0.3 105 GnRH agonist
19 77 34 3 7 107 2.6 11 1.0 55 GnRH agonist
2 67 65 3 10 2.9 3.7 23 0.3 16 Orchidectomy
5 86 52 3 9 70 53 7 1.0 8 Orchidectomy
8 63 44 3 8 650 134 13 0.9 83 Orchidectomy
15 59 90 4 9 736 29 8 0.9 46 Orchidectomy
16 82 ND 3 7 16 1.1 16 0.6 49 Orchidectomy
17 84 46 4 8 438 138 9 0.6 29 Orchidectomy
20 83 100 3 9 89 23 10 0.3 40 Orchidectomy
Abbreviations: ND = not done; cT = clinical tumor stage; GG = Gleason grade; GS = Gleason score.
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(Table 1). The mean time and standard deviation from orchidec-
tomy to repeated biopsy was 26 19 days and from administration
of GnRH-agonist to repeated biopsy 54  14 days. At the time of
postcastration biopsy, the serum testosterone levels varied from
0.3 to 0.9 nmol/L in surgically castrated patients and 0.3 to
1.7 nmol/L in patients receiving GnRH agonist therapy.
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Two biopsy specimens before and two after castration were
analyzed in each patient. The biopsy speciens were embedded in
paraffin and sectioned. One section from each biopsy specimen
was stained with hematoxylin and eosin (HE) and graded according
to the Gleason system (13). Sections adjacent to the HE-stained
sections were used for immunofluorescence studies. These sections
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antirabbit-alexa 555, Molecular probe) for 1 hour at room temper-
ature. DNAwas counterstained with ToPro (Molecular probe), and
slides were mounted with prolong gold (Molecular probe).
A tumor area with a good immunofluorescence signal was
selected in each slide. To verify the tumor, the corresponding
area in the HE-stained section was identified. In the tumor area,
three images 100  100 mm, containing approximately 50 to 150
cells, were chosen for analysis. The images were analyzed with
ImageJ software (National Institute of Health) with respect to
mean intensity of HIF-1a in the nucleus and cytoplasm. The ToPro
signal was used as a marker for nuclei (Fig. 1). Biopsy specimens
without cancer were excluded. Fluorescence images were obtained
with a Zeiss LSM 510 inverted confocal microscope using a plana-
pochromat 20X/NA 0.75 objective. Bright light images were
obtained with a Nikon eclipse C600 microscope using a planapo-
chromat 20X/NA 0.75 objective.
RESULTS
Castration therapy of prostate cancer resulted in
downregulation of HIF-1a levels
HIF-1a expression was observed in the nucleus and in the
cytoplasm (Fig. 1). After castration, the intensity of HIF-1a
decreased to approximately half of the original values, both
in the nuclei and in the cytoplasm (Wilcoxon matched pairs,
p < 0.001) (Fig. 2A, B). Because no differences were
observed of HIF-1a expression between the nucleus and
the cytoplasm, mean intensities of total HIF-1a signal
were determined in all the following experiments (Fig. 2C).
Reduction of HIF-1a was most pronounced in tumors with
strong HIF-1a expression
Among the biopsy specimens taken from the 14 patients
before castration, a strong HIF-1a expression (mean inten-
sity more than 30) was shown in 5 patients, a weak expres-
sion (mean intensity 10–30) in 3 patients, and background
levels of HIF-1a (mean intensity 0–10) in 6 patients
(Fig. 3A). This is in accordance with other studies showing
that not all malignant prostate tumors have elevated levels
of HIF-1a (14, 15). Downregulation of HIF-1a after
castration was pronounced in the patients with high
initial HIF-1a levels, whereas levels were unaffected in the
group who initially had background levels of HIF-1a
(Figure 3A, Table 2).
Inspection of individual patients showed that a large and
statistically significant downregulation of HIF-1a after
castration was observed in 100% (5/5) of patients belonging
to the group showing strong HIF-1a expression before
castration, and 67% (2/3) of the group showing a weak
HIF-1a expression (Fig. 3B). In the group with background
level HIF-1a, only a minor difference in HIF-1a signal was
seen after castration, even though 1 patient showed
Fig. 1. HIF-1a levels in prostate tumors decrease after castration. Prostate tumor biopsy specimens from prostate cancer
patients before castration (left) and after surgical castration (right). Above, common hematoxylin and eosin staining.
Below, immunofluorescent staining with antibodies against HIF-1a. Middle, HIF-1a expression (red) superimposed
on ToPro-staining (DNA, blue). Bar = 100 mm.
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the cytoplasm, mean intensities of total HIF-1a signal
were determined in all the following experiments (Fig. 2C).
Reduction of HIF-1a was most pronounced in tumors with
strong HIF-1a expression
Among the biopsy specimens taken from the 14 patients
before castration, a strong HIF-1a expression (mean inten-
sity more than 30) was shown in 5 patients, a weak expres-
sion (mean intensity 10–30) in 3 patients, and background
levels of HIF-1a (mean intensity 0–10) in 6 patients
(Fig. 3A). This is in accordance with other studies showing
that not all malignant prostate tumors have elevated levels
of HIF-1a (14, 15). Downregulation of HIF-1a after
castration was pronounced in the patients with high
initial HIF-1a levels, whereas levels were unaffected in the
group who initially had background levels of HIF-1a
(Figure 3A, Table 2).
Inspection of individual patients showed that a large and
statistically significant downregulation of HIF-1a after
castration was observed in 100% (5/5) of patients belonging
to the group showing strong HIF-1a expression before
castration, and 67% (2/3) of the group showing a weak
HIF-1a expression (Fig. 3B). In the group with background
level HIF-1a, only a minor difference in HIF-1a signal was
seen after castration, even though 1 patient showed
Fig. 1. HIF-1a levels in prostate tumors decrease after castration. Prostate tumor biopsy specimens from prostate cancer
patients before castration (left) and after surgical castration (right). Above, common hematoxylin and eosin staining.
Below, immunofluorescent staining with antibodies against HIF-1a. Middle, HIF-1a expression (red) superimposed
on ToPro-staining (DNA, blue). Bar = 100 mm.
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a significant decrease and 1 other patient a significant
increase of HIF-1a after castration (Figure 3B).
Factors correlated to HIF-1a downregulation
To further investigate factors that might be related to
HIF-1a downregulation, we calculated the coefficient of
determination (R2) to get the explanatory power of the
variables (Table 3). The level of HIF-1a before castration
correlated well with the decrease of HIF-1a. Approximately
40% of the variation in the HIF-1a decrease could
be explained by the initial HIF-1a value. Besides that, we
found no significant correlations with other parameters
investigated (Table 3).
DISCUSSION
We report that HIF-1a levels are decreased after castration
in prostate cancer. We suggest that decreases in HIF-1a
levels reflect a decrease in tumor hypoxia after castration.
It is well established that tumor hypoxia is correlated with
radioresistance (10), likely owing to the need for oxygen
to produce tissue toxicity by radiotherapy. The concentration
of oxygen dissolved in tissues at the time of irradiation is
Fig. 2. HIF-1a is expressed at equal levels in the nucleus and cytoplasm. Quantification of HIF-1a immunofluorescent
staining intensity in (A) nuclei, (B) cytoplasm, and (C) nuclei and cytoplasm of prostate tumor biopsy specimens taken
before (white bars) and after (black bar) castration. The means and standard errors of 14 patients are shown. Values
marked with asterisks are statistically significant (*** p < 0.001: Wilcoxon matched pairs).
Fig. 3. HIF-1a is upregulated in a fraction of prostate tumors. Quantification of HIF-1a immunofluorescent staining
intensity in prostate tumor biopsy specimens before (white bars) and after (black bars) castration. Upregulation of
HIF-1awas classified as strong, weak, or at background level. (A) Patients pooled after HIF-1a classification. The means
and standard errors of indicated number of patients are shown. Values marked with asterisks are statistically significant
(*** p < 0.001; t test). (B) Individual patients are depicted. Themeans and standard errors of six images from two different
biopsy specimens are shown (s = significant, p < 0.05; ns = not significant, p > 0.05; t test).
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a significant decrease and 1 other patient a significant
increase of HIF-1a after castration (Figure 3B).
Factors correlated to HIF-1a downregulation
To further investigate factors that might be related to
HIF-1a downregulation, we calculated the coefficient of
determination (R2) to get the explanatory power of the
variables (Table 3). The level of HIF-1a before castration
correlated well with the decrease of HIF-1a. Approximately
40% of the variation in the HIF-1a decrease could
be explained by the initial HIF-1a value. Besides that, we
found no significant correlations with other parameters
investigated (Table 3).
DISCUSSION
We report that HIF-1a levels are decreased after castration
in prostate cancer. We suggest that decreases in HIF-1a
levels reflect a decrease in tumor hypoxia after castration.
It is well established that tumor hypoxia is correlated with
radioresistance (10), likely owing to the need for oxygen
to produce tissue toxicity by radiotherapy. The concentration
of oxygen dissolved in tissues at the time of irradiation is
Fig. 2. HIF-1a is expressed at equal levels in the nucleus and cytoplasm. Quantification of HIF-1a immunofluorescent
staining intensity in (A) nuclei, (B) cytoplasm, and (C) nuclei and cytoplasm of prostate tumor biopsy specimens taken
before (white bars) and after (black bar) castration. The means and standard errors of 14 patients are shown. Values
marked with asterisks are statistically significant (*** p < 0.001: Wilcoxon matched pairs).
Fig. 3. HIF-1a is upregulated in a fraction of prostate tumors. Quantification of HIF-1a immunofluorescent staining
intensity in prostate tumor biopsy specimens before (white bars) and after (black bars) castration. Upregulation of
HIF-1awas classified as strong, weak, or at background level. (A) Patients pooled after HIF-1a classification. The means
and standard errors of indicated number of patients are shown. Values marked with asterisks are statistically significant
(*** p < 0.001; t test). (B) Individual patients are depicted. Themeans and standard errors of six images from two different
biopsy specimens are shown (s = significant, p < 0.05; ns = not significant, p > 0.05; t test).
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a critical factor in determining the efficiency in radiotherapy.
Inasmuch as tumor hypoxia seems to decrease after castra-
tion, the increase of oxygen in tumors would be a plausible
explanation for the improved response to radiotherapy in
patients receiving neoadjuvant castration.
The influence of castration on hypoxia has previously
been investigated in mice bearing Shionogi tumors, which
is a model for androgen-sensitive prostate cancer (16). The
authors reported decreased hypoxia in regressed mouse tu-
mors 7 days after castration, in accordance with our results
in human prostate cancer. In the mouse experiment, this is
likely explained by increased apoptosis of tumor cells,
which may not be the case in the human prostate cancer
observed here. In the relapsed androgen-independent
tumors, the authors reported increased hypoxia (16). If this
is applicable to human prostate cancer, the timing of radio-
therapy after castration is crucial, and radiotherapy should
be carried out at the right time before the outgrowth
of androgen-independent tumor cells. Most patients with
localized untreated prostate cancer show a good biochemical
response to androgen deprivation therapy, but unfortunately
this correlates only weakly with the long-term prognosis of
the disease (17). Randomized clinical studies have shown
improvement on the long-term effect of androgen depriva-
tion therapy in combination with radiotherapy in high-risk
patients (2).
Here, we investigated the levels of HIF-1a as a marker of
hypoxia. Previously, it was shown that the androgen receptor
(AR) is coexpressed with HIF-1a and VEGF in androgen-
sensitive tumors (18). There is a possibility that the AR itself
may influence HIF-1a and VEGF expression, stimulating
angiogenesis in early prostate cancer development (8, 18).
In this scenario, it is possible that the decrease in HIF-1a
levels observed after castration is related to AR expression.
However, in a previous report of 22 patients, it was
observed that androgen withdrawal (through castration)
reduced hypoxia in prostate cancer, as measured by the
ultrasound-guided transrectal needle electrode technique
(19), which suggests that the decreased levels of HIF-1a
observed here could be associated with a reduction in
hypoxia.
It has previously been shown that tumor hypoxia downre-
gulates DNA repair, which could potentially contribute to
genetic instability in prostate cancer and decreased repair
Table 3. Coefficient of determination (R2) for HIF-1a levels and different parameters used in this study
Parameters
HIF–1a levels before castration HIF–1a decrease
R2 Sign p R2 Sign p
HIF1-1a decrease 0.39 + * 1.00 +
Age 0.00 – NS 0.00 + NS
PSA before castration (ng/ml) 0.03 + NS 0.01 – NS
Testosterone before castration (nmol/L) 0.00 + NS 0.02 – NS
Gleason grade 0.04 + NS 0.13 + NS
PSA after castration (ng/mL) 0.03 + NS 0.02 + NS
Testosterone after castration (nmol/L) 0.08 – NS 0.14 – NS
Days between biopsies 0.21 – NS 0.18 – NS
PSA decrease (ng/mL) 0.02 + NS 0.02 – NS
Testosterone decrease (nmol/L) 0.00 + NS 0.08 + NS
PSA decrease (%) 0.01 – NS 0.15 – NS
Testosterone decrease (%) 0.00 + NS 0.01 – NS
Abbreviations: HIF-1a = hypoxia-inducible factor-1a; PSA = prostate-specific antigen; NS = not significant.
p > 0.05 = NS, p < 0.05 =*.
Table 2. Mean values for parameters used in this study for the three groups sorted after their HIF-1a levels before castration
Parameters
HIF-1a expression before castration
Strong (above 30)
mean
Weak (10–30)
mean
Background (0–10)
mean
Background Vsv
strong*
HIF-1a before castration 42.8 16.9 5.7 p < 0.001
HIF-1a after/HIF-1a before 0.29 0.67 1.13 p < 0.01
Age (y) 76 77 76 NS
PSA before castration (ng/mL) 256 485 193 NS
Testosterone before castration (nmol/L) 13 10,1 11,9 NS
PSA after castration (ng/mL) 39.0 26.2 33.5 NS
Testosterone after castration (nmol/L) 0.59 0.78 0.91 NS
Days between biopsies 36 65 61 NS
PSA decrease (%) 85 94 83 NS
Testosterone decrease (%) 95 92 94 NS
Abbreviations: HIF-1a = hypoxia-inducible factor-1a; PSA = prostate-specific antigen; NS = not significant; Vsv = Vis-a-vis.
* t test, p > 0.05 = NS.
Downregulation of HIF-1a after castration in prostate cancer d F. L. T. AL-UBAIDI et al. 1247
a critical factor in determining the efficiency in radiotherapy.
Inasmuch as tumor hypoxia seems to decrease after castra-
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is applicable to human prostate cancer, the timing of radio-
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localized untreated prostate cancer show a good biochemical
response to androgen deprivation therapy, but unfortunately
this correlates only weakly with the long-term prognosis of
the disease (17). Randomized clinical studies have shown
improvement on the long-term effect of androgen depriva-
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(19), which suggests that the decreased levels of HIF-1a
observed here could be associated with a reduction in
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capacity in response to DNA-damaging agents (20). Effec-
tive DNA repair reduces the efficiency of radiotherapy;
thus, a reduced level of hypoxia in castrated prostate cancers
would be expected to be associated with an increase in DNA
repair, causing radioresistance in tumors. Clearly, sensitivity
to radiotherapy is enhanced after castration, which suggests
that any change in DNA repair caused by decreased hypoxia
is of less importance to the overall effect of radiotherapy.
Indeed, the influence of castration on DNA repair should
be the focus for future studies.
In conclusion, we demonstrate reduced levels of HIF-1a
in prostate cancer after castration, which is likely explained
by reduced hypoxia and may explain the increased radiosen-
sitivity of neoadjuvant castration in prostate cancer.
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Cancer Therapy: Clinical
Castration Therapy Results in Decreased Ku70 Levels in
Prostate Cancer
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Abstract
Purpose: Neoadjuvant castration improves response to radiotherapy of prostate cancer. Here, we
determine whether castration therapy impairs nonhomologous end-joining (NHEJ) repair of DNA
double-strand breaks (DSB) by downregulating Ku70 protein expression.
Experimental Design: Twenty patients with locally advanced prostate cancer were enrolled, and 6 to 12
needle core biopsy specimens were taken from the prostate of each patient before treatment. Bilateral
orchidectomy was conducted in eight patients and 12 patients were treated with a GnRH agonist. After
castration, two to four similar biopsies were obtained, and the levels of Ku70 and g-H2AX foci were
determined by immunoﬂuorescence in veriﬁed cancer tissues.
Results:Weobserved that the androgen receptor binds directly toKu70 inprostate tissue.We also found a
reduction of the Ku70 protein levels in the cell nuclei in 12 of 14 patients (P < 0.001) after castration. The
reduction in Ku70 expression correlated signiﬁcantly with decreased serum prostate-speciﬁc antigen (PSA)
levels after castration, suggesting that androgen receptor activity regulates Ku70 protein levels in prostate
cancer tissue. Furthermore, a signiﬁcant correlation between the reductions of Ku70 after castration versus
changes induced of castration of g-H2AX foci could be seen implicating a functional linkage of decreased
Ku70 levels and impaired DNA repair.
Conclusions: Castration therapy results in decreased levels of the Ku70 protein in prostate cancer cells.
Because the Ku70 protein is essential for the NHEJ repair of DSBs and its downregulation impairs DNA
repair, this offers a possible explanation for the increased radiosensitivity of prostate cancer cells following
castration. Clin Cancer Res; 19(6); 1547–56. 2013 AACR.
Introduction
Approximately one million new cases of prostate cancer
are diagnosed in the world each year (1). Nonmetastatic
prostate cancer is potentially curable and one treatment
modality is radiotherapy, either alone or in combination
with neoadjuvant castration therapy using gonadotropin-
releasing hormone (GnRH) agonists for a limited period of
time. Clinical studies have shown synergistic effects
between castration and radiotherapy (2). A more detailed
understanding of the cellular and molecular mechanisms
behind this synergism would allow us to optimize treat-
ment and may also give rise to novel therapeutic applica-
tions. We have previously shown that the hypoxia levels in
prostate cancer tissue decrease following castration (3).
Because hypoxia is associated with poor response to radio-
therapy (4, 5), reduced hypoxia after castration may offer
one plausible mechanistic explanation.
The androgen receptor plays an important role in the
genesis, growth, and survival of normal prostate cells.
Epidemiologic studies have failed to show any relationship
between high serum levels of testosterone/dihydrotestos-
terone or adrenal androgen and prostate cancer risk (6, 7).
In a rat model, a reduction in serum dihydrotestosterone
after castration resulted in a 70% loss of secretory epithelial
prostate cells by means of apoptosis (8). In the cytoplasm,
the androgen receptor is found in inactive complexes bound
to the HSP70 andHSP90 and as a corepressor. Testosterone
and dihydrotestosterone bind to the androgen receptor as
ligands. Androgen receptor translocates to the nucleus
and binds to androgen response elements (ARE) in the
promoter regions of target genes, thus inducing cell prolif-
eration (9).
Castration therapy by orchidectomy or pharmacologic
castration adequately reduces the serum testosterone below
1.7 nmol/L. However, intraprostatic tissue testosterone
levels reduce only by 75% (10) which in turn leads to
reduction rather than abrogation of androgen receptor
activities. Castration is not curative as a single treatment
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modality but is the most effective palliative treatment in
metastasized prostate cancer. There is no difference in long-
term survival between the 2 castration methods (11, 12).
Castration is achieved almost immediately after bilateral
orchidectomy and approximately 4 weeks after initiating
treatment with GnRH agonists (13). Randomized clinical
trials have shown longer survival of patients with prostate
cancer after combined castration and radiotherapy of the
primary tumor than after radiotherapy alone (2, 14). This
clinically observed increased radiosensitivity of prostate
cancer after castration was not seen in vitro with cell lines
LNCaP and PC-3 (15, 16).
The expression of prostate-speciﬁc antigen (PSA) is pri-
marily regulated by androgen receptor via AREs (17) and is
considered to be the most effective single biomarker for
monitoring the metabolic activity of prostate cancer cells
before, during, and after radiotherapy (18).
Nonhomologous end-joining (NHEJ) is the major DNA
repair pathway involved in the repair ofDNAdouble-strand
breaks (DSB) after ionizing radiation (IR; ref. 19). Unre-
paired or misrepaired DSBs lead either to cell death or
chromosomal translocations and genomic instability. DNA
protein kinase (DNA-PK) is a key component of NHEJ
(20), which consists of the Ku70–Ku80 heterodimer and
the DNA-PK catalytic subunit (DNA-PKcs) to form the
DNA-PK complex. Ku proteins play a central role in NHEJ
by detecting DSB ends and tethering them together (21,
22). Cells deﬁcient in Ku70 and Ku80 proteins are
extremely sensitive to IR (23, 24). Even though Ku70 is
mainly located in the nucleus, a fraction of it is located in
the cytoplasm. The cytoplasmic fraction of Ku70 binds
the proapoptotic protein Bax, preventing its translocation
to mitochondria and thereby suggesting that Ku70 sup-
presses mitochondrially mediated apoptosis. Depletion
of the level of cytosolic Ku70 has been shown to induce
apoptosis in colorectal cancer (25). Because the Ku70
protein has been shown, in prostate cell lines, to act as a
coactivator of androgen receptor (26), we wanted to test
whether the differential AR function after castration inﬂu-
ences Ku70 protein levels. If so, it might offer an expla-
nation for increased apoptosis and radiosensitivity after
castration.
Using prostate needle core biopsy specimens from
patients with prostate cancer, we tested whether castration
downregulates the expression of Ku70 proteins in prostate
cancer specimens, subsequently leading to defective DNA
repair and increased cell death.
Materials and Methods
Patient material and collection
Twenty patients with newly diagnosed prostate cancer
were enrolled in the study, after the approval of the regional
ethics committee at Uppsala University (Uppsala, Sweden;
Dnr 2007/170).
At diagnosis, the ﬁrst biopsy setting, 6 to 12 prostatic
needle core biopsy specimens were taken randomly from
each patient. All patients were then treated with castration
therapy, eitherwith bilateral orchidectomyorwith aGnRH-
agonist (leuprorelin; Table 1). After castration, that is,
approximately 1 month after orchidectomy and 2 months
after the initiation of the GnRH agonist, the second biopsy
setting, 2 to 4 prostatic needle core biopsy specimens were
taken from each patient. To increase the likelihood of
obtaining representative specimens, only presumed tumor
areas were chosen for the second biopsy setting. Six patients
were excluded from the study because biopsy specimens
from their second biopsy setting did not contain represen-
tative cancer areas. Fourteen patients were included in the
study and their median age was 78 years (range, 59–89
years). Themedian PSA level was 98 ng/mL (range, 3–1,021
ng/mL). The median serum testosterone level was 11.0
nmol/L (range, 6.6–23.0 nmol/L). The median prostate
volume measured by means of transrectal ultrasound was
52 mL (range, 20–160 mL). Thirteen patients had locally
advanced cT3-4 tumors and only one patient had an organ-
conﬁned cT2 tumor. Half of the patients received a GnRH
agonist, whereas bilateral orchidectomy was conducted in
the other half. Themean time and SD fromorchidectomy to
the second biopsy was 26  19 days and from initiating
GnRHagonist treatment to secondbiopsywas 5414days.
After orchidectomy, the PSA levels varied from 1 to 148 ng/
mL and the serum testosterone levels from 0.3 to 0.9 nmol/
L. After GnRH agonist treatment, the PSA was 0.3 to 55 ng/
mL and serum testosterone 0.3 to 1.7 nmol/L.
Histological and immunoﬂuorescence evaluation
From each patient, 2 biopsy specimens before and two
after castrationwere chosen. The specimenswere embedded
in parafﬁn and sectioned. One section from each biopsy
specimenwas stainedwithhematoxylin and eosin (HE) and
graded according to the Gleason system (27). Sections
adjacent to the HE-stained sections were used for immu-
noﬂuorescence studies.
Deparafﬁnization and rehydration of the sections from 2
series of slides were conducted before antigen retrieval in
Tris/EDTA, pH 9.0, in a pressure cooker. The sections were
blocked in 3% bovine serum albumin (BSA). Afterward,
sections from the ﬁrst set were incubated with the primary
Translational Relevance
Clinical studies have shown improved radiotherapy
response and longer overall survival for patients with
prostate cancer after neoadjuvant androgen deprivation,
but mechanistic insights are missing. In this study, the
levels of the Ku70 protein, critical for DNA double-
strand break repair, decrease after castration in parallel
with corresponding reduction in serum prostate-speciﬁc
antigen (PSA). This reduced level of the repair protein
offers a probable explanation for the increased treatment
efﬁciency, when radiotherapy is combined with castra-
tion therapy. Furthermore, according to our data, the
castration-induced decrease in PSA may predict a suc-
cessful response to radiotherapy.
Al-Ubaidi et al.
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antibody KU-70 (1:500, 3C3.11 Santa Cruz) at 4C over-
night. While sections from the second set were incubated
with the primary antibody g-H2AX (1:500, 3F2, Abcam) at
4C overnight. Extensive rinsing was conducted once the
sections were incubated with the secondary antibody (don-
key anti mouse IgG-Alexa 488, Molecular probe) for 1 hour
at room temperature. DNA was counterstained with TO-
PRO-3 iodide (Molecular probe) and slides mounted with
pro long gold (Molecular probe).
An image from a tumor area with a good degree of
immunoﬂuorescence signals from each biopsy was selected.
The corresponding area in the HE-stained section was iden-
tiﬁed for the histologic veriﬁcation of the tumor area. In
Ku70-stained slides, 3 areas containing approximately 50 to
100cellswere chosen for analysis. The3 areaswere analyzed,
using NIH ImageJ, with respect to medium intensity in the
nucleus (TO-PRO-3was used asDNAmarker), andmedium
intensity outside the nucleus. In the g-H2AX–stained slides,
a tumor area containing approximately 150 to 300 cellswere
chosen for analysis with NIH ImageJ. Areas inside the
nucleus with a g-H2AX intensity higher than 75% of max
intensity were considered as g-H2AX foci. The number of
foci were counted and expressed as foci/DNA unit.
Fluorescence images were obtained with a Zeiss LSM
510–inverted confocalmicroscopeusing aplanapochromat
20/numerical aperture (NA) 0.75 objective. Bright light
images were obtained with a Nikon eclipse C600 micro-
scope using a planapochromat 20/NA 0.75 objective.
Coimmunoprecipitation of androgen receptor with
Ku70
Frozen prostate tissue biopsies were disintegrated in a
Potter homogenizer, andproteinswere extractedwith a lysis
buffer 10 mmol/L HEPES, pH 7.5, 300 mmol/L NaCl, 0.2
mmol/L EDTA, 10mmol/L dithiothreitol (DTT), 20% glyc-
erol, and 0.1% Triton X-100 supplemented with a complete
protease inhibitor cocktail (Roche Applied Science). After
centrifugation at 23,000 g for 20minutes, the supernatant
was incubated with mouse monoclonal anti-Ku70 Ab (sc-
12729, Santa Cruz) by rotation at 4C overnight. Protein A/
G-agarose beads (sc-2003, Santa Cruz) were added and the
mixture was incubated for 2 hours at 4C. The beads were
collected at 1,000  g and washed twice with a lysis buffer
and once with a lysis buffer without glycerol. The co-
immunoprecipitated proteinswere eluted by boiling in LDS
sample buffer with a reducing agent (Invitrogen). Samples
were, after electrophoresis, blotted on to nitrocellulose
membranes and probed with the monoclonal mouse
anti-human androgen receptor Ab (Dako M356201-2),
anti-Ku70 Ab (sc-12729), and anti-actin Ab (sc-1616) fol-
lowed by incubation with a horseradish peroxidase–con-
jugated secondary antibody (Thermo Scientiﬁc), and pro-
tein bands were visualized using a SuperSignal West Femto
chemiluminescence substrate (Thermo Scientiﬁc).
Results
Ku70 interacts with the androgen receptor in prostate
cancer tissue
Radiosensitive cells have previously been isolated, and
the underlyingmechanism explaining the sensitivity has, in
most cases, been defects in DNA repair (28). We hypoth-
esized that castration therapy may alter the DNA repair
capacity of prostate cancer cells. Androgen receptor activity
is altered following castration and it has previously been
reported that Ku70 interacts with the androgen receptor in
the prostate cell line LNCaP (26). To investigate whether
this interaction is also present in in vivo material, a co-
immunoprecipitation of androgen receptorwithKu70 from
Table 1. Patient demography and tumor characteristics of patients included in this study
PSA, ng/mL Testosterone, nmol/L
Patient
number
Patient
age
Prostate
volume, ml cT GS
Before
castration
After
castration
Before
castration
After
castration
Days between
castration and
biopsies II
Castration
method
6 70 71 4 8 1,021 21 12 0.9 47 GnRH agonist
9 83 20 3 7 8 0.3 14 0.8 62 GnRH agonist
10 87 59 3 7 34 1.9 15 0.7 36 GnRH agonist
12 61 26 2 7 17 6.4 ND 1.7 36 GnRH agonist
14 78 90 3 7 326 55 7 0.3 48 GnRH agonist
18 69 50 3 10 380 5.4 11 0.3 83 GnRH agonist
19 77 34 3 7 107 2.6 11 1.0 48 GnRH agonist
2 67 65 3 10 2.9 3.7 23 0.3 4 Orchidectomy
5 86 52 3 9 70 53 7 1.0 6 Orchidectomy
8 63 44 3 8 650 134 13 0.9 8 Orchidectomy
15 59 90 4 9 736 29 8 0.9 46 Orchidectomy
16 82 ND 3 7 16 1.1 16 0.6 49 Orchidectomy
17 84 46 4 8 438 138 9 0.6 29 Orchidectomy
20 83 100 3 9 89 23 10 0.3 40 Orchidectomy
Abbreviations: cT, clinical tumor stadium; GS, Gleason score; ND, not done.
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prostate tissue extracts before and after castration indicated
an interaction between androgen receptor and Ku70 both
before and after castration (Fig. 1), and we also found that
the castration itself did not inﬂuence the interaction
between the two proteins.
Ku70 protein levels decrease following castration
Because the androgen receptor and Ku70 proteins inter-
act, we subsequently wanted to determine whether the
Ku70 protein levels are inﬂuenced by castration. We quan-
tiﬁed the levels of Ku70 protein in cancer areas in paired
slides from 14 eligible patients (Table 1) with high-grade
prostate cancer before and after castration (Fig. 2). The
levels of Ku70 in the nuclei were reduced by approximately
half the value observed before castration (P ¼ 0.001; Fig.
3A). A decrease of the samemagnitude could also be seen in
the Ku70 localized outside the nuclei (P ¼ 0.006; Fig. 3B).
However, the intensity of Ku70 was always higher in the
nuclei than outside, both before and after castration (Figs. 2
and 3A and B).
We observed large individual variations in Ku70 protein
levels both for the intranuclear fraction, ranging from 20 to
180, and the extranuclear fraction, ranging from 4 to 120
arbitrary intensity units (Fig. 3C and D). After castration, a
decrease in the Ku70 level was seen in almost all patients in
both fractionsofKu70 (Fig. 3CandD). Patientswhodidnot
respond with a Ku70 decrease after castration had very low
initial Ku70 values (Fig. 3C and D). In fact, the initial Ku70
value, that is, before castration, correlated well with the
decrease in Ku70 after castration in both fractions of Ku70
(intranuclear R2 ¼ 0.811, P < 0.0001; Fig. 3E, extranuclear
(R2 ¼ 0.944, P  0.0001; Fig. 3F). Even though the level of
Ku70 varied greatly between patients, the Ku70 value
between the 2 fractions, intra- and extranuclear, correlated
well for each patient (R2 ¼ 0.817, P < 0.0001; Fig. 3G).
Ku70 does not correlate with prostate size, serum PSA,
serum testosterone, Gleason score, or patient age
The interindividual variations in initial Ku70 levels are
large and can vary by a factor of 10 for both nuclear and
cytoplasmic Ku70 (see Fig. 3C and D). We investigated
whether there was any correlation between the Ku70 levels
and other parameters measured in this study. There was no
signiﬁcant correlation to prostate size (R2¼ 0.14, P¼ 0.97),
PSA level (R2 ¼ 0.004, P ¼ 0.97), testosterone level (R2 ¼
0.0004, P ¼ 0.80), Gleason score (R2 ¼ 0.09, P ¼ 0.81), or
age (R2 ¼ 0.007, P ¼ 0.48) versus the nucleic fraction of
Ku70. This observation was also valid for the cytoplasmic
fraction of Ku70 [prostate size (R2 ¼ 0.20, P ¼ 0.66), PSA
level (R2¼ 0.0001, P¼ 0.94), testosterone level (R2¼ 0.02,
P¼ 0.49), Gleason score (R2¼ 0.07, P¼ 0.82), and age (R2
¼ 0.004, P ¼ 0.60)].
Ku70 reduction after castration correlates with
decreased PSA, but not with decreased testosterone
levels
Although there was signiﬁcant decrease in Ku70 levels in
prostate cancer cells after castration, the interindividual
variations of the castration-induced changes in Ku70 levels
were large, spanning from 2% to 126% in nuclei and 2% to
340% in cytoplasm. There was also a large variation in the
testosterone and PSA reductions. The castration-induced
reduction in serum PSA varied from 24% to 99% (Table 1).
For patient number 2, who had a low PSA and did not
respond to hormonal treatment, we noticed a 28% increase
of PSA compared with the precastration value. The reduc-
tion of serum testosterone varied from 85% to 98%.
We compared pharmacologically castrated with orchi-
dectomized patients. Patient number 8 belonged to the
surgical castration group and showed atypical data in com-
parison with the rest of this subgroup and was, therefore,
considered an outlier and was excluded from the calcula-
tions of coefﬁcient of determination and probability values.
The valueofpatient 8 is depicted as anunﬁlled circle in every
ﬁgure. Between the 2 subgroups, there were no signiﬁcant
differences inmeasuredparameters. Both types of castration
showa signiﬁcant correlationbetween thedecrease inKu70,
both in the nuclear and the cytoplasmic fractions, and the
decrease inPSA after castration (chemical nuclearR2¼0.91,
P ¼ 0.003, cytoplasmic R2 ¼ 0.77, P ¼ 0.023 and surgical
nuclear R2 ¼ 0.73, P ¼ 0.018, cytoplasmic R2 ¼ 0.84, P ¼
0.005 Fig. 4A–D). No such correlation could be seen
between the decrease in Ku70 and the decrease in testos-
terone after castration (chemical nuclear R2 ¼ 0.014, P ¼
0.96, cytoplasmic R2¼ 0.002, P¼ 0.70 and surgical nuclear
R2 ¼ 0.002, P ¼ 0.96, cytoplasmic R2 ¼ 0.11, P ¼ 0.62).
Ku70 and PSA kinetics after castration are related
The kinetics of PSA and testosterone decrease depends on
the castration method and this may inﬂuence the effect on
Ku70 levels differently. Therefore, PSA kinetics could poten-
tially be used to calculate the optimal time for starting
radiotherapy.
To obtain an indication of the kinetics of the Ku70
decrease, the correlation between Ku70 decrease and the
interval between the ﬁrst and second biopsies was investi-
gated. Patients treated with bilateral orchidectomy showed
a strong signiﬁcant correlation (R2 ¼ 0.77, P ¼ 0.02; Fig.
1         2          3         4
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Androgen receptor
Actin
Ku 70
Figure 1. Ku70 interacts with the androgen receptor (AR) in prostate
cancer tissue. Coimmunoprecipitation of AR with Ku70 from prostate
cancer tissue extract. Lanes 1 and 3, 10% of tissues extract input. Lanes
2 and 4, AR eluted from anti-Ku70 Abþ Protein A/G beads. Western blot
analysis of total tissue extract and eluted AR. Antibodies used for
immunoblots are identiﬁed on the right.
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Because the androgen receptor and Ku70 proteins inter-
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Ku70 protein levels are inﬂuenced by castration. We quan-
tiﬁed the levels of Ku70 protein in cancer areas in paired
slides from 14 eligible patients (Table 1) with high-grade
prostate cancer before and after castration (Fig. 2). The
levels of Ku70 in the nuclei were reduced by approximately
half the value observed before castration (P ¼ 0.001; Fig.
3A). A decrease of the samemagnitude could also be seen in
the Ku70 localized outside the nuclei (P ¼ 0.006; Fig. 3B).
However, the intensity of Ku70 was always higher in the
nuclei than outside, both before and after castration (Figs. 2
and 3A and B).
We observed large individual variations in Ku70 protein
levels both for the intranuclear fraction, ranging from 20 to
180, and the extranuclear fraction, ranging from 4 to 120
arbitrary intensity units (Fig. 3C and D). After castration, a
decrease in the Ku70 level was seen in almost all patients in
both fractionsofKu70 (Fig. 3CandD). Patientswhodidnot
respond with a Ku70 decrease after castration had very low
initial Ku70 values (Fig. 3C and D). In fact, the initial Ku70
value, that is, before castration, correlated well with the
decrease in Ku70 after castration in both fractions of Ku70
(intranuclear R2 ¼ 0.811, P < 0.0001; Fig. 3E, extranuclear
(R2 ¼ 0.944, P  0.0001; Fig. 3F). Even though the level of
Ku70 varied greatly between patients, the Ku70 value
between the 2 fractions, intra- and extranuclear, correlated
well for each patient (R2 ¼ 0.817, P < 0.0001; Fig. 3G).
Ku70 does not correlate with prostate size, serum PSA,
serum testosterone, Gleason score, or patient age
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large and can vary by a factor of 10 for both nuclear and
cytoplasmic Ku70 (see Fig. 3C and D). We investigated
whether there was any correlation between the Ku70 levels
and other parameters measured in this study. There was no
signiﬁcant correlation to prostate size (R2¼ 0.14, P¼ 0.97),
PSA level (R2 ¼ 0.004, P ¼ 0.97), testosterone level (R2 ¼
0.0004, P ¼ 0.80), Gleason score (R2 ¼ 0.09, P ¼ 0.81), or
age (R2 ¼ 0.007, P ¼ 0.48) versus the nucleic fraction of
Ku70. This observation was also valid for the cytoplasmic
fraction of Ku70 [prostate size (R2 ¼ 0.20, P ¼ 0.66), PSA
level (R2¼ 0.0001, P¼ 0.94), testosterone level (R2¼ 0.02,
P¼ 0.49), Gleason score (R2¼ 0.07, P¼ 0.82), and age (R2
¼ 0.004, P ¼ 0.60)].
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prostate cancer cells after castration, the interindividual
variations of the castration-induced changes in Ku70 levels
were large, spanning from 2% to 126% in nuclei and 2% to
340% in cytoplasm. There was also a large variation in the
testosterone and PSA reductions. The castration-induced
reduction in serum PSA varied from 24% to 99% (Table 1).
For patient number 2, who had a low PSA and did not
respond to hormonal treatment, we noticed a 28% increase
of PSA compared with the precastration value. The reduc-
tion of serum testosterone varied from 85% to 98%.
We compared pharmacologically castrated with orchi-
dectomized patients. Patient number 8 belonged to the
surgical castration group and showed atypical data in com-
parison with the rest of this subgroup and was, therefore,
considered an outlier and was excluded from the calcula-
tions of coefﬁcient of determination and probability values.
The valueofpatient 8 is depicted as anunﬁlled circle in every
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differences inmeasuredparameters. Both types of castration
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decrease inPSA after castration (chemical nuclearR2¼0.91,
P ¼ 0.003, cytoplasmic R2 ¼ 0.77, P ¼ 0.023 and surgical
nuclear R2 ¼ 0.73, P ¼ 0.018, cytoplasmic R2 ¼ 0.84, P ¼
0.005 Fig. 4A–D). No such correlation could be seen
between the decrease in Ku70 and the decrease in testos-
terone after castration (chemical nuclear R2 ¼ 0.014, P ¼
0.96, cytoplasmic R2¼ 0.002, P¼ 0.70 and surgical nuclear
R2 ¼ 0.002, P ¼ 0.96, cytoplasmic R2 ¼ 0.11, P ¼ 0.62).
Ku70 and PSA kinetics after castration are related
The kinetics of PSA and testosterone decrease depends on
the castration method and this may inﬂuence the effect on
Ku70 levels differently. Therefore, PSA kinetics could poten-
tially be used to calculate the optimal time for starting
radiotherapy.
To obtain an indication of the kinetics of the Ku70
decrease, the correlation between Ku70 decrease and the
interval between the ﬁrst and second biopsies was investi-
gated. Patients treated with bilateral orchidectomy showed
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5A), whereas patients treated with GnRH agonist had no
signiﬁcant correlation (R2¼ 0.36, P¼ 0.26; Fig. 5B). Similar
results were achieved for the cytoplasmic fraction of Ku70
(Supplementary Fig. S1). This suggests that theKu70 level in
patients treated with bilateral orchidectomy is still decreas-
ing in the time span used here, whereas the Ku70 levels in
patients treated with GnRH agonist have reached a plateau.
To see whether the PSA levels had similar kinetics, the
correlation between PSA decrease and the number of days
between biopsies was analyzed. Indeed, in patients treated
with bilateral orchidectomy, a signiﬁcant correlation was
seen between the decrease in the PSA value and the number
of days after castration (R2 ¼ 0.84, P ¼ 0.019; Fig. 5C). In
contrast, patients treatedwithGnRH agonist did not show a
signiﬁcant correlation (R2 ¼ 0.25, P ¼ 0.26; Fig. 5D).
Investigating the decrease in testosterone versus the days
after castration, we found that patients treatedwith bilateral
orchidectomy hadno signiﬁcant correlation (R2¼ 0.03, P¼
0.66; Fig. 5E), which was expected because all the reduction
in testosterone levels normally occurs the ﬁrst few days after
bilateral orchidectomy. A similar picture was seen in the
group treated with a GnRH agonist (R2 ¼ 0.19, P ¼
Figure 2. Determination of Ku70 in
prostate tumors. A, top left, an
immunohistoﬂuorescence-stained
section of a prostate biopsy before
castration. The 3 squares outlined in
the middle of the image mark the
area chosen for intensity
measurement. Ku70 is stainedwith a
mouse-monoclonal antibody (green)
and the DNA is costained with
TO-PRO-3 (blue). Top right, a
corresponding area fromanadjacent
section stained with hematoxylin
and eosin. The 3 panels below are
close-ups of the 3 areas depicted for
intensity measurements. B, as in A,
but the biopsy is taken after
castration, but from the same
patient.
A
B
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0.062; Fig. 5F). These data suggest that the kinetics of PSA
decrease is themost relevant parameter to use for predicting
when the minimum level of Ku70 has been reached and,
thereby, the most optimal time point for radiation
treatment.
Ku70 reduction after castration correlates with an
increase of g-H2AX foci
To investigate whether the initial Ku70 values or the
decrease of Ku70 after castration would be reﬂected in the
amount of unrepaired endogenous DNA damages, we
stained slides from the biopsies with an antibody against
g-H2AX. Images of tumor areas were then analyzed with
respect to the number of g-H2AX foci/DNA unit with a
program written in ImageJ (Fig. 6A–C). No signiﬁcant
difference in g-H2AX foci could be seen in mean values of
biopsies before and after castration (Fig. 6D). Neither could
any correlation between the initial Ku70 values versus the
amount of g-H2AX foci be seen (R2 ¼ 0.009, P ¼ 0.3).
However, a signiﬁcant correlation between the reductions
of Ku70 after castration versus changes induced of castra-
tion of g-H2AX foci could be seen (Fig. 6E, R2 ¼ 0.37, P ¼
0.022). These data could point to a reduced repair of DNA
damage following a decrease of Ku70 levels.
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Figure 3. Effect of castration on
Ku70 in prostate tumors. A, mean
intensity of Ku70 in nuclei before
(white bars) and after (black bars)
castration. Error bars show SEM.
, P < 0.001, Student t test. B,
mean intensity of Ku70 outside the
nuclei before (white bars) and after
(black bars) castration. Error bars
show SEM. , P < 0.01, Student
t test. C, Ku70 intensity in nuclei of
individual patients before (white
bars) and after (black bars)
castration. Error bars show SEM.
D,Ku70 intensity outside thenuclei
of individual patients before (white
bars) and after (black bars)
castration. Error bars show SEM.
E, correlation between the Ku70
intensity in nuclei before castration
versus the decrease in intensity
in the nuclei after castration.
R2 ¼ 0.81; P < 0.0001. F,
correlation between the Ku70
intensity outside the nuclei before
castration versus the decrease in
intensity outside the nuclei after
castration. R2 ¼ 0.94; P < 0.0001.
G, correlation between the Ku70
intensity in nuclei before castration
versus the intensity outside the
nuclei before castration.R2¼ 0.82;
P < 0.0001. Statistics used:
Spearman rank correlation
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0.062; Fig. 5F). These data suggest that the kinetics of PSA
decrease is themost relevant parameter to use for predicting
when the minimum level of Ku70 has been reached and,
thereby, the most optimal time point for radiation
treatment.
Ku70 reduction after castration correlates with an
increase of g-H2AX foci
To investigate whether the initial Ku70 values or the
decrease of Ku70 after castration would be reﬂected in the
amount of unrepaired endogenous DNA damages, we
stained slides from the biopsies with an antibody against
g-H2AX. Images of tumor areas were then analyzed with
respect to the number of g-H2AX foci/DNA unit with a
program written in ImageJ (Fig. 6A–C). No signiﬁcant
difference in g-H2AX foci could be seen in mean values of
biopsies before and after castration (Fig. 6D). Neither could
any correlation between the initial Ku70 values versus the
amount of g-H2AX foci be seen (R2 ¼ 0.009, P ¼ 0.3).
However, a signiﬁcant correlation between the reductions
of Ku70 after castration versus changes induced of castra-
tion of g-H2AX foci could be seen (Fig. 6E, R2 ¼ 0.37, P ¼
0.022). These data could point to a reduced repair of DNA
damage following a decrease of Ku70 levels.
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Discussion
We show a reduction of the Ku70 protein in prostate
cancer tissues after castration. The Ku70 protein is a major
determinant of radiosensitivity. In several unbiased muta-
tional screens in mammalian cells, the Ku70 mutant cells,
defective in NHEJ (24), were isolated as the most radiosen-
sitive (28). It is well established that the Ku70/Ku80 com-
ponents of NHEJ are the most critical for effective DSB
repair and they work in aDNA-PK–dependentmanner after
irradiation (19, 29). Hence, the severe depletion of Ku70
protein levels after castration is likely to impair NHEJ in the
prostate cancer tissues and explain the increased sensitivity
to radiotherapy. Several previous studies have shown that
cells depleted with Ku70 are using an alternative backup
pathway termed B-NHEJ in repairing irradiation-induced
DSBs and PARP-1 is a major component of this alternative
repair pathway (30). After castration, effective B-NHEJ
mediated by PARP-1 would be expected to improve DSBs
repair and reduce the efﬁcacy of radiotherapy. Thus, sup-
pression of B-NHEJ by PARP inhibitors would further
improve radiosensitivity. However, the role of PARP-1 in
prostate cancer is very complex as it has recently been shown
to mediate androgen receptor function (31). Certainly, the
role of PARP-1 in the repair of irradiation inducedDSBs and
androgen receptor transcription with and without castra-
tion warrant further studies.
To test whether the reduction of Ku70 seen after castra-
tion changed the repair kinetics of endogenous DNA
lesions, we stained for the DNA DSB marker g-H2AX. A
signiﬁcant positive correlation could be seen between Ku70
reductions and increase in g-H2AX foci (Fig. 6E). However,
no signiﬁcant difference could be seen between biopsies
before and after castration (Fig. 6D). This seemingly con-
tradictory resultmay be explained by the castration effect on
cell proliferation. Cells are constantly exposed to endoge-
nous reactive oxygen species (ROS) production and repli-
cation failure leading to DNA lesions. This is particularly
true for cancer cells that often have an elevated ROS level. A
high ROS level leads toDNA single-strand breaks, and if not
repaired, collapsed replication forks during replication
(32). Collapsed replication forks are one ended DNA DSBs
andwill bemarkedwith g-H2AX. Androgen depletion leads
to decreased rates of proliferation and thereby fewer col-
lapsed replication forks. On the other hand, as shown
Figure 4. ADT-induced Ku70
decrease correlates with a decrease
in PSA in patients with prostate
cancer. A, correlation between the
changes induced by chemical
castration in Ku70 in the nuclei
versus changes induced by
chemical castration in serum PSA.
R2 ¼ 0.91; P ¼ 0.003. The values of
Ku70 and PSA are given in
percentage of value before
castration. B, as in A, but for Ku70
outside the nuclei. R2 ¼ 0.77;
P ¼ 0.023. C, correlation between
the changes induced by surgical
castration in Ku70 in the nuclei
versus changes induced by surgical
castration in serum PSA. R2 ¼ 0.73;
P ¼ 0.018. The values of Ku70 and
PSA are given in percentage of value
before castration. D, as in C, but for
Ku70, outside the nuclei. R2 ¼ 0.84;
P ¼ 0.005. Statistics used:
Spearman rank correlation
coefﬁcient. The unﬁlled circles in C
and D represent the value from
patient 8, who was considered an
outlier and is therefore not included
in the calculations of R2 and P.
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Discussion
We show a reduction of the Ku70 protein in prostate
cancer tissues after castration. The Ku70 protein is a major
determinant of radiosensitivity. In several unbiased muta-
tional screens in mammalian cells, the Ku70 mutant cells,
defective in NHEJ (24), were isolated as the most radiosen-
sitive (28). It is well established that the Ku70/Ku80 com-
ponents of NHEJ are the most critical for effective DSB
repair and they work in aDNA-PK–dependentmanner after
irradiation (19, 29). Hence, the severe depletion of Ku70
protein levels after castration is likely to impair NHEJ in the
prostate cancer tissues and explain the increased sensitivity
to radiotherapy. Several previous studies have shown that
cells depleted with Ku70 are using an alternative backup
pathway termed B-NHEJ in repairing irradiation-induced
DSBs and PARP-1 is a major component of this alternative
repair pathway (30). After castration, effective B-NHEJ
mediated by PARP-1 would be expected to improve DSBs
repair and reduce the efﬁcacy of radiotherapy. Thus, sup-
pression of B-NHEJ by PARP inhibitors would further
improve radiosensitivity. However, the role of PARP-1 in
prostate cancer is very complex as it has recently been shown
to mediate androgen receptor function (31). Certainly, the
role of PARP-1 in the repair of irradiation inducedDSBs and
androgen receptor transcription with and without castra-
tion warrant further studies.
To test whether the reduction of Ku70 seen after castra-
tion changed the repair kinetics of endogenous DNA
lesions, we stained for the DNA DSB marker g-H2AX. A
signiﬁcant positive correlation could be seen between Ku70
reductions and increase in g-H2AX foci (Fig. 6E). However,
no signiﬁcant difference could be seen between biopsies
before and after castration (Fig. 6D). This seemingly con-
tradictory resultmay be explained by the castration effect on
cell proliferation. Cells are constantly exposed to endoge-
nous reactive oxygen species (ROS) production and repli-
cation failure leading to DNA lesions. This is particularly
true for cancer cells that often have an elevated ROS level. A
high ROS level leads toDNA single-strand breaks, and if not
repaired, collapsed replication forks during replication
(32). Collapsed replication forks are one ended DNA DSBs
andwill bemarkedwith g-H2AX. Androgen depletion leads
to decreased rates of proliferation and thereby fewer col-
lapsed replication forks. On the other hand, as shown
Figure 4. ADT-induced Ku70
decrease correlates with a decrease
in PSA in patients with prostate
cancer. A, correlation between the
changes induced by chemical
castration in Ku70 in the nuclei
versus changes induced by
chemical castration in serum PSA.
R2 ¼ 0.91; P ¼ 0.003. The values of
Ku70 and PSA are given in
percentage of value before
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herein, androgen deprivation leads to reduction of Ku70
levels whichmay slow down the repair kinetics and thereby
lead to an increased amount of unrepaired DNA lesions.
Thus, androgen deprivation starts processes that can lead to
either increase or decrease of g-H2AX. Indeed, as shown
in Fig. 6E, patients with no or minor decrease of Ku70 after
androgen depletion shows a decrease of g-H2AX, mean-
while patients with a large decrease of Ku70 shows an
increase of g-H2AX, implicating a functional linkage of
decreased Ku70 levels and impaired DNA repair.
An interaction between the androgen receptor and Ku70
has been reported in the prostate cell line LNCaP (26) and
we can conﬁrm the interaction between the androgen
receptor and Ku70 proteins in prostate cancer tissue. The
interaction between the androgen receptor and Ku70 may
unveil a mechanistic link between castration treatment and
reduced Ku70 protein levels. It is indeed very difﬁcult to test
this potential mechanistic link experimentally in patients.
However, the high correlation between decreased levels of
PSA and decreased Ku70 levels (Fig. 4) supports the notion
that the downregulation of Ku70 is related to a decrease in
androgen receptor activity. We speculate that the binding
between Ku70 and androgen receptor may inﬂuence the
long-term stability of the Ku70 protein in prostate cancer
cells. Another possibility is that androgen receptor inhibi-
tion or downregulation results in a decrease in the expres-
sion of NHEJ proteins.
In this study, none of the included patients were offered
any curative therapy such as radiotherapy because they all
had an advanced prostate cancer with a short life expectan-
cy. However, all patients were treated with castration.
Androgen deprivation leads to decreased rates of cell pro-
liferation and induces apoptosis in prostate cancer cells
(33). The pool of cytoplasmic Ku70 has been shown to
totally disappear in cells entering senescence (34). Further-
more, the cytoplasmic fraction of Ku70 has been shown to
sequester the proapoptotic protein Bax and, thereby, func-
tions as an antiapoptotic protein (35). Because the cyto-
plasmic Ku70 was reduced to approximately half following
castration, this may contribute to apoptosis induced by
androgen depletion (36).
The optimal duration of neoadjuvant hormonal treat-
ment is unknown.However, to achieve an optimal outcome
of combined castration and radiotherapy, it might be of
importance to start the radiation therapy when the level of
Ku70 has reached its lowest value. Nevertheless, in most
clinical studies, neoadjuvant hormonal therapy is recom-
mended to start 2 to 6 months before the initiation of
radiotherapy (37–39). To date, many studies have tried to
relate the time of neoadjuvant hormonal therapy to their
effect on prostate volume (40). However, other studies,
have tried to ﬁnd out a cutoff point for the serum PSA level
(41–43)
The results of this study suggest that the PSAdecrease after
castration reﬂects the decrease in Ku70 levels in prostate
cancer cells and, therefore, could be a good marker for
deﬁning the optimal time for radiotherapy.
Future studies should investigate the correlation between
Ku70 and PSA decrease over time to validate the ﬁndings
made in this study and, thereby, open for an improved
clinical outcome of combined castration and radiotherapy.
Furthermore, it would be of great interest to investigate
whether the huge individual variations in Ku70 levels in
cancerous prostate tissue also reﬂect radiation sensitivity.
Abiraterone and enzalutamide (formerly known as
MDV3100) are 2 new target therapies with clinical beneﬁts
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Figure 5. ADT-induced Ku70 decrease correlates with a decrease in PSA
in patients with prostate cancer. A, correlation between the changes
induced by surgical castration in Ku70 in the nuclei versus days after
castration. R2 ¼ 0.77; P ¼ 0.02. The values of Ku70 are given as a
percentage of the value before castration. B, as in A, but patientswhohad
undergone chemical castration. R2 ¼ 0.36; P ¼ 0.26. C, correlation
between the changes induced by surgical castration in serumPSAversus
days after castration.R2¼0.84;P¼0.019. The valuesof PSAare givenas
a percentage of the value before castration. D, as in C, but patients who
had undergone chemical castration. R2 ¼ 0.25; P ¼ 0.26. E, correlation
between the changes induced by surgical castration in testosterone
versus days after castration. R2 ¼ 0.03; P ¼ 0.66. The values of
testosterone are given as a percentage of the value before castration. F,
as in E, but patients who had undergone chemical castration. R2¼ 0.19;
P ¼ 0.062. Statistics used: Spearman rank correlation coefﬁcient. The
unﬁlled circles in A, C, and E represent the values from patient 8 whowas
considered an outlier and these values are therefore not included in the
calculation of R2 and P.
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herein, androgen deprivation leads to reduction of Ku70
levels whichmay slow down the repair kinetics and thereby
lead to an increased amount of unrepaired DNA lesions.
Thus, androgen deprivation starts processes that can lead to
either increase or decrease of g-H2AX. Indeed, as shown
in Fig. 6E, patients with no or minor decrease of Ku70 after
androgen depletion shows a decrease of g-H2AX, mean-
while patients with a large decrease of Ku70 shows an
increase of g-H2AX, implicating a functional linkage of
decreased Ku70 levels and impaired DNA repair.
An interaction between the androgen receptor and Ku70
has been reported in the prostate cell line LNCaP (26) and
we can conﬁrm the interaction between the androgen
receptor and Ku70 proteins in prostate cancer tissue. The
interaction between the androgen receptor and Ku70 may
unveil a mechanistic link between castration treatment and
reduced Ku70 protein levels. It is indeed very difﬁcult to test
this potential mechanistic link experimentally in patients.
However, the high correlation between decreased levels of
PSA and decreased Ku70 levels (Fig. 4) supports the notion
that the downregulation of Ku70 is related to a decrease in
androgen receptor activity. We speculate that the binding
between Ku70 and androgen receptor may inﬂuence the
long-term stability of the Ku70 protein in prostate cancer
cells. Another possibility is that androgen receptor inhibi-
tion or downregulation results in a decrease in the expres-
sion of NHEJ proteins.
In this study, none of the included patients were offered
any curative therapy such as radiotherapy because they all
had an advanced prostate cancer with a short life expectan-
cy. However, all patients were treated with castration.
Androgen deprivation leads to decreased rates of cell pro-
liferation and induces apoptosis in prostate cancer cells
(33). The pool of cytoplasmic Ku70 has been shown to
totally disappear in cells entering senescence (34). Further-
more, the cytoplasmic fraction of Ku70 has been shown to
sequester the proapoptotic protein Bax and, thereby, func-
tions as an antiapoptotic protein (35). Because the cyto-
plasmic Ku70 was reduced to approximately half following
castration, this may contribute to apoptosis induced by
androgen depletion (36).
The optimal duration of neoadjuvant hormonal treat-
ment is unknown.However, to achieve an optimal outcome
of combined castration and radiotherapy, it might be of
importance to start the radiation therapy when the level of
Ku70 has reached its lowest value. Nevertheless, in most
clinical studies, neoadjuvant hormonal therapy is recom-
mended to start 2 to 6 months before the initiation of
radiotherapy (37–39). To date, many studies have tried to
relate the time of neoadjuvant hormonal therapy to their
effect on prostate volume (40). However, other studies,
have tried to ﬁnd out a cutoff point for the serum PSA level
(41–43)
The results of this study suggest that the PSAdecrease after
castration reﬂects the decrease in Ku70 levels in prostate
cancer cells and, therefore, could be a good marker for
deﬁning the optimal time for radiotherapy.
Future studies should investigate the correlation between
Ku70 and PSA decrease over time to validate the ﬁndings
made in this study and, thereby, open for an improved
clinical outcome of combined castration and radiotherapy.
Furthermore, it would be of great interest to investigate
whether the huge individual variations in Ku70 levels in
cancerous prostate tissue also reﬂect radiation sensitivity.
Abiraterone and enzalutamide (formerly known as
MDV3100) are 2 new target therapies with clinical beneﬁts
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Figure 5. ADT-induced Ku70 decrease correlates with a decrease in PSA
in patients with prostate cancer. A, correlation between the changes
induced by surgical castration in Ku70 in the nuclei versus days after
castration. R2 ¼ 0.77; P ¼ 0.02. The values of Ku70 are given as a
percentage of the value before castration. B, as in A, but patientswhohad
undergone chemical castration. R2 ¼ 0.36; P ¼ 0.26. C, correlation
between the changes induced by surgical castration in serumPSAversus
days after castration.R2¼0.84;P¼0.019. The valuesof PSAare givenas
a percentage of the value before castration. D, as in C, but patients who
had undergone chemical castration. R2 ¼ 0.25; P ¼ 0.26. E, correlation
between the changes induced by surgical castration in testosterone
versus days after castration. R2 ¼ 0.03; P ¼ 0.66. The values of
testosterone are given as a percentage of the value before castration. F,
as in E, but patients who had undergone chemical castration. R2¼ 0.19;
P ¼ 0.062. Statistics used: Spearman rank correlation coefﬁcient. The
unﬁlled circles in A, C, and E represent the values from patient 8 whowas
considered an outlier and these values are therefore not included in the
calculation of R2 and P.
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in treatment of castration-resistant prostate cancer (44, 45).
However, any connections between these therapies and
Ku70/NHEJ remain unexplored. Because the mechanism
of action of these new target therapies will lead to further
suppression of active androgen receptor, we presume that
used neoadjuvantly they will consequently lead to further
suppression of Ku70 and increase the radiosensitivity of
prostate cancer cells.Obviously, this issuewill be amatter of
future studies.
In conclusion, we observed that the Ku70 protein level
decreases in prostate cancer cells following castration and
this may possibly explain the increased response to radio-
therapy observed after neoadjuvant castration.
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in treatment of castration-resistant prostate cancer (44, 45).
However, any connections between these therapies and
Ku70/NHEJ remain unexplored. Because the mechanism
of action of these new target therapies will lead to further
suppression of active androgen receptor, we presume that
used neoadjuvantly they will consequently lead to further
suppression of Ku70 and increase the radiosensitivity of
prostate cancer cells.Obviously, this issuewill be amatter of
future studies.
In conclusion, we observed that the Ku70 protein level
decreases in prostate cancer cells following castration and
this may possibly explain the increased response to radio-
therapy observed after neoadjuvant castration.
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One Sentence Summary: Androgen-deprivation therapy and PARP inhibitors synergistically 
kill androgen receptor (AR) positive cancers, and that is explained by a novel role of AR in 
regulating homologous recombination repair.   
 
Abstract  
 
Emerging data demonstrate homologous recombination (HR) defects in castration resistant 
prostate cancers, rendering these sensitive to PARP inhibitor treatments. Here, we demonstrate a 
direct link between the androgen receptor (AR) being required for maintenance of HR gene 
expression and activity in prostate cancer cells, as well as in maintenance of DNA damage 
response signaling. As a consequence, we show PARP-mediated backup repair pathway is 
upregulated in prostate cancer tissues in patients following androgen-deprivation therapy (ADT). 
Furthermore, upregulation of PARP activity is essential for prostate cancer survival, and we 
demonstrate a synthetic lethality between ADT and PARP inhibitors in vivo. These data 
demonstrate that HR may be functionally impaired earlier in prostate cancer etiology as a 
consequence of ADT; prior to emerging castration resistance and that this potentially can be 
exploited therapeutically using PARP inhibitors in combination with in ADT upfront in 
advanced or high risk prostate cancer. 
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Introduction 
The androgen receptor (AR) is a ligand-inducible transcription factor that plays a key role 
in the initiation, growth and progression of Prostate cancer {Chen, 2004 #69}. Therefore 
androgen-deprivation therapy (ADT), which targets the androgen-signalling axis, provides an 
effective first line treatment for advanced prostate cancer {Attard, 2009 #278}. Progression to 
lethal castration-resistant prostate cancer (CRPC) is accompanied by reactivation or maintenance 
of AR signalling involved in cell cycle checkpoints {Sharma, 2010 #195}, promotion of 
metastatic phenotypes {Lucas, 2014 #268} and regulation of DNA repair {Goodwin, 2013 
#202;Polkinghorn, 2013 #221;Al-Ubaidi, 2013 #734}. Recent data also demonstrate aberrations 
of BRCA2, BRCA1, and ATM in about 20% of advanced prostate cancer (Robinsson Cell May 
2015). PARP is a backup repair pathway in cells that lost BRCA1, BRCA2 or ATM function 
(Helleday Mol Oncol 2011 Aug;5(4):387-93). As a result, BRCA2 deficient cells are acutely 
sensitive to PARP inhibition {Bryant, 2005 #655;Farmer, 2005 #595}, a phenomenon known as 
synthetic lethality. In line with this, emerging data demonstrate profound clinical responses using 
PARP inhibitors in CRPC mutated in BRCA2 (VanderWeele DJ1, Paner GP2, Fleming GF1, 
Szmulewitz RZ1. Front Oncol. 2015 Jul 22;5:169; Mateo J Annals Oncol 2014;Robinsson Cell 
May 2015).  
In Prostate cancer, a number of clinical studies have shown that ADT combined with 
radiotherapy which induces DNA DSBs, is a more effective treatment option for locally 
advanced Prostate cancer and is associated with better survival and disease-free outcome 
compared with radiotherapy alone {D'Amico, 2008 #630;Mason, 2015 #820}. Previously others 
and we demonstrated that non-homologous end joining repair of DNA double-strand breaks 
(DSBs) is affected by ADT, which could be one explanation for this increased sensitivity {Al-
Ubaidi, 2013 #734;Polkinghorn, 2013 #192;Goodwin, 2013 #202}. Since HR is also important in 
radiation-induced DSB repair, we here investigated a functional link between AR signalling and 
HR in prostate cancer, which also could open up a novel therapeutic opportunity using PARP 
inhibitors.   
Results  
 
The Androgen Receptor Promotes Homologous Recombination and DNA damage signalling  
 
We set out to study how AR regulates genes involved in DNA repair. In-depth analysis of the 
expression pattern of DNA repair genes induced by AR signalling revealed a potential link 
between AR signaling and HR (Figure 1A). In line with these results we observed that the 
expression of RAD51, a key player in HR, was significantly upregulated in prostate cancer 
tumours compared with normal benign tissue (Supplementary Figure 1A, available online). To 
interrogate the functional link between AR signalling and HR, we tested whether AR signalling 
can affect ionizing radiation (IR)-induced RAD51 foci formation. To test this we used an 
isogenic CRPC model cell line C4-2 with “high AR” and “low AR” levels, with low AR levels 
achieved by the doxycycline-mediated induction of a short-hairpin RNA targeting the AR 
(Supplementary Figure 1B, available online). In line with AR regulating HR genes, we observed 
impaired IR-induced RAD51 foci in “low AR” cells (Figure 1B).  
   To test a direct role of the AR in regulating HR, we performed a direct repeat-green fluorescent 
protein (DR-GFP) based gene conversion assay in C4-2 cells with a stably integrated DR-GFP 
reporter. Consistent with its role in promoting RAD51 foci formation, cells with AR knockdown 
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protein (DR-GFP) based gene conversion assay in C4-2 cells with a stably integrated DR-GFP 
reporter. Consistent with its role in promoting RAD51 foci formation, cells with AR knockdown 
showed a 40% reduction of HR (Figure 1C and Supplementary Figure 1C, available online), 
which is a true effect on HR, as no difference in cell cycle stage was observed (Supplementary 
Figure 1C, available online). 
   Next, we wanted to determine in detail how AR regulates the DNA damage response and 
repair and found a strong correlation between ATM and the AR-regulated transcriptome of DNA 
repair genes in prostate cancer cells (Supplementary Figure 1D, available online). In agreement 
with this we find patients treated with degarelix, a gonadotropin-releasing hormone antagonist, 
have overall lower levels of γH2AX foci (Supplementary Figure 1E, available online). To test if 
AR influences DDR directly we observe an overall defect in IR-induced үH2AX foci formation 
in “low AR” cells 2 h after 10 Gy irradiation (Figure 1D). We also observed that siRNA 
depletion of ATM in “AR high” cells bring down the γH2AX intensity to “low AR” levels 
(Supplementary Figure 1F, available online). Further links between AR and ATM signalling was 
observed used isogenic inducible AR mutant (T877A) expressed in the PC3 cell line in which 
doxycycline treatment triggered AR expression. We observed that from 48 hr after exposure to 
radiation the “full AR” cells grew faster than “AR null” cells, but this differential response was 
eliminated by ATMi treatment (Supplementary Figure 1G, available online). No differential 
growth response was observed in PC3-EV cells (Supplementary figure 1H, available online).  
   The ATM protein affect MRE11 activity to resect DNA ends, which is required or HR. Mining 
the AR transcriptome (GEO identifier GDS4113), we observed a down-regulation of the MRE11 
transcript by AR knockdown, which was also directly suppressed at the protein level by AR 
knock down (Supplementary Figure 1I and 1J, available online). As ATM regulates MRE11 
activity we tested formation of hydroxyurea-induced MRE11 foci which were higher in “high 
AR” cells (Figure 1E). That the MRE11 foci represent active MRE11 resection was 
demonstrated by addition of MRE11 inhibitor Mirin, which when added reduced the number of 
MRE11 foci.  
   Taken together these data suggest that AR, in prostate cancer is required for effective ATM 
signalling in response DNA damage, influencing MRE11 mediated resection required for 
proficient HR. 
 
Anti-Androgen Therapy Activates PARP in Prostate cancer 
 
Previously, we demonstrated that PARP1 is activated in HR defective cells and that sensitivity to 
PARP inhibitors is related to PARP activation {Gottipati, 2010 #800}. Since AR promotes HR, 
we hypothesized that ADT may then impair HR leading to an increase in backup PARP activity. 
To test this hypothesis, we set up a prospective study with prostate cancer patients (n=48). The 
Prostate cancer was diagnosed at biopsy and then received pharmacological castration with neo-
adjuvant leuprolide, a gonadotropin-releasing hormone analogue. A second biopsy was taken 
eight weeks post leuprolide treatment. Half the cohort had leuprolide before radiation treatment, 
the other half started radiotherapy before leuprolide. Immunofluorescence signalling levels of 
PARP1 and its substrate PAR were quantified in cancer areas in corresponding paired slides 
(Figure 2A and Supplementary Figure 2A, available online). To measure the activity of the 
PARP1 enzyme, we calculated the ratio of PAR and PARP1 intensity in the nuclei. In castrated 
patients, we found a significant increase in PARP1 activity as reflected in increased PARylation 
(p=0.003) (Figure 2A and 2B) suggesting that PARP1 is activated as a result of androgen 
repression further strengthening our findings that AR regulates HR in Prostate cancer. 
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 Synthetic lethality between the AR and inhibition of Poly (ADP-ribose) polymerase 
 
Previously, we demonstrated that HR defective cells show an increased reliance on PARP 
activity and demonstrated a synthetic lethality between PARP and BRCA mutated cancers 
{Bryant, 2005 #597}{Farmer, 2005 #727}. Here, we observed an ADT-induced HR defect, 
suggesting that it may be possible to generate a context dependent synthetic lethality with PARP 
inhibitors, induced by ADT. Because we observed high PARP activity after ADT in patients 
(Figure 2A and 3B) and also high PARP activity in Prostate cancer cells (Supplementary Figure 
2B, available online), we reasoned that a combined inhibition of both pathways might selectively 
induce a synthetic lethality in Prostate cancer.  
   To test this hypothesis, we used the anti-androgens bicalutamide or enzalutamide in 
combination with olaparib, which decreased cell viability of AR positive cell line C4-2 but not in 
AR negative PC3 cells (Figure 3A and 3B), which was also confirmed by using other prostate 
cancer cell lines (Supplementary Figure 3A-C, available online). The proliferation of C4-2 cells 
was also reduced by co-treatment with olaparib and either bicalutamide or enzalutamide, (Figure 
3C) and the effects of AR shRNA-mediated knockdown in decreasing proliferation was 
enhanced by olaparib (Figure 3D). Consistent with that the synthetic lethality is AR-dependent, 
knockdown of the ectopically expressed T877A AR mutant in PC3-T877A and C4-2 cell lines 
(which endogenously express this mutant) had only marginal effects on the cell viability. 
However, AR knockdown coupled with increasing doses of Olaparib decreased the viability of 
both cell lines, demonstrating a functional synthetic lethality (Supplementary Figure 3D and 3E, 
available online). The clonogenic potential of control shNT expressing C4-2 cells was 
unchanged by dox treatment, while Olaparib treated cells formed fewer colonies independent of 
doxycycline treatment (Figure 3E). In contrast, clonogenic potential of shAR expressing “low 
AR” C4-2 cells was severely compromised by Olaparib (Figure 3F) indicating synthetic lethality. 
Two primary modes by which PARP inhibitors act are (1) catalytic inhibition of the PARP 
enzyme blocking PARylation of proteins and (2) trapping PARP on ssDNA intermediates 
generated by the DNA damage {Strom, 2011 #733}. If they are left unrepaired, these PARP 
trapped-ssDNA intermediates may be converted into DSBs in S-phase and may lead to cell 
death. In our study, we observed a complete loss of the growth inhibitory effect of Olaparib in 
C4-2 cells in which PARP1 was knocked down with RNAi, indicating that the growth inhibitory 
effect of Olaparib could be partially manifested via the trapping of PARP1 (Supplementary 
Figure 3F, available online). These experiments suggest that AR and PARP may act through 
functionally distinct pathways that converge to promote cell growth under genotoxic stress, 
further strengthening the model of contextual synthetic lethality.  
   Next, we wanted to evaluate the synthetic lethality between ADT and PARP inhibitors in vivo 
and generated tumour xenografts of C4-2 cells. In the vehicle, bicalutamide and Olaparib-treated 
groups a progressive increase in tumour volume was observed. However, combined treatment 
with bicalutamide and Olaparib significantly suppressed the growth of the xenografts (Figure 
4A), decreased tumour weight and size (Figure 4B and Supplementary Figure 4A, available 
online) and without causing any obvious toxicity to mice (Supplementary Figure 4B, available 
online). To reproduce in another model, we generated xenografts of PC3-ctrl or PC3-AR 
expressing cells (Supplementary Figure 4C, available online) and administered vehicle or 
Olaparib to the mice, demonstrating decreased tumour volume with olaparib only in the AR 
defective context (Figure 4C) and without any adverse effect on mice weight (Supplementary 
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Figure 1. AR signalling regulates homologous recombination (HR) and its inhibition 
triggers PARP activation in PCa.  
(A) Heatmap showing expression of homologous recombination regulators following AR RNAi 
knock-down, AR transcript and known AR targets controls are shown from microarray data 
(Cheng et al., 2006). (B) Upper panel showing confocal microscopy images showing Rad51 foci 
in the nuclei of “high AR” and “low AR” C4-2 cells exposed to IR. Lower panel showing bar 
graphs with mean error of Rad51 foci formation time course showing high content cytometry 
based quantification of Rad51 nuclear foci intensity in “high AR” (black bars) and “low AR” 
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determined using the Holm-Sidak method, with alpha=5.000%.  (C) Quantification of gene 
conversion assay from analysis of GFP positive C4-2-DRGFP cells transfected with siScr or 
siAR along with ISce1 endonuclease for 72 hrs followed by detection of GFP positive cells by 
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AR” (white bar) C4-2 cells treated with hydroxyl Urea (HU). 
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Figure 2. AR inhibition triggers PARP activation in human prostate cancer.  
Left panel showing Immunofluorescence microscopy images showing levels of PAR and PARP-
1 in men with prostate cancer 8 weeks pre- (pre-castration or AR+) and post-Leuprolide (post-
castration or AR-) treatment. Right panel showing bar graphs show PARP activity in prostate 
cancer patients pre- and post-Leuprolide treatment. One sample T test, 2- tailed, test value 100. 
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Figure 3. Synthetic lethality between AR and PARP pathways in prostate cancer. 
Bar graphs with mean of error showing viable fraction of (A) C4-2 and (B) PC3 cells treated 
with indicated doses of Olaparib and/or Enzalutamide (blue colour) or Bicalutamide (red colour) 
( both at 10µM) for 7 days or 95% confluence. Graph indicates results of a MTS cell viability 
assay. (C) Live cell imaging based confluence analysis of C4-2 cells treated with Olaparib 
(1µM), Enzalutamide (10µM) or Bicalutamide (10µM) for 7 days. (D) Live cell imaging based 
confluence analysis of a “high AR” and “low AR” C4-2 treated with doxycycline and Olaparib 
(1µM) as indicated for 5 days, significance calculated using two-way ANOVA. Clonogenic 
survival assay with inducible (E) shNT or (F) shAR expressing C4-2 cells. Cells were treated 
with Olaparib (2µM). 
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Figure 4. Dual inhibition of AR and PARP1/2 function represses PCa growth.  
(A) Tumour xenograft of C4-2 cells, mice administered with DMSO (vehicle) or Bicalutamide 
and/or Olaparib as indicated. (B) Scatter plot showing weight C4-2 xenograft in NSG mice 
treated with indicated drugs. (C) Tumour xenografts of PC3-controll (AR-) (white bars) or PC3-
AR (AR+) (black bars) cells, NSG mice were administered with DMSO (vehicle) or Olaparib as 
indicated. (D) Quantification of ki67 expression in ex vivo culture of human PCa treated with 
Bicalutamide (10µM) and/or Olaparib (2µM) for 72 hrs. (E) Quantification of ki67 expression in 
ex vivo culture of human PCa treated with Enzalutamide (10µM) and/or Olaparib (2µM) for 72 
hrs. 
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SUPPLEMENTARY EXPERIMENTAL METHODS 
Reagents/Antibodies/Consumables 
Methyltrienolone (R1881) and Enzalutamide were obtained from Perkin Elmer and Axon 
Medchem respectively. Camptothecin, dihydro testosterone (DHT), DMSO, doxycycline, 
bicalutamide, hydroxyl urea and Mirin were obtained from Sigma. Olaparib was purchased 
from LC laboratories and ATM inhibitor KU0055399 from Calbiochem. Cell culture media, 
FBS and other cell culture reagents including antibiotics were obtained from Life 
Technologies. Antibodies were obtained from commercial suppliers as below: 
1. Phospho-Histone H2A.X (Ser139) (JBW301; cat # 05-636) from Millipore-used in foci 
analysis. 
2. Rad51 (cat no. H-92; sc8349) from Santa cruz- used in high content cytometry. 
3. Mre11 (cat no. 4895S) from Cell signalling- used in high content cytometry. 
4. Total ATM (2C1; cat no. sc-23921) Santa cruz used in Western blot analysis. 
5. PhosphoS1981-ATM (EP1890Y from Abcam cat. ab81292)-used in Western blot analysis. 
6. Phospho KAP-1 (S824; cat no. A300-767A, Bethyl laboratories) used in Western blot 
analysis. 
7. Total Kap1 (A300-274A from Bethyl laboratories) used in Western blot analysis. 
8. Total p53 (1C12; cat no. 2524) and phospho-p53 (Ser15; cat # 9284) from cell signalling-
used in Western blot analysis. 
9. PAR antibody (cat no. GTX75054 from Source bioscience) for Western blot.  
10. Phsopho-histone H2A.X (ser139; cat # 2577) used in flow cytometry. 
11. үH2A.X (phosphoS139; cat # ab2893) from Abcam used for immuno histochemistry. 
12. AR (AR441; cat # M356201-2 from Dako) used in Western blot analysis. 
13. beta-actin antibody (Rabbit actin: Cell signaling (cat #4970), 1:1000 
Mouse actin: Abcam (cat #ab6276), 1:5000) 
 
Cell culture 
LNCaP, PC3, PNT1a, DUCaP cells were obtained from commercial suppliers and grown in 
RPMI cell culture media containing 10% foetal bovine serum (FBS) and 1% 
penicillin/Streptomycin in a humidified incubator at 37 ºC. C4-2 was grown as described 
previously (1). We generated and cultured C4-2-NT control (expressing non-targeting RNA; 
siNT) and C4-2-shAR cells as described earlier (2). LNCaP-LN3 cells have been described 
previously (3).  
 
Analysis of γH2AX and Rad51 foci in cells 
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Analysis of γH2AX and Rad51 foci in cells 
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C4-2 “high AR” and “low AR” shRNA cells were grown in 10% hormone-depleted serum 
containing RPMI media treated with R1881 (1 nM) or doxycycline (1 µg/mg) for 72 hr to 
induce shRNA expression. Cells were exposed to ionising radiation (10 Gy) using a CS
137
 
source. For imaging, cells were grown in Ibidi ibiTreat 8 well µ-slides (Ibidi GmbH, 
Germany), precleared with PBST containing (0.2% triton-X-100) for 1 min then fixed in 3% 
PFA-2% sucrose solution in PBS for 10 min, washed with PBS 3X and blocked in Odyssey 
buffer for 30 min at room temperature. Cells were incubated with the combination of 
antibodies against γH2AX (1:2500) and Rad51 (1:500) overnight in Odyssey blocking 
solution and washes thrice with PBST (0.1%). Cells were incubated with secondary 
antibodies Alexa Fluor® 488 and Alexa Fluor® 647 antibodies (both 1:1000; Life 
technologies) for 1 hr at room temperature. Cells were again washed with PBST (0.1%) and 
DNA counterstained with DAPI for 10 min followed by mounting with vectashield 
(Ibidi).  Images were acquired on a Leica SP5 confocal microscope (Leica Microsystems 
Ltd). Three channels were used for DAPI (blue), үH2AX_AlexaFluor488 (green) and 
Rad51_AlexaFluor647 (far red). For analysis, the Leica image file was imported directly into 
Columbus software (PerkinElmer, UK). Images were analysed using a custom analysis 
protocol set up on the three channels. The DAPI channel was used to segment individual 
nuclei using standard algorithms within the software. үH2AX and Rad51 signal per nucleus 
was calculated by the quantification of the green and far red signals within the DAPI nuclear 
mask. The “find spots” function was added into the protocol to detect үH2AX 
 foci (green channel) and Rad51 foci (far red channel) within the nucleus, using appropriate 
settings to correctly detect each individual focus. Functions were then added in to calculate 
morphology allowing foci number to be extracted. 
 
DR-GFP assay 
Stable clones of C4-2 cells harboring DR-GFP were generated by transfecting the cells with 
Lipofectamine 2000 and stable clones (called C4-2DRGFP cells) were selected on puromycin 
(2 µg/ml) and maintained in RPMI with 10%FBS. These cells were seeded in six-well culture 
dishes and transfected using Lipofectamine 200 reagent with ISce1 (0.75 µg/well) and siRNA 
(50 nM). After 72 hr cells were harvested and percentage of GFP positive cells was 
determined with flow cytometry using BD FacsCaliber. Data analysis was carried out using 
Flowjo software. 
 
Immunohistochemistry, Image processing, nuclei segmentation and spot quantification 
for үH2AX 
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections (4 μm) 
using an automated immunostainer with cover tile technology (Bond-III system, Leica 
Biosystems). Commercial antibody to γH2AX (Cell Signalling; 1:400 dilution) was used as 
the primary antibody. The Antigen retrieval was carried out using the combination of heat 
and Bond Epitope Retrieval Solution 1 (Leica Biosystems). The Bond™ Polymer Refine 
Detection kit (Leica Biosystems) was used for visualising the antigens. Negative control 
experiments, in which primary antibodies were omitted, resulted in a complete absence of 
staining.  
All the images were processed with FIJI software (or ImageJ, National Institute of Health, 
Bethesda, MD) using a set of semi- and fully-automated homemade macros. Briefly, artefacts 
within the image, i.e. bubbles, dust or out-of-focus regions were detected and removed upon 
user validation. Haematoxylin and DAB staining were then automatically separated as 
individual channels using a macro calling the “colour deconvolution” plugin (4) set with the 
“H&E DAB” vectors (see Figure S1E).  
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A final macro helped discarding any secretion feature that could be further detected as a 
positive signal within the DAB channel. Processed DAB images were then analyzed with 
Columbus software (PerkinElmer, Waltham, MA). Nuclei segmentation was performed and 
small, large or elongated objects were removed. However, as it resulted in a mixed 
population of cancer and sparse stromal cells, an original method was designed to 
automatically select cells clustered in a cancer area. Briefly, regions were defined as an 
extension by 50 pixels (12.5 μm) around each nucleus. By default, as no overlap is allowed 
by Columbus, measured areas for clustered cells were smaller than isolated stromal cells (see 
Figure S1E). Spot detection was finally achieved only for individual sorted cancer cells. 
Low-amplitude (maximum over local background intensity) spots were discarded to limit the 
contribution of false positives.  
 
Plasmids, siRNA and Transient transfections  
In order to achieve potent reduction in target mRNA expression, siRNA smart pool were used 
for gene knockdown (Dharmacon/Life technologies). Transient transfections with siRNA 
were performed using Lipofectamine RNAiMAX transfection reagent (Life technologies) as 
per manufacturer’s recommendations. We performed reverse transfections and used 25 nM 
siRNA in all knockdown experiments; MMTV-Luc and Renilla-Luc reporter plasmids were 
transfected using Lipofectamine 2000 as per manufacturers’ instructions.  
 
Reporter assay 
In all luciferase assays, Renilla luciferase plasmid (Promega) was used as an internal control. 
All cells treated with androgens, R1881 (1nM) were grown in hormone-depleted (charcoal-
stripped) FBS. Cells were harvested 48 hr post-transfection using passive lysis buffer 
provided with dual luciferase assay reagents (Promega) to measure both luciferase activity 
and Renilla luciferase activity using luminometer (Pherastar).  
 
Cell viability assay  
Cells were trypsinised and counted using a Vicell instrument. Cell growth assay was carried 
out in 96 well plates (1500-2000 cells per well). Cells were then plated and simultaneously 
treated with indicated chemicals/drugs until control vehicle treated cells reached 95% 
confluence level (5-7 days for different cell lines). Cell viability was determined by 
incubating the culture with MTS reagent based (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) colorimetric assay as per 
manufacturers protocol (Promega).  
 
Clonogenic assay 
Cells were seeded in a 6-well culture dish (Corning); (1000 cells per well were seeded) and 
48 hr later cells were treated with antagonists (10 µM) /inhibitor (1 µM). Fresh media and 
drugs were replenished bi-weekly. Two weeks later, cells were fixed in acetone:methanol 
(1:1) for 5 min and stained with Giemsa stain (from Raymond A Lamb ltd. chemicals; diluted 
and filtered 1:10 in water) for 10-15 min. Plates were washed with running tap water, air 
dried and the colonies were counted using colony analyser (Oxford Optronics). All colonies 
were counted, experiments were conducted in triplicates. 
 
Live cell imaging/confluence analyses 
Confluence analyses were performed using the Incucyte instrument (Essen Bioscience). Cells 
were plated and simultaneously treated with drugs in TPP 96-well culture dishes and placed 
in a humidified chamber incucyte instruments. Experiments were conducted in 8 replicates 
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and live cell images were recorded every 3 hr. However, for ease of understanding only 12 hr 
time interval data are shown. 
 
Western blot analysis 
Samples subjected to SDS-PAGE were transferred to a PVDF membrane (Amersham) and 
transfer efficiency was checked with Ponceau red. Membrane was blocked with Licor 
blocking buffer for 1 hr at room temperature. Membrane was washed with TBS-T (TBS, 
0.05% Tween-20) and incubated with indicated antibody dilutions as per manufacturer’s 
instruction overnight at 4 ºC. Upon washing with TBS-T, membrane was incubated with HRP 
antibody for 1 hr at room temperature and chemiluminiscence detected by Licor Odyssey 
instrument. 
 
Ex vivo prostate explant culture 
Fresh human PCa tissue was collected after informed consent (70-80 years hormone naïve 
patient cT3 disease with a PSA value of 82) and according to the institutional policy. Tissue 
was excised into 1-2 mm
3
 size explants and grown on collagen cushions kept on steel grids 
for one week. The tissue was treated as indicated by drugs in RPMI with 10%FBS, 
1%penicilln, streptomycin and gentamycin. To make collagen cushions, 250 μl of collagen 
mix (rat tail collagen, plain RPMI media, FBS and 10% RPMI in the ratio of 7:1:1:1) was 
solidified on a nylon membrane. At the end of experiment, tissue was fixed in formalin for 20 
hr and then transferred to ethanol followed by immunohistochemistry.  
 
 
Immuno histo-chemistry for ki67 and cleaved caspase-3 (CC3) of ex vivo culture 
Immuno-histochemical staining of paraffin embedded slides was performed to detect ki67 
and CC3. Slides were stained on a BondMax Autostainer (Leica, Milton Keynes, UK). 
Antigen retrieval was performed using standard trisEDTA method at 100 ºC for 20 min 
followed by a 15 min incubation with primary antibodies for ki67 (Rabbit polyclonal from 
Santa cruz, sc-816 at 1:750 dilution) and CC3 (cleaved caspase-3; 9664, Cell signalling 
Technology) at room temperature, 8 min incubation with a secondary antibody (biotinylated 
donkey anti-rabbit; cat. No 711-065-152 from Jackson immunoresearch) using a polymer 
secondary system (Leica) followed by developing with Diaminobenzidine using enhancer 
(SP-2001; vector labs). Haematoxylin counterstaining was performed automatically on the 
Bond system, and finally, the slides were dehydrated, cleared and mounted using a Leica 
ST5020 attached coverslipper CV5030 (Leica). Slides were scanned onto 
Aperio/SpectrumTM v10.2.2.2317 and were analysed using ImageScope (Aperio software 
v12.0.0.5039). The intensity and number of nuclear AR and CC3 was quantified using an 
algorithm that identifies nuclear staining, and the number of positive nuclei was counted 
between the different treatments. In order to identify epithelial structures for quantification, 
images H&E and cytokeratin staining were used to pinpoint the exact location on serially 
sectioned slides that have weak AR staining. For each condition at least 400 cells were 
counted and percentage was calculated based on total number of cells in the tissue explants 
(n=>3). 
 
Generation of tumour xenografts 
All animal experiments were performed in compliance with the Home office directive of 
Animal (scientific procedures) act, under a project and personal license. In all experiemnts 
Non-obese non-diabetic NSG mice bearing xenografts were generated by subcutaneous 
injection of cells as follows: 
4 
 
and live cell images were recorded every 3 hr. However, for ease of understanding only 12 hr 
time interval data are shown. 
 
Western blot analysis 
Samples subjected to SDS-PAGE were transferred to a PVDF membrane (Amersham) and 
transfer efficiency was checked with Ponceau red. Membrane was blocked with Licor 
blocking buffer for 1 hr at room temperature. Membrane was washed with TBS-T (TBS, 
0.05% Tween-20) and incubated with indicated antibody dilutions as per manufacturer’s 
instruction overnight at 4 ºC. Upon washing with TBS-T, membrane was incubated with HRP 
antibody for 1 hr at room temperature and chemiluminiscence detected by Licor Odyssey 
instrument. 
 
Ex vivo prostate explant culture 
Fresh human PCa tissue was collected after informed consent (70-80 years hormone naïve 
patient cT3 disease with a PSA value of 82) and according to the institutional policy. Tissue 
was excised into 1-2 mm
3
 size explants and grown on collagen cushions kept on steel grids 
for one week. The tissue was treated as indicated by drugs in RPMI with 10%FBS, 
1%penicilln, streptomycin and gentamycin. To make collagen cushions, 250 μl of collagen 
mix (rat tail collagen, plain RPMI media, FBS and 10% RPMI in the ratio of 7:1:1:1) was 
solidified on a nylon membrane. At the end of experiment, tissue was fixed in formalin for 20 
hr and then transferred to ethanol followed by immunohistochemistry.  
 
 
Immuno histo-chemistry for ki67 and cleaved caspase-3 (CC3) of ex vivo culture 
Immuno-histochemical staining of paraffin embedded slides was performed to detect ki67 
and CC3. Slides were stained on a BondMax Autostainer (Leica, Milton Keynes, UK). 
Antigen retrieval was performed using standard trisEDTA method at 100 ºC for 20 min 
followed by a 15 min incubation with primary antibodies for ki67 (Rabbit polyclonal from 
Santa cruz, sc-816 at 1:750 dilution) and CC3 (cleaved caspase-3; 9664, Cell signalling 
Technology) at room temperature, 8 min incubation with a secondary antibody (biotinylated 
donkey anti-rabbit; cat. No 711-065-152 from Jackson immunoresearch) using a polymer 
secondary system (Leica) followed by developing with Diaminobenzidine using enhancer 
(SP-2001; vector labs). Haematoxylin counterstaining was performed automatically on the 
Bond system, and finally, the slides were dehydrated, cleared and mounted using a Leica 
ST5020 attached coverslipper CV5030 (Leica). Slides were scanned onto 
Aperio/SpectrumTM v10.2.2.2317 and were analysed using ImageScope (Aperio software 
v12.0.0.5039). The intensity and number of nuclear AR and CC3 was quantified using an 
algorithm that identifies nuclear staining, and the number of positive nuclei was counted 
between the different treatments. In order to identify epithelial structures for quantification, 
images H&E and cytokeratin staining were used to pinpoint the exact location on serially 
sectioned slides that have weak AR staining. For each condition at least 400 cells were 
counted and percentage was calculated based on total number of cells in the tissue explants 
(n=>3). 
 
Generation of tumour xenografts 
All animal experiments were performed in compliance with the Home office directive of 
Animal (scientific procedures) act, under a project and personal license. In all experiemnts 
Non-obese non-diabetic NSG mice bearing xenografts were generated by subcutaneous 
injection of cells as follows: 
5 
 
PC3/PC3-AR xenografts: 1 million cells in 50 µl PBS were mixed with 50 µl high 
concentrations Matrigel and were injected in the flank region of each mouse. Mice were 
given vehicle (cyclodextrin) or Olaparib (1 mg/mouse daily) via intra-peritoneal route (n=12 
per group). Tumour size was measured weekly using callipers.  
C4-2 xenografts: 2 million cells in 50 µl PBS were mixed with 50 µl high concentrations 
Matrigel and were injected in the flank region of each mouse. Mice were given vehicle 
(DMSO) or Olaparib (50 mg/kg twice weekly) and/or bicalutamide (20 mg/kg twice weekly) 
via intra-peritoneal route. Tumour size was measured with callipers weekly, and calculated 
using the formula volume = (π/6)/abc or (π/6)/abb (if only 2 diameters are available) and a,b,c 
are the orthogonal axis of the tumour. Mice were culled at completion of experiment or when 
tumours reached 10% of body weight.  
 
Patients and Leuprorelin study design 
After ethical approval from the regional ethics committee of Uppsala University (EPN Dnr 
2011:066), patients with localized, i.e. non-metastatic prostate cancer, eligible for curative 
RT, were enrolled in the study. After the completion of a written informed consent, the 
patients were allocated to one of the two study arms.  
In Arm 1, the patients received neo-adjuvant pharmacological castration with leuprorelin, a 
GnRH analogue, followed by external beam RT in daily 2 Gy fractions to a total dose of 78 
Gy. In Arm 2, the patients first received RT, in 2 Gy daily fractions for 5 consecutive days, 
followed by neo-adjuvant leuprolide and then an equivalent, higher RT dose to a total of 82 
Gy, due to the greater lapse of time. Before treatment, prostate needle-core biopsy specimens 
were obtained from all patients. In Arm 1, a second biopsy was taken eight weeks after the 
leuprolide injection, i.e. before RT was started and a third biopsy about three hours after the 
fifth RT fraction. In Arm 2, a second biopsy was taken about three hours after the fifth RT 
fraction, i.e. before hormone treatment was initiated and a third biopsy eight weeks after the 
administration of leuprolide (see flow chart).  
 
Histological and immunofluorescence evaluation of PAR and PARP-1 
All prostatic needle biopsy specimens were embedded in paraffin, sectioned and stained with 
haematoxylin and eosin (H&E). In all specimens, the cancer area was assessed according to 
the Gleason system (5) and marked by a uro-pathologist. Two cancer-rich specimens from 
each batch of biopsies were further sectioned for immunofluorescence analysis. These 
sections were deparaffinised and rehydrated before antigen retrieval with Tris/EDTA (Citrus 
buffer, pH 9) in a pressure cooker. After blocking with 2% BSA, the sections were incubated 
with different primary antibodies at 4 
o
C overnight. Extensive rinsing was performed once; 
48 patients with non-
metastasized  PCa. 
At diagnosis   
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After 8 weeks:  
Biopsy nr 2  
Radiotherapy 
2Gy fractions 
At the fifth day of 
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Full dos radiotherapy 
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23 patients 
Radiotherapy  
2Gy fractions  X 5 
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the sections were incubated with the secondary antibodies (donkey anti mouse IgG-alexa 488 
(1:500), Molecular probe and donkey anti rabbit IgG-alexa 555 (1:500), Molecular probe) for 
one hour at room temperature. DNA was counterstained with TO-PRO-3 iodide (Molecular 
probe) and slides mounted with pro long gold (Molecular probe). Dual staining was 
performed on the same slide PARP1 (1:200, H-250, sc-7150, Santa Cruz) together with PAR 
(1:200, pADPr (10H): sc-56198, Santa Cruz). Images from a tumour area with a good degree 
of immunofluorescence signals were selected from each biopsy. The corresponding areas in 
the HE-stained section were identified for histological verification of the tumour area. 
Selected areas from each slide containing 300-600 cells were chosen for analyses. TO-PRO-3 
was used as a DNA marker. All images were analysed, with respect to medium intensity 
inside the nuclei and in the cytoplasm. The nuclear area was defined by the TO-PRO-3 signal 
(Figure S1D). PARP1 is a protein with both nuclear and cytoplasmic localisation and 
intensity values are presented without background subtraction. All measurements were 
performed using an in house-written programme for NIH-imageJ. Fluorescence images were 
obtained with either a Zeiss LSM 510-inverted confocal microscope or a Zeiss LSM 780-
inverted confocal microscope, using a planapochromat 40X/NA 1.2 objectives. Through-
focus maximum projection images were acquired from optical sections 0.5μm apart and with 
a section thickness of 1.0μm. HE-stained images were obtained with a Leica scan system. 
Degarelix study design 
Full ethical approval was obtained (11/H0311/2) for clinical studies NCT01852864 and 
NCT00967889. 15 patients with high risk organ confined prostate cancer were treated with 
240mg of degarelix s.c. 7 days before surgery. Fresh prostate cancer samples were obtained 
at the time of radical prostatectomy and snap frozen. Confirmation of castrate levels of serum 
testosterone in degarelix treated patients was achieved by mass spectrometry. These samples 
were compared with matched controlled samples from 19 untreated patients. Tissues were 
spotted on microscopic slides to generate tissue microarray. 
Statistical analysis 
Unless otherwise indicated in the figure legends, tailed Student's t-test was used in all 
statistical analyses. Data in the bar graphs are shown as the mean ± SEM., and statistical 
significance is expressed as follows: *P < 0.05, **P < 0.005, ***P < 0.0005. We have seen 
consistent differences and significant P values in functional studies however it is possible that 
some p values may be driven by low variance. 
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SUPPLEMENTARY FIGURE LEGENDS  
Figure S1.  AR signalling regulates homologous recombination.  
(A) Distribution plot showing log2 expression value of RAD51 transcripts in three different 
cohorts from PCa clinical samples. (B) Western blot showing level of AR in “low AR” and 
“high AR” C4-2 cells treated with doxycycline (1µg/ml) and androgen R1881 (1nM) for 72 
hrs. (C) Graphs showing flow cytometry images of C4-2-DRGFP cells, box encircled cells 
represent percentage of GFP cell population. (D) Gene set enrichment plots for AR up-
regulated genes versus ATM-regulated DNA damage response gene signature from LNCaP 
cell line (GDS1852) and AR occupied and downregulated following castration in xenografts 
(GSE21817).  (E) Scatter plot showing average number of үH2AX foci per nucleus from 
benign glands and PCa tissue from patients treated with Degarelix (n=15) or tumour grade 
matched control (n=19). Each dot represents average number of foci per nucleus in individual 
glands. Statistical significance was calculated by unpaired two-tailed Students’t-test. (F) Bar 
graph show average үH2AX levels per nucleus in “low AR” and “high AR” C4-2 cells using 
high-content cytometry analysis “low AR” and “high AR” C4-2 cells transfected with siScr 
or siATM in response to IR (10Gy) for 2 hrs, results showing level of үH2AX with 
significance calculated by unpaired students’ t-test. (G) Live cell imaging based confluence 
analysis of dox-inducible mutant AR (T877A) expressing PC3 cell line treated with ATMi 
(10µM) and exposed to radiation as indicated by arrow (IR; 10Gy) for indicated times, 
standard error of mean is presented. (H) Live cell imaging based confluence analysis of 
expressing PC3 cell line treated doxycycline (1µg/ml) with ATMi (10µM) and exposed to 
radiation as indicated by arrow (10 Gy) for 7 days. (I) Bar graph showing MRE11 expression 
in LNCaP cells transfected with control siRNA or siAR (J) Western blot of C4-2 cells 
transfected with control siRNA (siScr) or siAR, picture shows MRE11 protein expression in 
indicated conditions, B-actin is used as internal control. 
Figure S2. 
(A) Immunofluorescence images showing original and computer processed images of the 
PCa tissue stained with PARP-1 (red), PAR (green) and DNA (blue). While lines encircle the 
area used for intensity measurement. (B) Western blot showing PARylated proteins from 
LNCaP and C4-2 cells treated with PARP-1/2 inhibitor Olaparib (1µM) for 24 hrs. 
 
Figure S3.  Synthetic lethality between AR and PARP signalling pathways in PCa. 
Viable fraction of (A) DuCaP, (B) LN3 and (C) PNT1a cells treated with indicated doses of 
Olaparib and/or Enzalutamide or Bicalutamide (10 µM) for 7 days or 95% confluence. Graph 
indicates results of a MTS cell viability assay. Viable fraction of (D) PC3-AR and (E) LN3 
cells transfected with control and siAR and treated with indicated doses of Olaparib for 5 
days. Graph indicates results of a MTS cell viability assay. (F) Viable fraction of C4-2 cell 
transfected with control, AR or PARP-1 siRNA and treated with Olaparib (1µM) for 5 days. 
Graph shows results of a MTS cell viability assay.  
 
Figure S4.  Dual inhibition of PARP and AR represses tumour growth. 
 (A) Tumour images of C4-2 xenograft in NSG mice treated with indicated drugs. (B) Graph 
showing body weight of mice bearing C4-2 xenografts administered with indicated drugs. (C) 
Western blot of PC3 and PC3-AR cells shows AR protein expression in indicated cell lines, 
β-actin is used as internal control.  Statistical significance calculated by Mann-Whitney’s test. 
(D) Graphs showing body weight of mice bearing PC3 or PC3-AR xenografts administered 
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with indicated drugs. (E) Quantification of cleaved caspase-3 expression in ex vivo culture of 
human PCa treated with Bicalutamide (10µM) and/or Olaparib (2µM) for 72 hrs, significance 
calculated by Mann-Whitney test. (F) Quantification of cleaved caspase-3 expression in ex 
vivo culture of human PCa treated with Enzalutamide (10µM) and/or Olaparib (2µM) for 72 
hrs, significance calculated by Mann-Whitney test. 
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One Sentence Summary: Chemical castration decreases Ku70 expression impairing non-
homologous end joining DNA repair and improving the radiotherapy response of prostate cancer 
patients.  
 
 
Abstract  
Chemical castration improves responses to radiotherapy in prostate cancer but the mechanism is 
unknown. We hypothesized that this radiosensitization is caused by castration-mediated down-
regulation of non-homologous end joining (NHEJ) repair of DNA double-strand breaks (DSBs). 
To test this, we enrolled forty-eight patients with localized prostate cancer in two arms of the 
study: either radiotherapy first or radiotherapy after receiving neo-adjuvant castration treatment. 
We biopsied patients at diagnosis, and before and after castration and radiotherapy treatments to 
monitor androgen receptor, NHEJ and DSB repair in verified cancer tissue. We show that 
patients receiving neo-adjuvant castration treatment prior to radiotherapy had reduced amounts 
of the NHEJ protein Ku70, impaired radiotherapy-induced NHEJ activity and higher amounts of 
unrepaired DSBs, measured by γ-H2AX foci in cancer tissues. This study demonstrates that 
chemical castration impairs NHEJ activity in prostate cancer tissue, explaining the improved  
response of patients with prostate cancer to radiotherapy after chemical castration.  . 
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Introduction 
Despite the technical improvements achieved in radiotherapy, the final outcome of this 
single treatment modality is still uncertain, with a high risk of recurrence among patients with 
unfavorable prognostic risk factors (1-5). However, several randomized clinical trials have 
revealed that the addition of neoadjuvant castration improves long-term local control and 
survival (6-10).  
Thus, the combination of neo-adjuvant castration with radiotherapy has currently 
become, in many treatment centres, the standard of care for patients with intermediate and high 
risk prostate cancer. However, timing and duration of this castration in combination with RT 
needs to be better defined (11). A better understanding of the biological mechanism of action is 
essential for the optimization of treatment and the development of new therapeutic methods.  
Radiotherapy induces various forms of DNA damage, the most important and toxic lesion 
being DNA double-strand breaks (DSBs). Non-homologous end joining (NHEJ), catalysed by 
DNA-dependent protein kinase (DNA-PK), is the most effective DNA repair mechanism for 
DSBs and works during all phases of the cell cycle (12, 13). In NHEJ, the DSB ends are bound 
by the abundant Ku70/80 heterodimer, which in turn attracts the catalytic subunit DNA-PKcs, 
that orchestrates the end-joining process and phosphorylates itself (on serine 2056) and other 
proteins, such as ligase IV and XRCC4 for final re-joining and ligation (14, 15). Using biopsies 
from patients with prostate cancer, we previously demonstrated that castration with a neo-
adjuvant setting (i.e., therapy given before definitive local treatment with curative intent) 
decreases the expression of Ku70 (16), which, could potentially influence NHEJ and explain 
improved survival following radiotherapy. These findings have been confirmed by two other 
studies demonstrating both in vitro and in vivo with mouse xenografts that androgen receptor 
regulates the transcription of DNA repair genes (17, 18). Here, we test the hypothesis that neo-
adjuvant castration reduces the DNA repair capacity of the NHEJ repair pathway in prostate 
cancer cells after radiotherapy. 
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Results  
 
Upregulation of Ku70 by radiotherapy is prevented by neo-adjuvant castration  
 
In a previous study, we showed that the Ku70 protein interacts with androgen receptor and the 
levels of Ku70 protein were reduced following castration in prostate cancer cells (16). Since 
Ku70 is a vital component of NHEJ, we suggested that impaired DSB repair could potentially be 
the mechanistic explanation for the increased radiosensitivity subsequent to castration. However, 
androgen receptor regulates numerous genes and the decreased levels of Ku70 or other repair 
proteins may not influence NHEJ activity and DSB repair in cells. To test this hypothesis 
directly, we recruited 48 patients with prostate cancer into a two arm prospective study (Fig. 1A), 
and used a computational approach to measure responses within individual cells in the tissue 
(Fig. 1B). In the first arm, we performed neo-adjuvant castration prior to 5 days radiotherapy, 
whereas in the second arm we prescribed radiotherapy 5 days prior to castration. We obtained 
tumor biopsies along the treatments to analyze  the DSB repair. . 
 In both arms, castration treatment either before or after radiotherapy resulted in a similar 
decrease in serum Prostate-specific antigen (PSA) (p<0.001; Table S1) and median testosterone 
levels in serum were 0.7 nmol/L in both arms. Serum testosterone  <1.7 nmol/L was not achieved 
in two patients in arm 1 and 4 patients in arm 2 after 8 weeks of chemical castration, although 
serum PSA decreased markedly.. These patients were still included in our  study and statistical 
analysis.  
 We determined cytosolic and intra-nuclear Ku70 protein using immunofluorescence and 
observed no difference between patient arms at diagnosis. In both arms, castration decreased 
Ku70 levels to the same extent regardless of prior radiotherapy treatment (p<0.01) (Fig. 2A, B). 
There was a statistically significant increase in the mean intensity of intra-nuclear Ku70 after 5 x 
2 Gy radiotherapy fractions (p=0.014). We interpret this as upregulation of Ku70, and likely 
other NHEJ proteins, after 5 days of radiotherapy treatment to mediate DSB repair. Interestingly, 
no such upregulation of Ku70 was found in prostate cancer patients receiving chemical castration 
alone (Fig. 2B).  
 Intra-nuclear levels of androgen receptor were determined in prostate tumor material 
from all patient biopsies. As expected no difference was observed between the arms prior to 
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 Intra-nuclear levels of androgen receptor were determined in prostate tumor material 
from all patient biopsies. As expected no difference was observed between the arms prior to 
castration. It has previously been reported that androgen receptor activity is increased after 
radiotherapy. Figure 2A shows more distinct staining for androgen receptor after radiotherapy  
but no statistically significant increase in intra-nuclear androgen receptor (Fig. 2B). No 
difference was observed in the pre-treatment mean intensity of intra-nuclear androgen receptor 
between arm 1 and arm 2 (p=0.3) (Figure 2B). As expected, intra-nuclear androgen receptor 
staining intensity decreased following castration (Figure 2B). Using Spearmans´s rho rank 
correlation test (ρ), we observed in both arms a significant correlation between pre-treatment 
mean staining intensity of intra-nuclear Ku70 and androgen receptor  (ρ=0.62, p<0.001), and in 
arm 1 following castration (ρ=0.65, p<0.001) (Fig. 2C, D). To investigate whether the decrease 
in nuclear androgen receptor after castration correlated with a decrease in nuclear Ku70, the 
correlation between the induced decreases in those proteins was measured. The post-castration 
decrease in nuclear androgen receptor was accompanied by a corresponding decrease in intra-
nuclear Ku70. In arm 1, there was a significant correlation after castration (ρ=0.52, p<0.001), 
and, after combined castration and radiotherapy (ρ=0.33, p=0.001). In arm 2, there was a 
significant correlation after radiotherapy (ρ=0.64, p<0.001) and after subsequent castration 
(ρ=0.53, p<0.001). 
 
Increased residual radiation-induced DNA double-strand breaks after castration  
Next, we wanted to assess if neo-adjuvant castration affected DSB repair. To assess the extent of 
DNA damage after castration alone, or castration plus radiotherapy, biopsies were taken 3 hours 
after completion of radiotherapy to be stained with antibodies against p53-binding protein 1 
(53BP1) and phosphorylated H2AX histone, noted as γ-H2AX. Both 53BP1 and γ-H2AX are 
involved in early DNA damage signaling and are commonly used as markers of DSBs (19). 
Immunofluorescence staining with antibodies against 53BP1 and γ-H2AX was quantified in 
prostate cancer tissue in corresponding paired slides (Fig. 3A). Radiotherapy in both arms 
induced a statistically significant increase in both γ-H2AX and 53BP1 foci (p<0.001), and there 
was co-localization between the γ-H2AX and 53BP1 foci (Fig 3B and Fig. S1). Although 
castration alone did not increase the amount of DSBs (Fig. 3C), we observed that castration 
alone induced a significant reduction in the mean staining intensity of intra-nuclear 53BP1 foci 
in both arms (p<0.05, Fig. 3D), indicating that the androgen receptor itself may be involved in 
mediating the response to DNA damage.  
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 Importantly, we observed a clear increase in radiotherapy-induced γ-H2AX in arm 1 with 
neo-adjuvant castration treatment (p<0.05), demonstrating that the number of toxic DSBs was 
increased in patients receiving neo-adjuvant castration (Fig.3C). Hence, we predicted that the 
remaining DSBs would be more lethal to the prostate cancer cells in arm 1, translating to a better 
overall outcome among prostate cancer patients following radiotherapy. We did not observe a 
statistically significant difference in staining for 53BP1 foci between the two arms, which is 
likely owing to the fact that 53BP1 appears to be downregulated by castration itself, leading to 
reduced foci intensity (Fig. 3C).  
 
Neo-adjuvant castration impairs non-homologous end joining activity 
Here, we report that a decrease in Ku70 after castration is correlated with an increase in residual 
DSBs in prostate cancer tissue, suggesting that lost NHEJ activity may explain decreased DSB 
repair and improved prostate cancer patient survival after radiotherapy. Next, we wanted to 
determine if this hypothesis is correct so we measured NHEJ activity in prostate cancer tissue. 
The Ku70/80 heterodimer recruits DNA-PK to DNA ends, activating its kinase activity which 
results in DNA-PK autophosphorylation on Serine residue 2056, which is required to complete 
NHEJ (20). Here, we used a phosphorylated DNA-PKcs specific antibody recognizing 
phosphorylated S2056 on DNA-PK, as a method of measuring ongoing NHEJ repair (Fig. 4A). 
 DNA-PK phosphorylation was low before treatment and after castration (Fig. 4C). 
Following radiotherapy, we observed a robust increase in the mean staining intensity of nuclear 
phosphorylated DNA-PKcs (p=0.01) (Fig. 4B, C), demonstrating strong activation of DNA-PK-
mediated NHEJ repair of DSBs. In contrast, neo-adjuvant castration treatment before 
radiotherapy completely abolished radiotherapy-induced phosphorylated DNA-PKcs in arm 1. 
Interestingly, since the biopsies after radiotherapy and castration in arm 2 were taken 8 weeks 
after the last fraction of radiation, the subsequent phosphorylation of DNA-PKcs dropped below 
background levels (35%, p<0.001) (Fig.4C). 
 NHEJ and homologous recombination are two major DNA repair pathways that mediate 
DSB repair. NHEJ is the most efficient DSB repair pathway and works in all cell cycle phases 
(21, 22), whereas homologous recombination is a slow multistep process that requires several 
proteins and operates exclusively during the S and G2 phases of the cell cycle (23). Next, we 
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tested the possibility that homologous recombination could play a major role in repair of DSBs 
induced during radiotherapy.  
 Using the Ki67 protein as a marker of proliferative activity (cells in S and G2 phases), we 
assessed how castration and/or radiotherapy  affected prostate cancer cells during the cell cycle. 
The number of proliferating cells according to Ki67 staining was 7% in both arms prior to 
castration and radiotherapy (Fig. S2). Castration treatment resulted in a decrease to about 1.5% 
Ki67-positive cells in both arms, and 5 days of radiotherapy treatment resulted in a dramatic 
reduction in Ki67-positive cells in both arms to about 0.5% (p<0.001 for both) (Fig. S2). These 
results suggest that the prostate cancer cells entered into cell cycle arrest (G0) following both 
castration and radiotherapy treatment and therefore relied solely on NHEJ for repair of 
radiotherapy-induced DSBs. 
 
Discussion  
Prostate cancer is the most common type of cancer in many countries and the incidence is 
increasing worldwide. It is well established that the combination of chemical castration and 
radiotherapy improves survival of patients with localized intermediate and high-risk prostate 
cancer (9). Understanding the underlying molecular mechanism explaining how neo-adjuvant 
castration improves overall responses to radiotherapy is critical in order to rationally improve 
clinical protocols to increase overall patient survival. Previously, we reported a reduction in the 
Ku70 protein in prostate cancer tissue following castration (16), suggesting that NHEJ may be 
affected by castration. Pre-clinical results obtained using the LNCaP prostate cancer cell line 
showed that androgen deprivation therapy decreased NHEJ (17) and that androgen receptor 
expression induced and promoted DNA-PKcs expression and activity (18). However, these 
results were complicated by the fact that DNA-PKcs also serves as a co-factor in androgen 
receptor-mediated transcription (18, 24). Hence, the role of DNA-PK and androgen receptor is 
complex and the situation in prostate cancer patients may differ from the behavior of prostate 
cancer cell lines grown in vitro in the absence of a functional tumor microenvironment. Here, we 
demonstrate in prostate tumor tissue from patients that the decrease in Ku70 after chemical 
castration correlated with an increase in residual radiotherapy-induced DSBs, indicating a failure 
in NHEJ repair. Impaired activation of NHEJ was also supported by the decrease in DNA-PK 
(pS2056) in prostate tumor tissue after radiotherapy but before castration.  As the specificity of 
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demonstrate in prostate tumor tissue from patients that the decrease in Ku70 after chemical 
castration correlated with an increase in residual radiotherapy-induced DSBs, indicating a failure 
in NHEJ repair. Impaired activation of NHEJ was also supported by the decrease in DNA-PK 
(pS2056) in prostate tumor tissue after radiotherapy but before castration.  As the specificity of 
the DNA-PK (pS2056) antibody has not been validated in human formalin fixed, paraffin 
embedded samples, we cannot exclude that castration impairs other radiotherapy-induced 
phosphorylation cascades, such as the ATM signaling pathway. Previous in vitro studies only 
showed marginal reduction in NHEJ repair (17). However, in the current study the decrease in 
Ku70 after castration was more robust about 30% compared to its initial value before castration 
Altogether, these data suggest that androgen receptor regulation of NHEJ is more rigorous in 
prostate cancer tissue from patients than observed in vitro in cell lines. Also, this suggests that 
NHEJ proteins other than Ku70 may be regulated by androgen receptor to maintain proficient 
NHEJ. Homologous recombination repair of radiotherapy-induced DSBs appears not to be 
operating in prostate cancer tissue as there are too few (<1%) cells in the S or G2 phases of the 
cell cycle during radiotherapy, when homologous recombination is active.  
 An interesting observation is that the overall staining intensity for 53BP1 was reduced 
following castration. These data suggest that the DNA damage response is affected by castration 
in prostate cancer patients, which potentially could be exploited therapeutically in the future by 
combining DNA repair inhibitors.  
 Chemical castration affects only the androgen-synthesizing testicular Leydig cells, which 
are under the control of the pituitary-gonadal axis. Following castration, serum androgen 
decreases by 90-95% leaving the 5-10% of androgen produced by the adrenal glands (8). 
Emerging evidence suggests that residual androgen production by the adrenal glands and de novo 
steroid synthesis from cholesterol or progesterone precursors eventually lead to continued 
prostate cancer growth. Abiraterone and Enzalutamide prevent intratumoral androgen production 
by targeting androgen biosynthesis (through CYP17A) (25) or inhibiting androgen receptor 
nuclear translocation (26), respectively. Enzalutamide and ARN-509 (another anti-androgen 
drug) downregulate NHEJ and improve radiosensitivity in pre-clinical cancer models (17, 18). 
Clinical trials have shown that the use of second-generation drugs such as Abiraterone and 
Enzalutamide improves overall survival of patients with castration-resistant prostate cancer (25, 
26). Since castration alone does not suppress androgen-regulated genes sufficiently, the second-
generation drugs may be efficacious because they suppress these genes, potentially leading to 
further impairment of NHEJ in a neo-adjuvant setting and improving radiosensitivity (27). A 
remaining open question is whether prostate cancer relapse after castration plus radiotherapy is 
due to insufficient androgen depletion after castration.  
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A limitation of our study is that we cannot describe in detail how the androgen receptor 
mediates NHEJ repair, for example, if it is solely through transcriptional regulation of proteins 
involved in NHEJ or if there is a more direct role for androgen receptor in NHEJ. Such questions 
are more difficult to resolve with patient material and are better addressed in vitro. Our current 
study is focused on NHEJ repair but it is possible that androgen receptor also mediates other 
repair or signaling pathways that are important for sensitizing prostate cancer cells to 
radiotherapy. 
 We have shown  that the improved survival of prostate cancer patients achieved by 
combined castration and radiotherapy may be explained by impaired NHEJ repair of DSBs. This 
results in  an increase in radiotherapy-induced DSBs leading to apoptosis of prostate cancer cells. 
Importantly, given that  radiosensitization of prostate cancer tissue is optimally achieved after a 
combination of radiotherapy and castration  we predict even better radiosensitization of prostate 
tumor tissue that expresses more androgen-sensitive androgen receptor . 
Materials and Methods 
Study design 
Patients with localized, i.e. non-metastatic prostate cancer, eligible for curative radiotherapy, 
were enrolled in the study. Before inclusion, patients underwent examinations with bone scans 
and complementary imaging with computerized tomography or magnetic resonance imaging to 
exclude distant metastases. After completion of written informed consent, the patients were 
allocated to one of the two study arms. After signing the informed consent, three patients in arm 
1 and one patient in arm 2 refused further biopsies, so there remained 25 participants in arm 1 
and 23 in arm 2 who were eligible for this study. Patient characteristics are summarized in Table 
1. The regional ethics committee of Uppsala University granted ethical approval, EPN Dnr 
2011:066. 
In arm 1, the patients received neo-adjuvant chemical castration with leuprorelin, a 
gonadotropin-releasing hormone analogue, followed by external beam radiotherapy in daily 2 Gy 
fractions to a total dose of 78 Gy. In arm 2, the patients first received radiotherapy in 2Gy daily 
fractions for 5 consecutive days followed by neo-adjuvant leuprorelin and then an equivalent 
higher radiotherapy dose to a total of 82 Gy (see Figure 1A). Before treatment, prostate needle-
core biopsy specimens were obtained from all patients. In arm 1, a second biopsy was taken eight 
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fractions to a total dose of 78 Gy. In arm 2, the patients first received radiotherapy in 2Gy daily 
fractions for 5 consecutive days followed by neo-adjuvant leuprorelin and then an equivalent 
higher radiotherapy dose to a total of 82 Gy (see Figure 1A). Before treatment, prostate needle-
core biopsy specimens were obtained from all patients. In arm 1, a second biopsy was taken eight 
weeks after the leuprorelin injection, i.e. before radiotherapy was started, and a third biopsy was 
taken about three hours after the fifth radiotherapy fraction. In arm 2, a second biopsy was taken 
about three hours after the fifth radiotherapy fraction, i.e. before hormone treatment was 
initiated, and a third biopsy was taken eight weeks after the administration of leuprorelin (Fig. 
1A). 
Histology and Immunofluorescence 
All prostate tissue needle biopsy specimens were embedded in paraffin, sectioned and stained 
with haematoxylin and eosin. In all specimens, the cancer areas were assessed according to the 
Gleason system (28) and marked by a uro-pathologist. Two cancer-rich specimens from each 
batch of biopsies were further sectioned for immunofluorescence analysis. These sections were 
deparaffinised and rehydrated before antigen retrieval with R-buffer A (Electron Microscopy 
Sience) in a pressure cooker. After blocking with 2% BSA, the sections were incubated with 
different primary antibodies at 4
o
C overnight. Extensive rinsing was performed once; the 
sections were incubated with the secondary antibodies (donkey anti mouse IgG-alexa 488 (1:500; 
Molecular probe) and donkey anti rabbit IgG-alexa 555 (1:500; Molecular probe) for one hour at 
room temperature. DNA was counterstained with TO-PRO-3 iodide (Molecular probe) and slides 
mounted with prolong gold (Molecular probe). Slides were stained with antibodies against (1) 
androgen receptor  (1:500, N-20, sc-816 Santa Cruz) and Ku-70 (1:500, E-5, sc-17789 Santa 
Cruz) or (2)  53BP1 (1:1000, Bethyl laboratories) and γ-H2AX (1:1000, 3F2, Abcam) or (3) 
phosphorylated DNA-PKcs alone (1:750, S2056, Abcam) or (4) Ki67 alone (1:200, MIB-1, 
Dako).  
Images from a tumor area with a good immunefluorescence signal were selected from each 
biopsy. The corresponding areas in the haematoxylin and eosin-stained section were identified 
for histological verification of the tumor area. In slides stained for Ku70, androgen receptor, 
Ki67 or phosphorylated DNA-PKcs two areas from each slide containing 300-600 cells were 
chosen for analyses. TO-PRO-3 was used as a DNA marker.  
All images were analysed, with respect to medium staining intensity inside the nuclei and 
in the cytoplasm. The nuclear area was defined by the TO-PRO-3 signal and the cytoplasmic 
area as a 5 µm extension outside the nuclear area (Fig. 2A). For those proteins with exclusively 
nuclear localisation (53BP1 and phosphorylated DNA-PKcs), the intensity in the cytoplasm was 
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in the cytoplasm. The nuclear area was defined by the TO-PRO-3 signal and the cytoplasmic 
area as a 5 µm extension outside the nuclear area (Fig. 2A). For those proteins with exclusively 
nuclear localisation (53BP1 and phosphorylated DNA-PKcs), the intensity in the cytoplasm was 
considered as background. For other proteins, with both nuclear and cytoplasmic localisation 
(Ku70 and androgen receptor), staining intensity values are presented without background 
subtraction (Fig. 1B). The measurement of the number of Ki67-positive cells was performed 
using a threshold for Ki67 intensity in the nucleus in order to distinguish positive from negative 
cells (Fig. 1C). For those markers that form foci, the number and area of foci per DNA unit was 
measured (Fig. 1D). All measurements were performed using an in house-written program for 
NIH-imageJ.  
(29). Fluorescence images were obtained with either a Zeiss LSM 510-inverted confocal 
microscope or a Zeiss LSM 780-inverted confocal microscope, using a planapochromat 40X/NA 
1.2 objective. Through-focus maximum projection images were acquired from optical sections 
0.5 μm apart and with a section thickness of 1.0 μm. Haematoxylin and eosin-stained images 
were obtained with a Leica scan system. 
 
Statistical analysis 
Non-parametric test methods were applied. Related outcomes after different treatments within 
each arm were compared using the Wilcoxon Signed Ranks Test. Unrelated outcomes between 
the study’s two arms were compared using the Mann-Whitney U Test. Correlation analysis was 
conducted using Spearman´s rho rank correlation test (ρ). All statistical tests were two-tailed 
with significance established at p <0.05. Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS), version 21.0. 
 
Supplementary Materials 
Figure S1. Effects of castration and/or radiotherapy on the nuclear staining of 53BP1 and 
γ-H2AX. Bar graph showing the number of 53BP1 foci (blue bars), γH2AX foci (red bars) and 
the number of co-localised foci (green bars) in nuclei before treatment (base) and after different 
modalities of treatment in Arm 1 and Arm 2. Error bars show standard error of mean.  
Figure S2. Effects of castration and/or radiotherapy on the cell proliferation rate. 
Determination of proliferation rate using Ki67 in nuclei of prostate cancer tissue before and after 
different treatments. 
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Table S2. Correlation tests between different antibodies and the clinical parameters at the time of 
diagnosis for patients in the study.  
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Figure 1. Flow chart and images shows different technical methods applied for the 
measurement of immunofluorescence staining signals of different antibodies.    
(A) Flow chart of patients enrolled in the study. Patients received castration treatment with an 
gonadotropin-releasing hormone analogue for 8 weeks. 2 Gy x5 radiotherapy treatments were 
given on consecutive days and biopsies were taken 3 hours after the fifth dose of radiotherapy. 
(B) Upper left panel shows an original image used for intensity measurements. Upper right panel 
shows the same images after computer processing. Areas encircled with white lines were used 
for measurements of staining intensity inside the nuclei and were extracted by using the DNA 
signal as a mask. The DNA mask was processed with an algorithm to exclude stromal cells. 
Background measurements were performed in the 5 µm wide area outside the nuclei depicted as 
grey in the figure. Between the nucleus and the grey area there was a 1µm wide strip that was not 
measured to avoid background signals. (C) Original images were used for classification of Ki67-
positive cells. Extraction of nuclei was done as described above. A threshold was applied to the 
Ki67 staining intensity signal. The areas with a signal above the threshold were used to calculate 
the fraction of Ki67-positive cells. (D) Original images were used for DSB foci (53BP1 and γ-
H2AX) measurements. Lower right panel shows the same images after computer processing. 
Extraction of nuclei was done as described above. To extract the foci an algorithm that considers 
the local changes in staining intensity was used. 
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 Figure 2. Effects of castration and/or radiotherapy on the nuclear staining of androgen 
receptor (AR) and Ku70. Determination of nuclear AR and Ku70 in prostate cancer tissue 
before treatment (Baseline) and after different treatment modalities in arm 1 and arm 2. (A) 
Different sections of prostate cancer biopsies are shown and each biopsy is sectioned and 
stained. The first section was stained with hematoxylin and eosin (H&E) to identify tumor  areas. 
A further corresponding adjacent section obtained from the same biopsy was stained for  Ku70  
with an anti-Ku70 mouse-monoclonal antibody (green color) and an anti-androgen receptor 
rabbit-polyclonal antibody (red color). The DNA was co-stained with TO-PRO-3 (blue color). 
Upper sections were from a patient in arm 1; the upper panel was before treatment (baseline), 
middle panel was after castration and lower panel was after castration and radiotherapy (RT).. 
Lower sections were from a patient in arm 2; the upper panel was before treatment (baseline), 
middle panel was after RT and lower panel was after RT and castration. (B) Percentage of 
normalized mean staining intensity for androgen receptor (AR) (red bars) and Ku70 (green bars) 
in nuclei before treatment (baseline) and after different treatment modalities in arm 1 and arm 2 
for all patients. Error bars show standard error of the mean. (C) Spearman´s rho rank correlation 
test (ρ) between mean intensity of androgen receptor (AR) and Ku70 in nuclei in biopsies from 
all patients before treatment (baseline) in arm 1 and arm 2. (D) Spearman´s rho rank correlation 
test (ρ) between mean intensity of androgen receptor (AR) and Ku70 in nuclei in biopsies from 
all patients in arm 1 after chemical castration treatment. 
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Figure 3. Effects of castration and/or radiotherapy on the nuclear staining of 53BP1 and γ-
H2AX. Determination of nuclear 53BP1 and γ-H2AX in prostate cancer tissue before treatment 
(Baseline) and after different treatment modalities in arm 1 and arm 2. (A) Different sections of 
prostate cancer biopsies are shown and each biopsy is sectioned and stained. The first section 
was stained with haematoxylin and eosin (H&E) to identify cancer areas. A corresponding 
adjacent section obtained from the same biopsy was stained with anti- γ-H2AX mouse-
monoclonal antibody (green color) and anti-53BP1 rabbit-polyclonal antibody (red color). The 
DNA was co-stained with TO-PRO-3 (blue color). Upper sections were from a patient in arm 1; 
the upper panel was before treatment (baseline), middle panel was after castration and lower 
panel was after castration and radiotherapy (RT). Lower sections were from a patient in arm 2; 
the upper panel was before treatment (baseline), middle panel was after RT and lower panel was 
after RT and castration. (B) A selected section from previous patient images in Arm 1 after 
castration and RT and Arm 2 after RT (merged staining for 53BP1, γ-H2AX and DNA). (C) 
Normalized percentage of γ-H2AX foci (green bars) and 53BP1 foci (red bars) in nuclei in 
prostate cancer biopsy material before treatment (baseline) and after different treatment 
modalities in arm 1 and arm 2 for all patients. Error bars show standard error of the mean. (D) 
Normalised mean staining intensity for 53BP1 in nuclei of prostate cancer biopsies before 
treatment (baseline) and after different treatment modalities in arm 1 and arm 2 for all patients. 
Error bars show standard error of the mean. 
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Figure 4. Effects of castration and/or radiotherapy on the nuclear staining of 
phosphorylated DNA-PKcs (pS2056). Determination of nuclear phosphorylated DNA-PKcs (P-
DNA-PKcs) in prostate cancer tissue before treatment (Baseline) and after different treatment 
modalities in arm 1 and arm 2. (A) Different sections of prostate cancer biopsies are shown and 
each biopsy is sectioned and stained. The first section was stained with hematoxylin and eosin 
(H&E) to identify cancer areas. A corresponding adjacent section obtained from the same biopsy 
was stained with P-DNA-PKcs rabbit-polyclonal antibody (red color). The DNA was co-stained 
with TO-PRO-3 (blue color). ). Upper sections were from a patient in arm 1; the upper panel was 
before treatment (baseline), middle panel was after castration and lower panel was after 
castration and radiotherapy (RT). Lower sections were from a patient in arm 2; the upper panel 
was before treatment (baseline), middle panel was after radiotherapy (RT) and lower panel was 
after RT and castration. (B) A selected section from previous images in Figure 4A of patients 
both in arm 1 after castration and RT and in arm 2 after RT (merge P-DNA-PKcs with DNA). 
(C) Changes in P-DNA-PKcs foci/cell (normalized value) in nuclei in prostate cancer biopsies 
before treatment (baseline) and after different treatment modalities in arm 1 and arm 2 for all 
patients. Error bars show standard error of the mean. 
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Figure S1: Effects of castration and/or radiotherapy on the nuclear staining of 53BP1 and γ-H2AX and 
their co-localization. Bar graph showing the number of 53BP1 foci (blue bars), γH2AX foci (red bars) and the 
number of co-localised foci (green bars) in nuclei before treatment (base) and after different modalities of 
treatment in Arm 1 and Arm 2 for all patients. Error bars show standard error of mean.  
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Figure S2: Effects of castration and/or radiotherapy on the cell proliferation rate. Determination of 
proliferation rate using Ki67 levels in nuclei of prostate cancer tissue before and after different modalities of 
treatment. A) Different sections of prostate biopsies are shown and each biopsy is sectioned and stained. The 
first section was stained with Haematoxylin and Eosin staining for identifying cancer areas. A further 
corresponding adjacent section obtained from the same biopsy was stained with immunofluorescence staining 
with Ki67 mouse-monoclonal antibody (green). The DNA was co-stained with TO-PRO-3 (blue). Sections in 
left panel were from a patient in arm 1; the upper left was before treatment (base), middle left was after 
castration and lower left after castration and RT. Sections in right panel were from patient in arm 2; the upper 
right was before treatment (base), middle right was after RT and lower right after RT and castration.  B) 
Percentage of Ki67 positive cells before treatment (base) and after different modalities of treatment in arm 1 
and arm 2 for all patients. Error bars show standard error of mean. 
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Table S1: Characteristics of patients at the time of diagnosis and after different treatments in arm 1 and arm 
2. 
 
 Arm 1 
 
Arm 2 
 
p value 
Number of patients 25 23  
Median age years  
(Min – Max) 
 
70 (56-78)  
 
69 (55-78) 
 
0.6 
Median Gleason Score (%) 6 (4%) 
7 (60%) 
8 (12%) 
9 (24%) 
6 (8%) 
7 (65%) 
8 (8%) 
9 (17%) 
ns  
ns 
ns 
ns 
Median time to prostate 
needle biopsy specimen in 
days (Quartiles) 
 
 
55 (54-59) 
 
 
58 (55-57) 
 
 
ns 
Median serum PSA ng/ml 
(Quartiles) 
At diagnoses 
After castration  
After castration and RT 
After RT  
After RT and castration 
 
 
11 (7.6-19.5) 
0.8 (0.36-1.6) 
1.2 (0.34-2.2)  
 
 
8.3 (3.9-15)  
 
 
9.5 (4.7-19.25) 
0.69 (0.26-1.5) 
 
 
0.16 
 
 
 
Median serum 
Testosterone nmol/L 
(Quartiles) 
At diagnosis  
After castration  
After castration and RT 
After RT  
After RT and castration 
 
 
 
ND 
0,7 (0-0.95) 
0.5 (0-0.93) 
 
 
 
ND 
 
 
9,4 (7.8-12.5) 
0,7 (0-1.0) 
 
Median volume prostate 
cm
3 
(Quartiles)  
At diagnosis 
After castration 
After castration and RT 
After RT  
After RT and castration 
 
 
 
41 (30-49) 
24 (19-36) 
24 (19-33) 
 
 
 
35 (26-49) 
 
 
37 (30-47) 
26 (19-34) 
 
 
 
0.4 
 ND: not done 
 ns: not significant  
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Table S2: Correlation tests between different antibodies and the clinical parameters at the time of diagnosis for 
patients in the study.  
Spearmans
´
s rho rank correlation (ρ) test between initial values, obtained at the time of diagnosis, of serum 
PSA, prostate size, age, Gleason score, clinical stage and levels of Ku70, phosphorylated DNA-PKcs, AR, for 
all valid patients enrolled in the study. 
 
 Serum 
PSA 
ng/ml 
Prostate size 
Cm
3 
Age  
Years 
Gleason 
score 
Clinical stage  
Ku70  
 
ρ=0.007 
P=0.96 
ρ =0.217 
P=0.14 
ρ =0.193 
P=0.18 
ρ =0.21 
P=0.13 
ρ =0.13 
P=0.36 
phosphorylated DNA-PKcs ρ =0.15 
P=0.29 
ρ =0.20 
P=0.16 
ρ =0.43* 
P=0.002 
ρ =0.04 
P=0.76 
ρ =0.15 
P=0.28 
AR ρ =0.24 
P=0.93 
ρ =0.15 
P=0.32 
ρ =0.09 
P=0.54 
ρ =0.19 
P=0.18 
ρ =0.01 
P=0.94 
* Correlation is significant at the 0.05 level (2-tailed), ** Correlation is significant at the 0.01 level (2-tailed) 
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Abstract 
Despite the early diagnosis and subsequently effective treatment of intermediate and high-
risk prostate cancer, the recurrence rate remains regrettably high. It is well-established that 
primary prostate tumour is a multifocal disease. Here, we wanted to investigate how 
effectively castration suppresses androgen receptor (AR) signalling, thereby affecting DNA 
damage repair in primary hormone-naïve prostate cancer. In a prospective study, five patients 
with localized prostate cancer, eligible for curative treatment were enrolled. Four patients 
received combined neo-adjuvant pharmacological castration and radiotherapy (RT) whilst 
one patient received in addition, low-dose radiation before the combined treatment was 
initiated. Prostatic needle core biopsies were secured at diagnosis, after castration and after 
RT.  Serum PSA was measured at diagnosis and after castration while serum testosterone 
was only measured after castration. The levels of AR, Ku70, phosphorylated DNA-PKcs and 
PAR were measured. We observed a significant and correlated reduction in the mean 
intensity of nuclear AR in four patients whose serum PSA was reduced to the greatest extent, 
about 90% (ρ=1, p <0.001). Although complete castration was obtained using serum 
testosterone levels in these patients, the levels of AR, and consequently of Ku70 and 
phosphorylated DNA-PKcs remained high and positively co-varied in clusters of cells 
throughout prostate tumour areas. Meanwhile, a tendency towards an inverse correlation was 
observed between AR, Ku70 and phosphorylated DNA-PKcs and PARP-1 activity.  In 
conclusion, we are first to demonstrate the heterogeneous landscape of AR and the 
consequent divergent although co-varied response of DNA damage repair. To date, it 
remains unclear whether the emergence of these castration-resistant cells in hormone-naïve 
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prostate cancer, is due to the high levels of intra-tumoral residual androgen following 
castration and consequently suboptimal androgen suppression of otherwise androgen-
dependent cells or caused by quiescent castration-resistant cells that promote progression 
according to clonal selection pressure. The current finding certainly warrants further 
investigation in the future. 
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Introduction 
        The extensive availability of PSA testing revolutionized the diagnosis and treatment of 
localized prostate cancer. However, the recurrence rate following primary curative treatment 
remains high, in approximately 30-50 % of the patients with intermediate and high risk 
tumours1-3. Prostate cancer recurrence occurs either locally or systemically and cancer 
fatalities are attributable to metastatic, castration-resistant disease that has progressed despite 
androgen deprivation therapy (ADT). 
Primary prostate cancer is generally multifocal and heterogeneous, co-existing in a single 
prostate gland and often consisting of a dominant tumour and one or multiple separate 
smaller tumours with histologically different Gleason grades4,5. Multifocal primary 
cancerous foci are biologically and genetically independent with distinct genetic features that 
are often characterized by different DNA sequence alterations, which are strongly dominated 
by copy-number alterations, small insertions or deletions, chromosomal re-arrangements, 
point mutations6-8 and aberrant DNA methylations9. Divergent clonal populations can be 
identified in a single biopsy10. In contrast to the genomic heterogeneity of primary prostate 
cancer, metastatic disease often has a monoclonal origin with common genetic 
signatures11,12. 
Three main cell types can be characterized in normal prostate gland epithelium: basal, 
luminal and neuro-endocrine. A progenitor basal epithelium made up of undifferentiated 
stem cells is characterized by the expression of basal cell markers, such as p63 (16). They 
have low or undetectable levels of androgen receptors (AR)13and are independent of 
androgens for their survival14. Their progeny, luminal or so-called glandular cells, are 
differentiated and express luminal cell-specific markers, viz prostate specific antigen (PSA), 
prostatic acid phosphatase (PAP) and AR, on which they are dependent for their survival14,15. 
However, they lack expression of basal cell markers, such as p6316. The neuro-endocrine 
cells are sporadically scattered between these two cell layers and are differentiated, 
androgen-insensitive cells 17. Human prostate cancer has a luminal phenotype. However,it is 
currently unclear which cells within the prostate epithelium are the origin of prostate cancer, 
stem/progenitor cells or their differentiated luminal cells/progeny which acquire tumour-
promoting mutations that initiate the formation of cancer stem cells(CSCs)18,19. 
In addition to AR´s critical role in prostate gland development, growth and physiological 
function, the AR signalling axis is thought to facilitate prostate carcinogenesis, although the 
mechanisms of cancer initiation and progression are still being elucidated. AR, like several 
other genes that participate in the development and differentiation of prostate epithelium, are 
de-regulated in prostate cancer20. While AR is not mutated in the primary hormone-naïve 
tumour, AR is often mutated or amplified in castration-resistant disease 21. Standard 
androgen deprivation does not consistently suppress androgen-dependent gene expression22. 
Currently, the point of time at which the development of castration-resistant disease occurs 
during prostate tumorigenesis, is unclear. The key question is whether castration-resistant 
cells arise through genetic/epigenetic transformation of previously androgen-dependent cells 
following ADT, or originate from previously quiescent castration-resistant cell populations 
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within an otherwise androgen-dependent tumour. The aim of the study is to investigate the 
heterogeneous landscape of AR in primary hormone-naïve prostate cancer and the impact of 
castration on certain DNA repair pathways at the single cell level. 
 
Results 
Heterogeneous response of prostate tumour cells to castration  
In previous prospective clinical studies, we demonstrated that castration impairs the DNA 
repair capacity of D-NHEJ by reducing the expression of its essential proteins such as Ku70 
and impairing phosphorylation of DNA-PKcs. However, a wide range of individual 
variations in the levels of these proteins was observed (25and Tarish et al., accepted in 
Science Translational Medicine with minor revisions). In this pilot study, we investigated 
any potential heterogeneity in the expression of AR and DNA repair proteins following 
castration. Despite the fact that examined patients had a primary untreated hormone-naïve 
prostate tumour, a remarkable heterogeneous response of AR signalling to castration was 
observed in different prostate tumour cells. Following castration, a significant decrease in the 
mean intensity of nuclear AR expression by almost 50% in patients 1-3 and in patient 
number 5 was observed. However, AR expression remained unaffected at a high level in 
clusters of tumour cells that gathered as subclones throughout prostate tumour areas with a 
variety in the number of cells (Figure 4 and Figure S1).  
 
Correlated differences between AR and Ku70 at the single cell level 
 
The levels of expression of nuclear AR and Ku70 at a single cell level in tumour areas were 
investigated. In a previous cohort study, a positive correlation between nuclear AR and Ku70 
levels before and after castration and/or RT (Tarish et al., accepted with minor revisions) was 
reported. Equally here, using Spearman´s rho rank correlation test (ρ), a significant 
correlation between the mean intensity of nuclear AR and Ku70 levels in each examined 
patient before and after different treatments was observed (Table 2, Figure 5 and Figure 
S2A-C). Interestingly, despite tumour heterogeneity in response to castration, almost 
comparable co-variations between AR and Ku70, at a single cell level, were observed in 
nearly all patients before and after treatment i.e. cells that retained high levels of AR 
expression after castration preserved almost comparable, high expression levels of Ku70 
(Figure S3). 
Correlated differences between AR and phosphorylated DNA-PKcs in tumour areas 
In the present study, investigated the correlation between AR and P-DNA-PKcs. We used 
tumour areas in two adjacent sections that were merged to study the correlations between AR 
and P-DNA-PKcs (Figure 3). As expected, the mean intensity of nuclear AR and P-DNA-
PKcs foci was significantly correlated in nearly all patients before and after treatment (except 
at the time of diagnosis in patients 2 and 5) (Table 2, Figure 5, and Figure S2A-C). 
Furthermore, the study revealed that the expressions of P-DNA-PKcs foci in clusters of cells 
co-varied with the expression pattern of both AR and Ku70 (Figure 5).  
Tarish F et al. 
within an otherwise androgen-dependent tumour. The aim of the study is to investigate the 
heterogeneous landscape of AR in primary hormone-naïve prostate cancer and the impact of 
castration on certain DNA repair pathways at the single cell level. 
 
Results 
Heterogeneous response of prostate tumour cells to castration  
In previous prospective clinical studies, we demonstrated that castration impairs the DNA 
repair capacity of D-NHEJ by reducing the expression of its essential proteins such as Ku70 
and impairing phosphorylation of DNA-PKcs. However, a wide range of individual 
variations in the levels of these proteins was observed (25and Tarish et al., accepted in 
Science Translational Medicine with minor revisions). In this pilot study, we investigated 
any potential heterogeneity in the expression of AR and DNA repair proteins following 
castration. Despite the fact that examined patients had a primary untreated hormone-naïve 
prostate tumour, a remarkable heterogeneous response of AR signalling to castration was 
observed in different prostate tumour cells. Following castration, a significant decrease in the 
mean intensity of nuclear AR expression by almost 50% in patients 1-3 and in patient 
number 5 was observed. However, AR expression remained unaffected at a high level in 
clusters of tumour cells that gathered as subclones throughout prostate tumour areas with a 
variety in the number of cells (Figure 4 and Figure S1).  
 
Correlated differences between AR and Ku70 at the single cell level 
 
The levels of expression of nuclear AR and Ku70 at a single cell level in tumour areas were 
investigated. In a previous cohort study, a positive correlation between nuclear AR and Ku70 
levels before and after castration and/or RT (Tarish et al., accepted with minor revisions) was 
reported. Equally here, using Spearman´s rho rank correlation test (ρ), a significant 
correlation between the mean intensity of nuclear AR and Ku70 levels in each examined 
patient before and after different treatments was observed (Table 2, Figure 5 and Figure 
S2A-C). Interestingly, despite tumour heterogeneity in response to castration, almost 
comparable co-variations between AR and Ku70, at a single cell level, were observed in 
nearly all patients before and after treatment i.e. cells that retained high levels of AR 
expression after castration preserved almost comparable, high expression levels of Ku70 
(Figure S3). 
Correlated differences between AR and phosphorylated DNA-PKcs in tumour areas 
In the present study, investigated the correlation between AR and P-DNA-PKcs. We used 
tumour areas in two adjacent sections that were merged to study the correlations between AR 
and P-DNA-PKcs (Figure 3). As expected, the mean intensity of nuclear AR and P-DNA-
PKcs foci was significantly correlated in nearly all patients before and after treatment (except 
at the time of diagnosis in patients 2 and 5) (Table 2, Figure 5, and Figure S2A-C). 
Furthermore, the study revealed that the expressions of P-DNA-PKcs foci in clusters of cells 
co-varied with the expression pattern of both AR and Ku70 (Figure 5).  
Tarish F et al. 
 
Neo-adjuvant castration may trigger alternative DNA repair machinery mediated via 
PARP-1 
We hypothesized that an impairment of D-NHEJ following castration in prostate tumours is 
critical in affecting genomic integrity and consequently will lead to an enhanced activity of 
back-up DNA repair machinery, the so-called B-NHEJ mediated by PARP-1. A former study 
showed that PARP-1 activities increased following castration, suggesting that prostate cancer 
relies on B-NHEJ, for the repair of its DSBs (Asim et al., in preparation). The current study 
aimed at further investigating the correlation between AR and PARP-1 activity in the 
heterogeneous landscape of AR in prostate cancer. Interestingly, a significant inverse 
correlation between the levels of PAR and nuclear AR (Table 2, Figure 5 and Figure S2 B-C) 
and nuclear Ku70 were observed following different treatments (Table 3A and Figure S4). 
However, in the case of P-DNA-PKcs, the inverse correlation with PAR levels was mainly 
observed after combined castration and RT (Table 3B and Figure S4). Likewise, a tendency 
of inverse correlation between the PAR levels and the levels of AR, Ku70 and P-DNA-PKcs 
were observed in different tumour areas (Figure 5). 
Divergent responses in AR, Ku70 or PSA despite castration serum testosterone levels 
Previously, a significant correlation was demonstrated between the decrease in serum PSA 
and nuclear Ku70 levels in patients with metastatic PCa following castration, suggesting that 
the PSA nadir may reflect simultaneously the nadir value of DNA repair activity25. A 
significant reduction in the mean intensities of nuclear AR and Ku70 levels were observed 
following castration in patients 1-3 and 5, whose serum PSA reduced most, by 89-99%, after 
castration. However, in patient number 4, whose serum PSA was only reduced by 70% 
despite castrate levels of serum testosterone, no reduction was observed in the mean intensity 
of nuclear AR or Ku70 after castration (Table 1).  
 
Nuclear AR and serum PSA levels correlate 
A significant correlation between the levels of AR in nuclei and serum PSA levels after 
castration was observed in all five patients (ρ=1, p <0.001). Indeed, the finding was 
expected, since AR controls PSA expression (Figure S5).  
 
Discussion 
          The current study demonstrates that, despite castration levels of serum testosterone, 
achieved by standard pharmacological castration, there is an inadequate suppression of 
androgen-responsive genes in subclones of cells throughout prostate tumour areas with 
persistent high levels of activity of AR and AR-related DNA repair genes. In these sub-
clones of cells, high levels of AR were observed that co-varied with Ku70 and 
phosphorylated DNA-PKcs, two central proteins connected to the D -NHEJ repair pathway, 
thus indicating its inactivation despite castration levels of serum testosterone. 
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          The mechanism behind, and timing for the development of castration-resistant prostate 
cancer (CRPC) may lead to a comprehensive understanding of the underlying mechanism 
behind the emergence of such resistant cells after primary hormone manipulation. In line 
with this, two models have been proposed: the adaptation model which hypothesized that 
selective pressure of ADT encourages mutational events in the androgen signaling pathway, 
and the clonal selection model which hypothesized the heterogeneous nature of prostate 
cancer and the pre-existing clone of castration-resistant cells 26,27. In fact, about 70% of 
patients with CRPC remain androgen-dependent and continue responding to further 
hormonal manipulation such as second-generation anti-androgens28.   
          Several scientific observations support the adaptation models and provide a rationale 
for the emergence of these resistant subclones in current study. To date, it is well-established 
that ADT leads to a decrease in intraprostatic androgens such as testosterone and 
dihydrotestosterone by only 75% to 80%, after accomplishing castrate serum testosterone 
levels with a GnRH -analogue29-31. Residual prostatic androgen levels in castrated patients 
are sufficient to stimulate androgen-responsive genes and activate AR32. An in vivo study by 
Mostaghel et al showed that many androgen-regulated genes are not suppressed after 3-9 
months of neo-adjuvant castration22.  
         Moreover, intense ADT with GnRH analogues in combination with the novel anti-
androgen agent, abiraterone acetate, in patients with primarily localized hormone-naïve 
prostate cancer, showed a further suppression of intraprostatic androgens33. The afore-
mentioned supports the assumption that the continued AR-mediated signalling after primary 
hormone manipulation is probably driven by the presence of residual tissue androgen. 
Furthermore, clinical trials on patients with CRPC using second-generation anti-androgens, 
such as abiraterone acetate and enzalutamide, suggest that AR signalling remains a 
fundamental promoting mechanism of CRPC34,35. The heterogeneity in AR response in the 
current study highlights findings in previous studies, which demonstrated continued 
substantial androgen-dependent gene expression following castration. 
         To date, different spliced variants of AR, which lack the ligand-binding domain and are 
functionally active despite the absence of androgens, have shown a putative role in 
developing resistance to anti-androgen therapy in CRPC36. This finding suggests that the 
production of the AR spliced variant could be a consequence of therapy-mediated selection 
pressure mediated by suboptimal intraprostatic androgen ablation, which, in turn, may lead to 
an adaptation by prostate tumour cells to survival in a low-level androgen environment, 
thereby undergoing mutation. 
         Several scientific observations back up the clonal model and provide a rationale for our 
current findings. Interestingly, they have shown that AR gene mutations were common and 
could arise in early hormone-naïve prostate cancer, yet more frequently in advanced disease 
before ADT37,38. Animal studies on the Dunning R-3327-H rat prostate adenocarcinoma 
model with a heterogeneous mixture of androgen-dependent and pre-existing androgen-
resistant tumour cells subjected to ADT, showed that castration provided selective pressure 
and enhanced growth prosperity of castration-resistant tumour cells while androgen-
dependent cells were eliminated 39. 
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          Interestingly, the CSC hypothesis, which has been frequently discussed during recent 
years, is another theory that can support the clonal selection model.  CSCs are a subgroup of 
tumour cells, about 0.1% 40 in number, characterized by a high level of expression of CD44 
and CD133 and a low expression level of AR, with properties of self-renewal and 
differentiation41. The most important question is whether these castration-resistant tumour 
cells are CSCs or not. In fact, since CSCs in prostate cancer are usually characterized by high 
expression levels of CD44 and CD133 and low expression levels of AR, this suggests fairly 
convincingly that, because of the high expression of AR observed in these sub-populations of 
cells in the current study, these cells are not CSCs. Unfortunately, the lack of any CSC-
marker staining such as CK or CD, may be regarded as a limitation in the current study. 
           In this study, it was rather expected that the correlation between AR and D-NHEJ 
proteins be in line with our previous reports and, undoubtedly, support the critical role of AR 
signalling in regulating DNA damage response. The most exciting findings are the co-
variation between, on the one hand, AR and, on the other hand, Ku70 and DNA-PKcs, which 
were demonstrated at a cellular level or at a level of sub-clones of cells. However, despite the 
great improvements achieved in radiation technologies during the last decades combined 
with the more aggressive approach in the treatment of intermediate and high risk PCa, 
frequently using combined neo-adjuvant ADT and high dose RT, the 5-year recurrence rate 
remains high 1-3. Furthermore, clinical trials have failed to identify whether ADT benefits all 
patients modestly or a sub-group to a greater degree. Our current finding may shed some 
light on at least some of the possible causes that may explain the high disease recurrence 
despite adequate oncological treatment. However, the underlining mechanisms behind these 
recurrences still have to be elucidated. 
 
            Interesting in the current work is the observed inverse correlation between PARP-1 
activity and AR. Indeed, we previously demonstrated that PARP-1 activity was induced after 
castration (Asim et al., in preparation). In fact, PARP-1 plays pivotal roles in the processing 
and resolution of a variety of DNA damaged repair such as single-strand break repair 
(SSBR), homologous recombination (HR) or NHEJ42. However, our study suggests that 
prostate tumour cells, in which castration leads to impairment of D-NHEJ, may rely on 
PARP-mediated backup-NHEJ (B-NHEJ) DNA repair. We believe that this is an important 
finding that certainly warrants further investigation in the future.  
 
Conclusion and future perspectives  
           Neo-adjuvant castration combined with radiotherapy remains the standard of care 
treatment for patients with high-risk, localized prostate cancer. In our previous studies 25 
(Tarish et al., accepted with minor revisions), we showed that combined castration and RT 
impair DNA repair due to a down-regulation of D-NHEJ and its essential proteins, Ku70 and 
p-DNA-PKcs, hence improving radiosensitivity. 
          However, our current findings revealed that, despite the significant suppression of the 
mean expression of AR and Ku70 following castration, there is remarkably suboptimal 
suppression of these proteins at the single cell level, which may in turn raise the question 
whether the poorer radiosensitization of prostate tumour cells after subsequent RT may be 
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one of the plausible explanations behind the high incidence rate of recurrence in patients with 
high-risk disease, who receive curative RT in combination with neo-adjuvant castration 1-3. 
          It is probable that tumour heterogeneity may be an important factor in predicting 
response to individually based targeted therapies and a detailed investigation of the concept 
of intra-tumoral heterogeneity, at the single cell level, would be essential. It is well-
established that the tumour microenvironment and surrounding non-malignant tissue may 
influence the growth and progression of tumour cells. Furthermore, the CSC population may 
need to be characterized using single cell resolution in tumour tissues. New technology such 
as spatial transcriptomics (ST), which is a novel approach that combines histology with RNA 
sequencing, could prove a promising tool in future studies. 
 
Materials and Methods 
Five patients with newly diagnosed, localized prostate cancer, eligible for curative 
radiotherapy were enrolled in the study. Ethical approval from the regional ethics committee 
at Uppsala University was acquired (EPN, Dnr 20011/066). Before treatment, prostatic 
needle core biopsy specimens were obtained from all patients. Four patients underwent neo-
adjuvant pharmacological castration with leuprorelin, a gonadotropin releasing hormone 
(GnRH) analogue, followed by external beam radiotherapy to 78 Gy. A second biopsy was 
taking eight weeks after the leuprorelin injection, when their serum testosterone levels had 
decreased to castration levels, < 1.7 nmol/L in all patients. At the same time, serum PSA 
levels decreased between 89-99% in the first three patients and by 70% in the fourth patient 
(Table 1).  
Patient number five first received RT, 2 Gy/fraction for 5 consecutive days followed by neo-
adjuvant pharmacological castration with leuprorelin and afterwards an effect-equivalent 
higher dose of RT to a total of 82 Gy. After castration, serum testosterone decreased to 
castration levels and serum PSA decreased by 97% (Table 1). A second biopsy was taken 
three hours after the fifth dose of RT, i.e. before hormone treatment was started, and a third 
biopsy was taken eight weeks after the administration of leuprorelin. 
Histological and immunofluorescence evaluation 
All prostatic needle biopsy specimens were embedded in paraffin, sectioned and stained with 
hematoxylin and eosin (HE). In all specimens, the cancer areas were graded according to the 
Gleason system 23 and marked by a pathologist. Two cancer-rich specimens from each batch 
of biopsies were further sectioned for immunofluorescence analysis. These sections were 
deparaffinized and rehydrated before antigen retrieval with R-buffer A (Electron Microscopy 
Science) in a pressure cooker. After blocking with 2% BSA, the sections were incubated with 
different primary antibodies at 4oC overnight. Extensive rinsing was performed once; the 
sections were incubated with the secondary antibodies (donkey anti mouse IgG-alexa 488 
(1:500), Molecular probe and donkey anti rabbit IgG-alexa 555 (1:500), for one hour at room 
temperature. DNA was counterstained with TO-PRO-3 iodide (Molecular probe) and slides 
mounted with pro long gold (Molecular probe). To determine the effect of castration on the 
expression of AR and D-NHEJ activity, the nuclear levels of AR, Ku70 and phosphorylated 
DNA-PKcs were measured. Moreover, the expression of poly(ADP-ribose) (PAR), which 
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assesses PARP-1 activity, was measured. Two antibodies were stained on the same slide, AR 
(1:500, N-20, sc-816 Santa Cruz) together with Ku-70 (1:500, E-5, sc-17789 Santa Cruz) and 
phosphorylated DNA-PKcs (1:750, S2056, Abcam) together with PAR (1:200, pADPr 
(10H): sc-56198, Santa Cruz).   
Immunofluorescence signals from the whole biopsy specimen were examined. However, the 
outer edges of all biopsy specimens were excluded from analysis since high expression levels 
of PAR were observed, which are believed to be caused by direct mechanical damage to the 
cells during the process of biopsy collecting, rather than a normal biological event in tumour 
cells owing to castration or RT (Figure 1). 
All images were analyzed with respect to the medium intensity inside nuclei for AR, Ku70 
and PAR.  For P-DNA-PKcs, the area of repair foci in the nucleus was used as a descriptor 
for ongoing repair. Nuclear areas were defined by the TO-PRO-3, a DNA marker (Figure 2). 
All measurements were done using an in-house written programme for NIH-image J 24.  
The immunofluorescence stainings of these proteins were carried out in two adjacent sections 
with a thickness of about 5 uM. However, different factors can determine the co-existence 
and positions of corresponding cells in adjacent sections. Since the stainings of AR and Ku70 
were carried out simultaneously, we could match the levels of these two proteins at a single 
cell level.  However, since stainings of AR/Ku70 and phosphorylated DNA-PKcs were 
carried out in two adjacent sections, the differences in expression between these proteins 
could only be matched at the level of corresponding cell clusters. A special programme was 
developed to fit the sections together and merge different proteins´ signals from 
corresponding clusters of cells (Figure 3). 
Tiled fluorescence images of the whole biopsies were obtained with a Zeiss LSM 780-
inverted confocal microscope using planapochromat 20X/NA 1.2 objectives. HE-stained 
images were obtained with a Leica scan system. 
Statistical analysis 
Correlation analysis was conducted using Spearman´s rho rank correlation test (ρ). All 
statistical tests were two-tailed with significance established at p <0.05. Statistical analysis 
was performed using the Statistical Package for the Social Sciences (SPSS), version 21.0.  
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Figures and Tables 
 
Figure 1 
 
 
Figure 1.The methodology in selecting the target areas for the measurement of 
protein signals in the whole needle core biopsy specimens. A) Cartoon image shows 
a graphic line (red colour), always identifying the midpoint of every part in the 
needle biopsy. The red line prolonged throughout  the length of the whole biopsy 
specimen with perpendicular small lines (blue colour) that run at a certain fixed 
distance on both sides of the central red line. The tissue areas located in the central 
part of the biopsy specimen i.e. along the red line and in between the small blue lines 
were selected for analysis, while tissue areas outside these blue lines were discarded 
from analysis. B) A computerized image of nuclear location from a whole biopsy 
specimen before preparation. C) A computerized image of protein signals from the 
same biopsy specimen in (fig1B) after preparation, selected for analysis. D) A close-
up image of an area implemented for analysis. The main intensity of specific protein 
signals from different cluster of cells in the whole biopsy specimen, were collected 
and analyzed. 
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Figure 2 
 
 A                                     B 
 
Figure 2.A) an original image used for intensity measurements of different proteins. B) The 
same image after computer processing. Areas encircled with white lines were used for 
intensity measurement inside the nuclei and had been extracted using the DNA signal as a 
mask. The DNA mask had been processed with an algorithm to exclude most of the stromal 
cells.  
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Figure 3 
 
 
Figure 3.Tiled fluorescence images of a whole biopsy specimen, had been taken 
from two adjacent sections stained simultaneously with A) P-DNA-PKcs and PAR 
antibodies and B) AR and Ku70 antibodies. C) The matched two adjacent images, 
i.e. in fig 3A and fig 3B, were merged using a special computer programme and the 
above-mentioned protein signals from corresponding clusters of cells in different 
areas of the core biopsy were merged and analyzed. D) A close-up image depicted 
for the intensity measurements of the afore-mentioned proteins. 
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Figure 4 
	  
	  Figure 4. Data from tiled fluorescence images of whole prostate needle biopsies 
stained for androgen receptor (AR). A) Tiled images of prostate needle biopsy 
stained for AR before castration and B) after castration. C) Close-up tiled 
fluorescence images of prostate epithelial cells stained for AR showed the 
homogeneous staining of AR before castration and D) after castration, where we can 
see an incomplete suppression of AR in clusters of epithelial cells in different areas 
throughout the prostate needle biopsy.	  E) Signals of nuclear AR from epithelial cells 
of the same prostate needle biopsy in 4A, plotted against the distance along the 
length axis of the whole needle biopsies were measured in approximately 16,000 
cells before castration. B) Signals of nuclear AR from epithelial cells of the same 
prostate needle biopsy in 4B, plotted against the distance along the length axis of the 
whole needle biopsies were measured in approximately 12,000 cells after castration. 	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Figure 5 
 
Figure 5. Determination of nuclear AR, Ku70, P-DNA-PKcs and PAR levels from prostate 
epithelial cells in prostate needle biopsies. A) Tiled fluorescence images of two matched 
adjacent sections in one needle biopsy before castration, where AR and Ku70 signals in 
section 1 were merged with P-DNA-PKcs and PAR signals from a corresponding area in the 
adjacent section 2. B) Graphs showing signals of AR (red), Ku70 (green), P-DNA-PKcs 
(yellow) and PAR (blue) plotted against the distance along the length axis of two matched 
adjacent sections of one whole needle biopsy before castration. The graph shows the positive 
co-variation between AR (red), Ku70 (green) and P-DNA-PKcs (yellow) and how these three 
proteins negatively co-variate with PAR (blue). C) The same as in fig. 5A, although after 
castration. D) The same as in fig 5B, although after castration. 
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Table1. Patients and tumour characteristics 
 
Patient 
nu 
Patient 
Age (y) 
cT GG GS PSA, ng/ml Testosterone 
nmol/L 
Nuclear AR mean 
intensity, AU 
Nuclear Ku70 mean 
intensity, AU 
Before 
castration 
After 
castration 
(decrease %) 
After 
castration 
Before 
castration 
After 
castration 
(decrease %) 
Before 
castration 
After 
castration 
(decrease %) 
1 60 3 4+3 7 274 2.4 (99) <0.4 72 23 (67) 44 21 (51) 
2 65 3 4+5 9 95 11 (89) 0.78 57 26 (55) 42 25 (40) 
3 62 3 3+4 7 19 1.3 (93) <0.4 42 23 (46) 45 34 (24) 
4 71 3 4+5 9 59 18 (70) 0.43 64 66 (-4) 47 45 (4) 
5 62 3 3+3 6 4 0.12 (97) 0.87 41 21 (58) 64 46 (27) 
 
Abbreviations: cT= clinical tumour stage; GG= Gleason grade; GS= Gleason score; AR= androgen 
receptor; AU = arbitrary unit 
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Table2. Spearman´s rho correlation co-efficient between AR and Ku70, AR and P-DNA-
PKcs, AR and PAR 
 
 
Spearman´s rho Correlation Coefficient 
After castration 
                                             Patient nu 
Mean intensity of 
nuclear Ku70 (AU) 
Mean intensity foci/area 
P-DNA-PKcs (AU) 
Mean intensity of 
nuclear PAR (AU) 
Rho p value Rho p value Rho p value 
Mean intensity of nuclear 
AR (AU) 
1  0.364** <0.001 0.296** <0.001 -0.173** 0.008 
2  0.712** <0.001 0.296** 0.001 -0.08 NS 
3  0.338** <0.001 0.548** <0.001 -0.343** <0.001 
4 0.645** <0.001 0.191** 0.003 -0.139* 0.03 
5  0.896** <0.001 0.411** <0.001 -0.359** <0.001 
 
 
Spearman´s rho Correlation Coefficient 
After castration and RT 
                                                   Patient nu 
Mean intensity of 
nuclear Ku70 (AU) 
Mean intensity 
foci/area P-DNA-PKcs 
(AU) 
Mean intensity of nuclear 
PAR (AU) 
Rho p value Rho p value Rho p value 
Mean intensity of nuclear 
AR (AU) 
  
  
1  0.714** <0.001 0.557** 0.001 -0.482** <0.001 
2  ND   ND   ND   
3  ND   ND   ND   
4  0.659** <0.001 0.621** <0.001 -0.474** <0.001 
5  ND   ND   ND   
 
Abbreviations: AR; Androgen receptor, P-DNA-PKcs; phosphorylated DNA-protein kinase catalytic 
subunit, PAR; poly(ADP-ribose), AU; arbitrary unit; ND 0 not done; NS; non-significant, ** 
Correlation is significant at the 0.01 level (2-tailed). 
 
Spearman´s rho Correlation Coefficient 
Before castration 
                                               Patient nu 
Mean intensity  
nuclear Ku70 (AU) 
Mean intensity foci/area  
P-DNA-PKcs (AU) 
Mean intensity nuclear 
PAR (AU) 
Rho p value Rho p value Rho p value 
Mean intensity of nuclear 
AR (AU) 
1  0.533** <0.001 0.249** <0.001 -0.023 NS 
2  0.312** <0.001 -0.181* 0.013 -0.185* 0.011 
3  0.750** <0.001 0.221** 0.003 -0.062 NS 
4  0.789** <0.001 0.407** <0.001 -0.495** <0.001 
5  0.650** <0.001 0.019 NS -0.055 NS 
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Table 3. Spearman´s rho correlation co-efficient 
A. Between nuclear Ku70 and PAR 
Spearman´s rho Correlation 
Coefficient 
                                                      
                                         Patient nu         
Mean intensity of PAR (AU) 
Before treatment  After castration  After combined Cast. &RT 
Rho p value  Rho p value Rho p value 
Mean intensity of 
nuclear Ku70 (AU) 
1 - 
0.513** 
<0.001 -0.267** <0.001 - 0.539** <0.001 
2   0.428** <0.001 -0.049* NS ND ND 
3     0.292 <0.001 -0.113 NS ND ND 
4 - 
0.325** 
<0.001 -0.372** <0.001 -  0.801** <0.001 
5 - 
0.267** 
0.001 -0.315** <0.001 ND ND 
 
B. Between phosphorylated DNA-PKcs and PAR 
Spearman´s rho Correlation 
Coefficient 
                                                                           
                                          Patient nu       
Mean intensity of PAR (AU) 
Before treatment  After castration  After combined Cast. &RT 
Rho p value  Rho p value Rho p value 
Mean intensity of 
foci/area P-DNA-PKcs 
(AU) 
1     0.283** <0.001     0.073 NS -  0.238** <0.001 
2    0.356** <0.001       
0.427** 
<0.001 ND ND 
3 -   0.015 NS 0.15 NS ND ND 
4 -  0.383** <0.001 -  0.128* 0.05 -  0.407** <0.001 
5     0.122 NS      0.173* 0.04 ND ND 
 
Abbreviations: P-DNA-PKcs; phosphorylated DNA-protein kinase catalytic subunit, PAR; poly(ADP-
ribose), AU; arbitrary unit; ND 0 not done; NS; non-significant, ** Correlation is significant at the 
0.01 level (2-tailed) 
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Supplementary Figure S1 
The intensity of AR in nuclei of the epithelial prostate cells measured from the whole needle biopsies before and 
after castration. Abbreviations P; patient, GS; Gleason score 
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Supplementary Figure S2 B 
After castration 
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 Supplementary Figure S2 C 
After castration and radiation 
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Supplementary Figure S2 
Correlation between the intensity of AR versus Ku70, P-DNA-PKcs and PAR in the nuclei of the epithelial 
prostate cells measured from the whole needle biopsies before treatment in patients 1-5  (S1 A), after 
castration in patients 1-5 (S1 B) and after combined castration and RT in patients 1 and 4 (S1 C). Statistics 
used: Spearman´s rho correlation coefficient. For rho and p value, se Table 2. 
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Correlation between the intensity of AR versus Ku70, P-DNA-PKcs and PAR in the nuclei of the epithelial 
prostate cells measured from the whole needle biopsies before treatment in patients 1-5  (S1 A), after 
castration in patients 1-5 (S1 B) and after combined castration and RT in patients 1 and 4 (S1 C). Statistics 
used: Spearman´s rho correlation coefficient. For rho and p value, se Table 2. 
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Supplementary Figure S3 
Correlation between the intensity of nuclear AR versus Ku70 in the epithelial prostate cells from one whole 
needle biopsy.  
Before castration (upper figure), a wide range of AR expression in different epithelial cell populations was 
observed. The AR intensity is significantly correlated with KU70 expression.  
After castration (lower figure), despite the observed general and significant decrease in AR and Ku70 
intensity in the majority of the epithelial cells, the intensity of these proteins remained highly correlated in 
the sub-population of other epithelial cells in the same biopsy. 
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Supplementary Figure S3 
Correlation between the intensity of nuclear AR versus Ku70 in the epithelial prostate cells from one whole 
needle biopsy.  
Before castration (upper figure), a wide range of AR expression in different epithelial cell populations was 
observed. The AR intensity is significantly correlated with KU70 expression.  
After castration (lower figure), despite the observed general and significant decrease in AR and Ku70 
intensity in the majority of the epithelial cells, the intensity of these proteins remained highly correlated in 
the sub-population of other epithelial cells in the same biopsy. 
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 Supplementary Figure S4 
After castration and radiation 
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Supplementary Figure S4 
Correlation between the intensity of PAR versus Ku70 and P-DNA-PKcs in the nuclei of the epithelial 
prostate cells measured from the whole needle biopsies after combined castration and RT in patients 1 and 
4. Statistics used: Spearman´s rho correlation coefficient. For rho and p value, se Table 3A-B 
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After castration and radiation 
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Supplementary Figure S4 
Correlation between the intensity of PAR versus Ku70 and P-DNA-PKcs in the nuclei of the epithelial 
prostate cells measured from the whole needle biopsies after combined castration and RT in patients 1 and 
4. Statistics used: Spearman´s rho correlation coefficient. For rho and p value, se Table 3A-B 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
0 20 40 60 80 100 120 
0 
20 
40 
60 
80 
100 
0 20 40 60 80 
0 
20 
40 
60 
80 
100 
120 
140 
160 
0 20 40 60 80 100 120 140 160 180 200 
0 
20 
40 
60 
80 
100 
0 20 40 60 80 100 120 140 160 
 Supplementary Figure S5 
 
      
 
 
        
Supplementary Figure S5 
Correlation between the main intensity of nuclear AR and serum PSA levels in 5 patients after castration. 
Spearman´s rho correlation test ρ=1, p <0.001. 
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Supplementary Figure S5 
Correlation between the main intensity of nuclear AR and serum PSA levels in 5 patients after castration. 
Spearman´s rho correlation test ρ=1, p <0.001. 
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